There is substantial evidence indicating that stress, reduced mood, diminished wellbeing, poor cardiovascular health, poor nervous system health, inflammation and poor sleep can significantly impair female sexual function. These factors often lead to decreased libido, arousal difficulties, and diminished sexual satisfaction. This is the reason we address all these elements within the Luminara formula. Below is a summary of key findings from human studies, which elucidate these relationships.

Stress

Reduced Sexual Arousal and Hormonal Imbalance: A study found that women experiencing high levels of chronic stress exhibited lower genital arousal, decreased levels of dehydroepiandrosterone sulfate (DHEAS), and higher cortisol levels compared to women with average stress levels. These physiological changes were associated with diminished sexual arousal and satisfaction.¹

Daily stress and female sexual dysfunction: Research has shown that internal daily stress accounted for 9% to 26% of the variance in sexual problems and 47% of the sexual aversion and desire problems, indicating a strong link between daily stress and female sexual dysfunction.²

Daily subjective stress and Sexual Desire, Arousal, and Activity in Healthy Men and Women: Clinical evidence demonstrated that daily stress negatively impacts sexual desire, arousal, and sexual activity in both men and women. Higher stress levels were associated with reduced sexual interest and engagement. Conversely, engaging in sexual activity was linked to lower stress the following day, suggesting a bidirectional relationship between stress and sexual function. This highlights the benefit of reducing stress to positively affect sexual desire, arousal and sexual activity, which in turn positively effects sexual activity thus reducing stress.³

Mood

Depression and Anxiety Correlation: A systematic medical journal review reported that mood disorders, including depression and anxiety, are closely linked to sexual dysfunction in menopausal women. The review found that women with these mood disorders had significantly lower sexual desire and satisfaction compared to those without such conditions.⁴

Impact of depression on sexual function and quality of life: Research has indicated that women with major depression often experience sexual dysfunction, which adversely affects their overall quality of life. A study emphasized the importance of addressing sexual health in the treatment of depressive disorders.⁵

Conceptualizing sexual dysfunction in depression and anxiety: A study found a multifaceted relationship between sexual dysfunction and mood disorders, emphasizing that psychological factors like depression and anxiety can significantly impair sexual desire and arousal in women.⁶

Wellbeing

Association of resilience with female sexual dysfunction: Research investigated the association between resilience—a measure of psychological wellbeing—and female sexual dysfunction (FSD). The findings suggest that lower resilience levels are significantly associated with higher instances of FSD, indicating that psychological vitality plays a crucial role in sexual health.⁷

Cardiovascular

Concurrent Measurement of Genital Lubrication and Blood Flow During Sexual Arousal: A study of women viewing stimuli of varying sexual intensity while researchers concurrently measured genital lubrication and blood flow found a link between genital blood flow and sexual arousal. Results demonstrated that increased genital blood flow was associated with higher levels of sexual arousal, highlighting the importance of vascular responses in female sexual function.⁸

Measuring female sexual arousal via genital blood flow: Research has evaluated the effectiveness of Laser Doppler imaging (LDI) as a noninvasive method to measure genital blood flow in women during exposure to various visual stimuli. The results demonstrated that erotic stimuli significantly increased genital blood flow compared to other conditions. Moreover, a strong correlation was found between physiological arousal (as measured by LDI) and subjective reports of sexual arousal. These findings underscore the importance of adequate genital blood flow in women’s sexual response.⁹

Anatomy and Physiology of Female Sexual Function and Dysfunction: Research has reviewed the anatomy and physiology of female sexual function, highlighting that sexual arousal is initiated by neurotransmitter-mediated vascular and nervous smooth muscle relaxation, resulting in increased pelvic blood flow. Impairments in this process can lead to sexual dysfunction, including reduced libido.¹⁰

Cardiovascular Disease and Female Sexual Health: Clinical evidence highlighted that cardiovascular disease (CVD) can impair female sexual function by affecting arousal, lubrication, and orgasm, emphasizing the need for cardiovascular health in maintaining sexual wellbeing.¹¹

Female sexual dysfunction as an early indicator of cardiovascular disease: Research has found evidence that sexual dysfunction in women may be an early indicator of cardiovascular disease, highlighting the interconnectedness of sexual and cardiovascular health. Growing evidence shows that female sexual function, especially arousal, is significantly affected by genital vascular impairment, which can lead to female sexual dysfunction.¹²

Nervous System

Neurological Foundations of Female Sexual Function: Health and Dysfunction: A study outlined how the central and peripheral nervous systems coordinate female sexual response, including arousal, lubrication, and orgasm. It emphasizes that intact sensory, autonomic, and somatic pathways are essential for normal sexual functioning. Disruption to these neural circuits can significantly impair libido and sexual satisfaction.¹³

Inflammation

Inflammation disrupts sexual arousal and pleasure in healthy women: Research has examined how inflammation, measured by C-reactive protein (CRP), affects sexual arousal and pleasure in healthy women. Results showed that higher CRP levels were linked to reduced arousal and pleasure, suggesting inflammation may impair sexual experience.¹⁴

Systemic Inflammation Linked to Lower Sexual Arousal in Healthy Women: A study found that elevated levels of C-reactive protein (CRP), a marker of systemic inflammation, predicted reduced sexual arousability in healthy women. The research suggests inflammation may interfere with sexual responsiveness, underscoring the importance of physical health and immune regulation in maintaining optimal female sexual function.¹⁵

Sleep

The Impact of Sleep on Female Sexual Response and Behavior: A Pilot Study: Research has found that women engaging in longer sleep duration was associated with increased next-day sexual desire and a higher likelihood of engaging in sexual activity. Each additional hour of sleep corresponded to a 14% increase in the odds of sexual activity the following day.¹⁶

Associations of Sleep and Female Sexual Function: Good Sleep Quality Matters: Research analyzing data from the DREAMS registry found that better sleep quality was significantly associated with higher sexual desire, arousal, and satisfaction among midlife women. Poor sleep quality correlated with increased sexual distress and dysfunction.¹⁷

Association Between Sexual Function in Women and Sleep Quality: A cross-sectional study has revealed that women with sexual dysfunction had a higher prevalence of poor sleep quality compared to those without sexual dysfunction, suggesting a strong association between sleep disturbances and impaired sexual function.¹⁸

Clavo Huasca (Tynanthus Panurensis)

Also known as Clavo vine, White Clove, Cipó Cravo and Cipó Trinidade.

Clavo Huasca (Tynanthus panurensis) is a vine native to the Amazon rainforest and is commonly used in traditional medicine to enhance sexual vitality, particularly in women. It is valued traditionally for its aphrodisiac properties and ability to promote overall energy and well-being.

Physical Characteristics:

• Vine: A large woody vine that grows in the Amazon, producing distinctive heart-shaped leaves.
  
• Bark: Aromatic with a clove-like scent, often used in infusions and decoctions.
  

Active Compounds:

• Alkaloids: may contribute to its potential aphrodisiac effects.
  
• Tannins: Known for their antioxidant and anti-inflammatory properties.
  
• Saponins: Have adaptogenic properties, supporting energy levels and vitality.
  

Research on Tynanthus Panurensis: Enhancing Female Libido

Naturopathic Doctors have researched the traditional use of this herb and while there is strong anecdotal and traditional support for the use of Clavo Huasca in enhancing female libido, scientific research is still in its early stages, and human studies are needed to validate these effects of traditional use. For now, the herb continues to be used widely in traditional Amazonian medicine and is increasingly popular as an alternative remedy for women’s health. Clavo Huasca has a rich history of use in Amazonian medicine, particularly as a sexual stimulant and energy booster. Although human clinical studies are still to emerge, its traditional use offers valuable insights into its potential health benefits.

Clavo Huasca is an aphrodisiac ingredient in Siete Raices and Rompe Calzon, which are two herbal formulas that are quite famous in South America for use with low libido and increasing sexual potency. These formulas are sold widely in herbal markets and stores around Peru. The Amazonian rainforest Shipibo-Konibo, Kayapo and Assurini tribes regard Clavo Huasca as an effective aphrodisiac for both women and men. It is reported to be highly effective with its use catching on in the US, with more Clavo Huasca products being available in natural product stores and as part of various herbal libido formulas for both women and men.¹⁹

Every ingredient in Luminara was selected because it has a history of traditional use, scientific investigation, or ideally both.

Some ingredients have extensive human clinical evidence. Others have promising early research or centuries of traditional use. We believe women deserve to know the difference.

SHATAVARI

Asparagus racemosus Willd.

Shatavari is an Ayurvedic botanical traditionally associated with women’s reproductive wellbeing, nourishment, resilience and vitality throughout different stages of life.

Its root contains naturally occurring steroidal saponins, including compounds known as Shatavarins, together with flavonoids, polyphenols and other plant constituents. These compounds have been investigated for their possible influence on reproductive signalling, tissues affected by changing oestrogen levels, stress responses, antioxidant defence and inflammatory pathways.

Modern human clinical research has investigated standardised Shatavari root extracts for perimenopausal and menopausal symptoms, vasomotor symptoms, menstrual comfort, female sexual wellbeing, postmenopausal physical function, lactation and several other areas.¹–¹⁷

SHATAVARI AT A GLANCE

Botanical name: Asparagus racemosus Willd.

Botanical family: Asparagaceae

Part used in Luminara: Root

Traditional system: Ayurveda

Key naturally occurring constituents: Steroidal saponins, including Shatavarins; flavonoids; polyphenols

Luminara daily amount: 1,000 mg Shatavari root extract

Luminara standardisation: Not less than 20% total saponins, measured by gravimetry

Minimum standardised constituents per daily serving: 200 mg total saponins

Country of origin of Luminara’s ingredient: India

The supplier specification identifies the ingredient as Asparagus racemosus root extract and requires at least 20% total saponins. It does not state the extraction ratio, extraction solvent, carrier content or an actual batch assay result. The 200 mg figure therefore represents the minimum required by the ingredient specification rather than a measured result for the finished Luminara batch.

HOW CLOSELY DOES LUMINARA’S SHATAVARI MATCH THE CLINICAL RESEARCH?

Luminara’s ingredient aligns with the clinical literature in several important respects:

• it is the same botanical species, Asparagus racemosus;
• it uses the root, which is the plant part used in the major modern women’s-health trials;
• it is a concentrated extract rather than unstandardised whole-herb powder;
• it is standardised to a class of constituents considered central to Shatavari: steroidal saponins.

However, direct clinical equivalence cannot presently be claimed.

Several recent studies used proprietary extracts standardised to specific Shatavarins measured by high-performance liquid chromatography. For example, some trials used 300 mg daily of a 13:1 root extract containing more than 10% total Shatavarins by HPLC.²˒⁴˒⁷ Another used 500 mg daily of an extract standardised to 5% total Shatavarins.¹ A 2026 study used 100 mg daily of a proprietary extract standardised to Shatavarin IV.⁵

Luminara’s specification instead measures at least 20% total saponins by gravimetry. “Total saponins” measured gravimetrically and “total Shatavarins” measured by HPLC are not interchangeable measurements. Gravimetry estimates a broader constituent class, while HPLC can quantify selected individual or grouped marker compounds.

This means it would be misleading to claim that Luminara’s 20% extract is twice as strong as a clinical extract standardised to 10% Shatavarins. What can accurately be said is that Luminara uses the same species and root plant part, in a saponin-standardised extract, while compositional equivalence to any proprietary clinical extract has not been established.

TRADITIONAL USE

In Ayurveda, Shatavari is classified as a rasayana: a restorative botanical traditionally used to promote nourishment, resilience and healthy ageing.

It has a particularly strong traditional association with women’s wellbeing and has historically been used during the reproductive years, after childbirth and through later-life transitions.

Traditional uses have included support for:

• female vitality and resilience;
• reproductive wellbeing;
• menstrual comfort;
• lactation;
• intimate wellbeing;
• recovery from physical and emotional stress;
• digestive comfort;
• healthy ageing.

Traditional use provides important historical context, but it is not equivalent to evidence from controlled human clinical trials.

WHAT HUMAN CLINICAL STUDIES HAVE INVESTIGATED

PERIMENOPAUSAL AND MENOPAUSAL WELLBEING

A growing group of randomised, double-blind, placebo-controlled trials has investigated standardised Shatavari root extracts in women experiencing perimenopausal or menopausal changes.¹–⁶

Across these studies, improvements have been reported in areas including:

• overall menopause or perimenopause symptom scores;¹–⁶
• vasomotor symptoms, including hot flushes or hot flashes and night sweats;¹–³˒⁵˒⁶
• somatic or physical menopause symptoms;¹–⁶
• psychological menopause symptoms;¹˒²˒⁴˒⁵
• stress measured during menopause;²˒⁴
• sleep-related menopausal symptoms;¹˒²˒⁵
• vaginal dryness in one controlled trial;¹
• loss-of-libido complaints measured within a broad menopause assessment in one trial;¹
• menopause-related quality of life.¹˒²˒⁶

The findings are encouraging, but most trials are recent, have modest sample sizes and have investigated proprietary extracts. Some studies were also funded by, supplied by or involved researchers connected with the ingredient manufacturer. Independent replication and longer-term studies remain important.

VASOMOTOR SYMPTOMS: HOT FLUSHES AND NIGHT SWEATS

Vasomotor symptoms are episodes of altered temperature regulation commonly experienced as hot flushes or hot flashes and night sweats.

In a 2024 trial involving 70 women, 500 mg of a standardised Shatavari root extract daily for eight weeks produced significantly greater reductions than placebo in hot flushes and night sweats.¹

An eight-week study in 80 perimenopausal women found that 300 mg daily significantly improved hot-flash scores compared with placebo.²

A 120-day study in 50 perimenopausal women found that 200 mg daily significantly reduced the Hot Flash Weekly Weighted Score and overall Menopause Rating Scale score.³

A 2026 trial involving 60 pre-, peri- and postmenopausal women found that 100 mg daily of a Shatavarin IV-standardised extract significantly improved overall menopausal symptoms, including somatic, psychological and urogenital domains.⁵

A 24-week dose-ranging study in postmenopausal women also reported dose-dependent improvements in menopause-related quality of life with Shatavari extracts.⁶

Not every study has demonstrated statistically significant improvement in hot flushes. In a 2025 three-arm trial, Shatavari alone significantly improved overall Menopause Rating Scale and perceived-stress scores, while improvements in hot flushes and menopause-specific quality of life were numerical trends that did not reach statistical significance.⁴

Taken together, the evidence supports describing Shatavari as having good emerging human evidence for supporting comfort from vasomotor symptoms. It does not establish that every Shatavari extract will produce the same outcome.

VAGINAL DRYNESS AND UROGENITAL WELLBEING

One randomised, double-blind, placebo-controlled menopause trial reported significantly greater improvement in vaginal dryness with Shatavari than placebo.¹

Other menopause trials have measured broader urogenital domains as part of the Menopause Rating Scale or menopause quality-of-life questionnaires.⁴˒⁵

This evidence requires careful interpretation:

• the clearest vaginal-dryness finding currently comes from one controlled clinical study;
• vaginal dryness measured as a menopausal complaint is not identical to the lubrication domain of a sexual-function questionnaire;
• the extracts used in the trials are not known to be compositionally equivalent to Luminara’s extract;
• Shatavari has not been established as a treatment for genitourinary syndrome of menopause or any medical condition.

The appropriate conclusion is that one human study provides promising evidence for vaginal-dryness support as part of broader menopausal wellbeing.

SLEEP, STRESS AND EMOTIONAL WELLBEING DURING MENOPAUSE

Several menopause studies have reported improvements in sleep disturbance, stress, mood or psychological symptom domains.¹˒²˒⁴˒⁵

The 2025 three-arm study is especially useful for interpreting these outcomes accurately. Shatavari alone significantly reduced overall Menopause Rating Scale scores and Perceived Stress Scale scores. Improvements in some secondary measures, including hot flushes and menopause-specific quality of life, did not reach statistical significance.⁴

These studies suggest that Shatavari may support emotional and sleep-related wellbeing during hormonal transitions. They do not establish it as a treatment for insomnia, anxiety or depression.

MENSTRUAL AND CYCLE-RELATED WELLBEING

Shatavari remains relevant to younger menstruating women as well as women approaching or moving through menopause.

A 120-day placebo-controlled study in perimenopausal women reported improvements in congestive and spasmodic menstrual discomfort. It also reported changes in follicle-stimulating hormone, luteinising hormone and anti-Müllerian hormone, together with improvements in skin and hair assessments.³

These findings are promising but need independent replication. Changes in selected hormone markers do not prove that an ingredient broadly “balances hormones,” restores fertility or normalises the menstrual cycle.

The most defensible consumer wording is that clinical research has investigated Shatavari for menstrual comfort and wellbeing through hormonal transitions.

SKIN AND HAIR OUTCOMES

The same 120-day perimenopause study reported improvements in investigator- or participant-assessed skin and hair quality.³

This is early evidence from one study that assessed many outcomes. It is not sufficient to position Shatavari as a clinically established skin or hair ingredient, but it belongs in a complete evidence record.

FEMALE SEXUAL WELLBEING

A 2026 randomised, double-blind, three-arm trial enrolled 135 women and compared:

1. Shatavari root extract alone;
2. Shatavari combined with ashwagandha;
3. placebo.⁷

After eight weeks, the Shatavari-only group experienced greater improvement than placebo in:

• total Female Sexual Function Index score;
• sexual satisfaction;
• female sexual-distress score at the end of the study.⁷

However, Shatavari alone did not significantly outperform placebo in the individual domains of:

• desire;
• arousal;
• lubrication;
• orgasm;
• pain.⁷

The Shatavari-and-ashwagandha combination produced broader improvements, including statistically significant changes in arousal, lubrication and orgasm. Those combination findings cannot be attributed to Shatavari alone.⁷

A separate menopause trial reported improvement in “loss of libido” as one item within a wider symptom assessment, but this is not equivalent to a dedicated libido trial.¹

The accurate conclusion is that emerging human evidence suggests Shatavari may support overall female sexual wellbeing, satisfaction and reduced sexual distress. Current evidence does not justify stating that Shatavari alone is clinically proven to increase desire, arousal, orgasm or vaginal lubrication.

POSTMENOPAUSAL QUALITY OF LIFE, VASCULAR FUNCTION AND BONE-TURNOVER MARKERS

A 24-week randomised, double-blind, placebo-controlled dose-ranging study compared Shatavari, ashwagandha, their combination and placebo in postmenopausal women.⁶

The Shatavari groups showed dose-dependent improvements in menopause-related quality of life and a vascular reflection index. Changes were also reported in bone-turnover or resorption markers, inflammatory markers and oxidative-stress markers.⁶

These results broaden the areas being investigated, but they do not establish that Shatavari:

• prevents cardiovascular disease;
• prevents osteoporosis;
• increases bone mineral density;
• prevents fractures;
• treats chronic inflammation.

Biomarker and vascular-function findings should be presented as preliminary healthy-ageing research rather than disease-prevention claims.

PHYSICAL STRENGTH AND MUSCLE FUNCTION

In a small randomised, double-blind trial, 20 postmenopausal women received 1,000 mg of Shatavari daily or placebo for six weeks.⁸

Women taking Shatavari experienced a modest improvement in handgrip strength. Researchers also observed changes in a muscle-signalling pathway associated with contractile function.⁸

The study did not find:

• improved knee-extensor strength;
• changes in the measured blood markers of bone turnover.⁸

A later exploratory analysis of muscle-biopsy samples from the same research programme found changes in proteins associated with skeletal-muscle adaptation. Only 12 participants were included in that analysis, and molecular changes do not automatically translate into noticeable functional benefits.⁹

A separate eight-week resistance-training study in 18 recreationally trained men reported greater improvements in upper-body strength and muscular endurance with 500 mg daily of Shatavari than placebo. The participants were not selected for women’s hormonal concerns, so its direct relevance to Luminara is limited.¹⁰

Current evidence for physical strength and muscle function is promising but preliminary. It does not support claiming that Shatavari prevents muscle loss or strengthens bones.

RESEARCH IN WOMEN WITH PCOS

Recent placebo-controlled trials have investigated standardised Shatavari extracts in women diagnosed with polycystic ovary syndrome.¹¹

Reported outcomes have included selected ovarian, reproductive, metabolic, menstrual and perceived-stress measures.¹¹

This research is part of the scientific record, but it must not be converted into a claim that Luminara diagnoses, treats, prevents, mitigates or manages PCOS. Research in a diagnosed medical population can help identify possible biological effects without authorising a disease-treatment claim for a dietary supplement.

LACTATION RESEARCH

Shatavari has a long traditional reputation as a galactagogue, and several human studies have investigated its use after childbirth.¹²–¹⁵˒¹⁷

The overall evidence is mixed.

Recent controlled studies have reported:

• greater breast-milk volume;
• a shorter time to breast fullness or establishment of lactation;
• improved maternal satisfaction with lactation-related wellbeing.¹²˒¹³

A 2011 randomised, double-blind trial reported a greater increase in maternal prolactin and infant weight-related outcomes with Shatavari than placebo.¹⁴

However, a 1996 randomised controlled trial found no significant differences between the Shatavari-containing preparation and placebo in maternal prolactin, infant weight gain or the need for supplemental feeding.¹⁵ A July 2026 review in the United States National Library of Medicine’s LactMed database therefore characterises the clinical results as mixed.¹⁷

The formulations, doses and study quality have varied. Some studies used whole root, a multi-herb preparation or a Shatavari-containing food product rather than an extract identical to Luminara’s ingredient.

This evidence is included for completeness, not as a recommended use for Luminara. Luminara is a multi-herb formula and should not be promoted as a lactation product. Research on Shatavari alone does not establish the safety of Luminara’s complete formula during breastfeeding. Anyone who is breastfeeding should consult a qualified healthcare professional before using it.

EARLY DIGESTIVE RESEARCH

A small 1990 crossover study involving eight healthy male volunteers investigated Shatavari’s effect on gastric emptying and compared it with metoclopramide.¹⁶

This is very limited early research involving a tiny sample, an older study design and a population unrelated to Luminara’s primary audience. It does not support a digestive-treatment claim, but it is recorded as part of the available human literature.

EVIDENCE STRENGTH

HOW WE RATE THE EVIDENCE

★★★★★ — Strong

Multiple high-quality human trials and/or systematic reviews with reasonably consistent findings, relevant preparations and meaningful replication.

★★★★☆ — Good

More than one relevant controlled human trial with encouraging or broadly consistent findings, but with limitations such as modest samples, proprietary extracts, manufacturer involvement or limited independent replication.

★★★☆☆ — Emerging

At least one controlled human study showing a relevant benefit, with further confirmation required.

★★☆☆☆ — Preliminary

Limited, mixed, indirect or very small human evidence, including combination studies, biomarker findings or early disease-population research.

★☆☆☆☆ — Traditional or preclinical

Traditional use, laboratory research or animal evidence without adequate standalone human clinical confirmation.

The rating describes the current body of evidence. It is not a guarantee that an individual will experience the benefit.

HEALTH AREA | EVIDENCE STRENGTH | CURRENT ASSESSMENT

Overall perimenopausal and menopausal symptoms | ★★★★☆ | Multiple recent placebo-controlled human trials, but mostly proprietary extracts and limited independent replication

Vasomotor symptoms: hot flushes and night sweats | ★★★★☆ | Positive findings across several controlled trials, with one trial reporting nonsignificant hot-flash trends

Menopause-related quality of life | ★★★★☆ | Improvements reported in several controlled studies

Menopause-related stress | ★★★☆☆ | Shatavari-alone benefit reported in a controlled trial

Menopause-related sleep disturbance | ★★★☆☆ | Improvements reported within broader menopause assessments

Mood and psychological menopause symptoms | ★★★☆☆ | Encouraging findings, but not evidence for treating a mood disorder

Vaginal dryness | ★★★☆☆ | Positive finding in one controlled menopause study

Menstrual comfort | ★★★☆☆ | Positive findings in one controlled perimenopause study

Overall female sexual function | ★★★☆☆ | One recent placebo-controlled trial

Sexual satisfaction | ★★★☆☆ | Improved in the Shatavari-only arm of one controlled trial

Sexual distress | ★★★☆☆ | Improved at the end of one controlled trial

Desire or libido | ★★☆☆☆ | Dedicated Shatavari-only evidence remains limited or mixed

Vaginal lubrication | ★★☆☆☆ | Significant benefit occurred in a Shatavari–ashwagandha combination arm, not Shatavari alone

Skin and hair quality | ★★☆☆☆ | Findings from one multi-outcome perimenopause trial

Vascular-function and healthy-ageing biomarkers | ★★☆☆☆ | One dose-ranging study; no disease-prevention conclusion

Bone health | ★★☆☆☆ | Changes in turnover markers in one study, but no established bone-density or fracture benefit and one small trial found no marker change

Physical strength and muscle function | ★★☆☆☆ | Small human studies with selective positive outcomes

PCOS-related outcomes | ★★☆☆☆ | Recent disease-population research; not suitable for a treatment claim

Lactation | ★★★☆☆ | Several human studies with mixed findings, varied formulations and no intended Luminara use

Digestive function | ★☆☆☆☆ | One very small early human study

WHAT THE KEY STUDIES FOUND

GUDISE ET AL., 2024¹

Design: Randomised, double-blind, multicentre, placebo-controlled clinical trial.

Participants: Seventy women experiencing menopausal symptoms.

Intervention: A standardised Shatavari root extract, 250 mg twice daily, or placebo.

Duration: Eight weeks.

Key findings: Compared with placebo, the Shatavari group experienced greater improvement in hot flushes, night sweats, insomnia, anxiety, nervousness, vaginal dryness, loss-of-libido complaints and Utian Quality of Life scores.

Why it matters: This trial provides directly relevant human evidence across several physical, psychological, urogenital and quality-of-life outcomes.

Limitations: The sample and duration were modest, numerous symptoms were assessed, and the findings relate to a proprietary extract standardised to 5% total Shatavarins rather than Luminara’s total-saponin specification.

MAHAJAN ET AL., 2025²

Design: Prospective, randomised, double-blind, placebo-controlled trial.

Participants: Eighty perimenopausal women were randomised; 73 completed the trial per protocol.

Intervention: A 13:1 Shatavari root extract, 300 mg once daily, standardised to more than 10% total Shatavarins by HPLC, or placebo.

Duration: Eight weeks.

Key findings: Shatavari improved overall perimenopausal symptom scores, perceived stress and hot-flash scores. Changes were also reported in selected hormone measures.

Why it matters: It provides controlled evidence for perimenopausal symptoms and vasomotor support.

Limitations: It used one proprietary extract, was relatively short and included exploratory hormone outcomes that should not be translated into a broad hormone-balancing claim.

YADAV ET AL., 2025³

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Fifty perimenopausal women aged 40–50 with mild-to-moderate climacteric symptoms.

Intervention: CL22205 standardised Shatavari root extract, 200 mg daily, or placebo.

Duration: 120 days.

Key findings: The Shatavari group experienced significant reductions in total Menopause Rating Scale and hot-flash scores. Improvements were also reported in congestive and spasmodic menstrual discomfort, selected hormone markers, skin and hair assessments and patient-satisfaction measures.

Why it matters: This study directly examined vasomotor and menstrual outcomes over four months.

Limitations: It was small, used a proprietary extract and measured numerous outcomes. The hormone, skin and hair findings need independent replication.

ADEMOLA ET AL., 2025⁴

Design: Randomised, double-blind, three-arm, multicentre, placebo-controlled trial.

Participants: One hundred and thirty-five women aged 45–65 were enrolled.

Interventions: Shatavari root extract alone at 300 mg daily; Shatavari 300 mg combined with ashwagandha 250 mg; or placebo.

Duration: Eight weeks.

Extract: The Shatavari was a 13:1 root extract standardised to more than 10% total Shatavarins by HPLC.

Key findings for Shatavari alone: Significant reductions in overall Menopause Rating Scale and Perceived Stress Scale scores.

Findings that did not reach statistical significance for Shatavari alone: Improvements in menopause-specific quality of life, hot flushes and hormone measures were reported as trends.

Why it matters: This is a useful controlled study because it separates statistically significant findings from favourable but inconclusive trends.

Limitations: Short duration, proprietary extract, modest group sizes and exploratory secondary analyses.

SWAROOP AND SWAROOP, 2026⁵

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Sixty healthy women aged 40–55 spanning pre-, peri- and postmenopausal stages.

Intervention: SheVari4, a water–ethanol Shatavari root extract standardised to 5% Shatavarin IV, 100 mg daily, or placebo.

Duration: Eight weeks.

Key findings: Shatavari significantly improved total Menopause Rating Scale scores and the somatic, psychological and urogenital symptom domains at weeks four and eight.

Why it matters: It adds another controlled trial using a distinct, low-dose standardised extract.

Limitations: Small sample, short duration, mixed menopause stages and manufacturer sponsorship and product supply.

PINGALI ET AL., 2025⁶

Design: Randomised, double-blind, placebo-controlled, six-arm dose-ranging study.

Participants: Postmenopausal women aged 40–55.

Interventions: Placebo; Shatavari aqueous extract at 250 mg or 500 mg; ashwagandha at 250 mg or 500 mg; or a combination containing 250 mg of each.

Duration: Twenty-four weeks.

Key findings: Shatavari produced dose-dependent improvements in menopause-related quality of life and a vascular reflection index. Changes were also reported in bone-turnover or resorption, inflammatory and oxidative-stress markers.

Why it matters: It is longer than most other trials and investigated broader healthy-ageing measures.

Limitations: Multiple groups and outcomes, manufacturer funding, biomarker endpoints and no basis for claiming prevention of cardiovascular disease or osteoporosis.

ADEMOLA ET AL., 2026⁷

Design: Prospective, randomised, double-blind, three-arm, parallel-group, placebo-controlled trial.

Participants: One hundred and thirty-five women were enrolled.

Interventions: Shatavari root extract alone; Shatavari combined with ashwagandha; or placebo.

Duration: Eight weeks.

Extract: A 13:1 Shatavari root extract standardised to more than 10% total Shatavarins by HPLC.

Key findings for Shatavari alone: Improved total Female Sexual Function Index score, sexual satisfaction and sexual-distress score at the study endpoint.

Findings not established for Shatavari alone: Significant superiority over placebo for desire, arousal, lubrication, orgasm or pain.

Combination findings: The Shatavari–ashwagandha arm produced broader effects, including significant changes in arousal, lubrication and orgasm.

Why it matters: It supplies direct emerging human evidence for overall female sexual wellbeing.

Limitations: One recent proprietary-extract trial; multiple outcomes; combination results cannot be assigned to Shatavari alone.

O’LEARY ET AL., 2021⁸

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Twenty postmenopausal women with a mean age of approximately 68 years.

Intervention: Shatavari, 1,000 mg daily, or placebo.

Duration: Six weeks.

Key findings: Handgrip strength improved modestly, and a muscle-signalling measure associated with contractile function changed.

Findings not demonstrated: Knee-extensor strength and measured blood markers of bone turnover did not improve.

Why it matters: It provides preliminary evidence at the same nominal daily milligram amount used in Luminara.

Limitations: Very small sample, short duration and insufficient extract-characterisation information to establish equivalence to Luminara.

O’LEARY ET AL., 2024⁹

Design: Exploratory proteomic analysis using muscle samples from the postmenopausal supplementation research programme.

Participants: Twelve women were included in the molecular analysis.

Key findings: Shatavari altered proteins associated with skeletal-muscle adaptation.

Why it matters: It provides possible mechanistic context for future healthy-ageing research.

Limitations: Tiny subgroup and exploratory molecular outcomes rather than demonstrated clinical benefits.

ANDERS ET AL., 2020¹⁰

Design: Randomised, placebo-controlled resistance-training study.

Participants: Eighteen recreationally trained men.

Intervention: Shatavari, 500 mg daily, or placebo during eight weeks of training.

Key findings: The Shatavari group had greater improvement in bench-press one-repetition maximum and repetitions to failure.

Why it matters: It adds preliminary human evidence related to muscular performance.

Limitations: Small study, exercise-specific context and not directly focused on women’s hormonal wellbeing.

MHATRE ET AL., 2026¹¹

Design: Prospective, randomised, double-blind, placebo-controlled trial.

Participants: Seventy women aged 20–40 with diagnosed PCOS; 66 completed the trial.

Duration: Twelve weeks.

Key findings: Improvements were reported in selected ovarian, reproductive, metabolic and perceived-stress outcomes.

Why it matters: It extends clinical investigation into reproductive-age women.

Limitations: One recent proprietary-extract trial in a diagnosed medical population. It cannot support a claim that Luminara treats or manages PCOS.

AJGAONKAR ET AL., 2025¹²

Design: Randomised, double-blind, placebo-controlled postpartum study.

Participants: Postpartum women seeking to establish lactation.

Key findings: The study reported benefits in lactation-related outcomes with Shatavari root extract.

Why it matters: It provides modern controlled evidence for Shatavari’s traditional galactagogue use.

Limitations: Postpartum-specific use and preparation; results do not establish the suitability of Luminara’s multi-herb formula during breastfeeding.

BIRLA ET AL., 2022¹³

Design: Controlled postpartum study of a Shatavari-containing nutrition bar.

Key findings: The intervention improved measured breast-milk output and supported early establishment of lactation.

Limitations: The product was a food formulation rather than Shatavari alone, so the result cannot be assigned solely to Shatavari or directly applied to Luminara’s extract.

GUPTA AND SHAW, 2011¹⁴

Design: Randomised, double-blind clinical study in lactating mothers.

Key findings: Shatavari was associated with improved prolactin and lactation-related outcomes.

Limitations: Older study, methodological limitations and uncertain equivalence of the preparation to modern standardised extracts.

SHARMA ET AL., 1996¹⁵

Design: Randomised controlled trial in mothers experiencing lactational inadequacy.

Participants: Sixty-four mothers were randomised; 53 completed the study.

Intervention: A Shatavari-containing preparation or placebo, together with breastfeeding guidance.

Duration: Four weeks.

Findings: Both groups improved, but there were no significant differences between groups in serum prolactin, infant weight gain or the amount of supplemental feeding.

Why it matters: This negative trial is important because it prevents the lactation literature from being presented as uniformly positive.

Limitations: The preparation contained Shatavari with other ingredients, the sample was modest and 11 participants did not complete the study.

DALVI ET AL., 1990¹⁶

Design: Small crossover study in eight healthy male volunteers.

Intervention: Shatavari was compared with metoclopramide for gastric-emptying effects.

Why it matters: It demonstrates that gastrointestinal effects have been investigated in humans.

Limitations: Extremely small, old, male-only study and no relevance to a disease or digestive-treatment claim.

HOW SHATAVARI MAY WORK

The mechanisms responsible for Shatavari’s clinical effects have not been fully established.

STEROIDAL SAPONINS AND SHATAVARINS

Shatavari root contains steroidal saponins, including Shatavarins I–IV and related compounds. These are widely regarded as important marker constituents.

Luminara’s extract is specified to contain at least 20% total saponins by gravimetry. Several clinical extracts were instead standardised to selected Shatavarins by HPLC. These assays measure related but different things.

OESTROGEN-RELATED PATHWAYS

Laboratory and mechanistic research suggests that some Shatavari constituents may interact with oestrogen receptors or influence tissues affected by changing oestrogen signalling.

This does not mean that Shatavari:

• is oestrogen;
• is equivalent to menopausal hormone therapy;
• has been proven to increase circulating oestrogen;
• is appropriate for every person with a hormone-sensitive condition.

STRESS-RESPONSE PATHWAYS

Shatavari is traditionally classified as a restorative or adaptogenic botanical. Clinical menopause studies have reported improvements in perceived stress, while laboratory research suggests possible effects on stress-response pathways.²˒⁴

The clinical evidence is better framed as support for stress-related wellbeing during hormonal transitions than as treatment for anxiety or stress disorders.

ANTIOXIDANT AND INFLAMMATORY PATHWAYS

Laboratory studies and one clinical biomarker study suggest that Shatavari may influence oxidative-stress and inflammatory signalling.⁶

These mechanisms may help explain broader physiological effects, but they do not prove that Shatavari prevents or treats inflammatory disease.

REPRODUCTIVE AND SEXUAL-WELLBEING PATHWAYS

Potential effects on reproductive signalling, stress, physical comfort, urogenital symptoms and hormone-sensitive tissues may collectively contribute to the reported menopause, menstrual and sexual-wellbeing outcomes.

The precise active compounds and the extent to which these mechanisms apply to Luminara’s total-saponin extract remain uncertain.

SAFETY AND RESPONSIBLE USE

Shatavari was generally well tolerated in the short-term human studies summarised above.¹–¹⁵ Reported adverse events were usually absent or mild. In one trial, one participant receiving Shatavari alone reported nausea.⁴ Another 2026 trial reported mild, transient adverse events that were comparable between groups.⁵

Important limitations remain:

• most studies lasted between six weeks and six months;
• long-term safety data are limited;
• safety and tolerability can vary with extract composition and dose;
• reliable interaction data are limited;
• pregnancy safety has not been established for Luminara;
• lactation studies of Shatavari alone do not establish the safety of Luminara’s complete multi-herb formula during breastfeeding;
• possible hormone-related activity warrants professional guidance for people using hormonal medicines or managing hormone-sensitive conditions.

Anyone who is pregnant, breastfeeding, taking prescription medication, using hormonal therapy or managing a medical condition should consult a qualified healthcare professional before using Luminara.

PLAIN-ENGLISH SUMMARY

Shatavari is a traditional Ayurvedic root with a rapidly growing body of modern human research.

Its strongest emerging evidence relates to supporting women during perimenopause and menopause. Several controlled trials have reported improvements in overall symptom burden, and multiple studies have found support for vasomotor symptoms such as hot flushes or hot flashes and night sweats.¹–⁶

Some studies have also reported benefits for stress, sleep-related symptoms, mood-related menopausal symptoms, vaginal dryness, menstrual comfort, skin and hair assessments and menopause-related quality of life. These outcomes vary between studies and extracts.¹–⁶

A recent controlled trial suggests Shatavari may support overall female sexual function, satisfaction and reduced sexual distress. It did not establish that Shatavari alone significantly improves desire, arousal, lubrication or orgasm.⁷

Small trials have explored physical strength, muscle adaptation, vascular function, bone-turnover markers and other healthy-ageing outcomes, but these findings remain preliminary.⁶˒⁸–¹⁰

Human research has also investigated Shatavari for lactation and in women with PCOS. Lactation findings are mixed, and neither area represents an intended use or disease claim for Luminara.¹¹–¹⁵˒¹⁷

Luminara provides 1,000 mg of Asparagus racemosus root extract daily, specified to contain at least 20% total saponins. This equates to a minimum specification of 200 mg total saponins per daily serving. Because this is measured by gravimetry rather than the Shatavarin-specific HPLC methods used in several trials, the formula should not be described as clinically equivalent to those proprietary extracts.

Overall, Shatavari is one of Luminara’s principal botanicals for supporting women through menstrual, perimenopausal and menopausal transitions. The evidence is encouraging, but the most responsible interpretation continues to distinguish established findings, emerging clinical evidence, traditional use and outcomes that remain preliminary.

REFERENCES

1. Gudise VS, Dasari MP, Kuricheti SSK. Efficacy and safety of Shatavari root extract for the management of menopausal symptoms: a double-blind, multicenter, randomized controlled trial. Cureus. 2024;16(4):e57879. doi:10.7759/cureus.57879. PMID: 38725785.

2. Mahajan S, Avad P, Langade J. Efficacy and safety of Shatavari (Asparagus racemosus) root extract for perimenopause: randomized, double-blind, placebo-controlled study. International Journal of Women’s Health. 2025;17:4057–4073. doi:10.2147/IJWH.S544267. PMID: 41209045.

3. Yadav P, Yadav S, Vedururu SS, Kumari G. A standardized Asparagus racemosus root extract improves hormonal balance and menstrual health and reduces vasomotor symptoms in perimenopausal women: a randomized, double-blind, placebo-controlled study. Journal of the American Nutrition Association. 2025;44(8):754–764. doi:10.1080/27697061.2025.2510474. PMID: 40434025.

4. Ademola J, Ajgaonkar A, Debnath T, Debnath K, Langade J. Efficacy and safety of Shatavari root extract (Asparagus racemosus) for menopausal symptoms: a randomized, double-blind, three-arm, placebo-controlled study. Frontiers in Reproductive Health. 2025;7:1654503. doi:10.3389/frph.2025.1654503. PMID: 41394012.

5. Swaroop A, Swaroop A. Asparagus racemosus root extract (SheVari4®) alleviates menopausal symptoms in pre-, peri-, and post-menopausal healthy women. Cureus. 2026;18(4):e106987. doi:10.7759/cureus.106987. PMID: 41982372.

6. Pingali U, Nutalapati C, Wang Y. Ashwagandha and Shatavari extracts dose-dependently reduce menopause symptoms, vascular dysfunction, and bone resorption in postmenopausal women: a randomized, double-blind, placebo-controlled study. Journal of Menopausal Medicine. 2025;31(1):21–34. doi:10.6118/jmm.24025. PMID: 40347163.

7. Ademola J, Mahajan S, Srivathsan M, Langade D. Effects of Shatavari (Asparagus racemosus) root extract on sexual wellness in women: findings from a prospective, randomized, double-blind, three-arm, parallel-group, placebo-controlled study. International Journal of Women’s Health. 2026;18:561213. doi:10.2147/IJWH.S561213. PMID: 41710148.

8. O’Leary MF, Jackman SR, Sabou VR, Campbell MI, Tang JCY, Dutton J, et al. Shatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light-chain phosphorylation but does not alter markers of bone turnover. Nutrients. 2021;13(12):4282. doi:10.3390/nu13124282. PMID: 34959836.

9. O’Leary MF, Jackman SR, Bowtell JL. Shatavari supplementation in postmenopausal women alters the skeletal muscle proteome and pathways involved in training adaptation. European Journal of Nutrition. 2024;63(3):869–879. doi:10.1007/s00394-023-03310-w. PMID: 38214710.

10. Anders JPV, Keller JL, Smith CM, Hill EC, Housh TJ, Schmidt RJ, Johnson GO. The effects of Asparagus racemosus supplementation plus 8 weeks of resistance training on muscular strength and endurance. Journal of Functional Morphology and Kinesiology. 2020;5(1):4. doi:10.3390/jfmk5010004. PMID: 33467220.

11. Mhatre Y, Jadhav P, Malik A, Srivathsan M, Langade D. Efficacy and safety of Shatavari root extract in women with Polycystic Ovarian Syndrome: a randomized, double-blind, placebo-controlled trial. Frontiers in Endocrinology. 2026;17:1769773. doi:10.3389/fendo.2026.1769773. PMID: 41816216.

12. Ajgaonkar A, Debnath T, Bhatnagar S, Debnath K, Langade J. Shatavari (Asparagus racemosus Willd) root extract for postpartum lactation: a randomised, double-blind, placebo-controlled study. Journal of Obstetrics and Gynaecology. 2025;45(1):2564168. doi:10.1080/01443615.2025.2564168. PMID: 41055223.

13. Birla A, Satia M, Shah R, Pai A, Srivastava S, Langade D. Postpartum use of Shavari Bar® improves breast milk output: a double-blind, prospective, randomized, controlled clinical study. Cureus. 2022;14(7):e26831. doi:10.7759/cureus.26831. PMID: 35974870.

14. Gupta M, Shaw B. A double-blind randomized clinical trial for evaluation of galactogogue activity of Asparagus racemosus Willd. Iranian Journal of Pharmaceutical Research. 2011;10(1):167–172. PMID: 24363697.

15. Sharma S, Ramji S, Kumari S, Bapna JS. Randomized controlled trial of Asparagus racemosus (Shatavari) as a lactogogue in lactational inadequacy. Indian Pediatrics. 1996;33(8):675–677. PMID: 8979551.

16. Dalvi SS, Nadkarni PM, Gupta KC. Effect of Asparagus racemosus (Shatavari) on gastric emptying time in normal healthy volunteers. Journal of Postgraduate Medicine. 1990;36(2):91–94. PMID: 2097375.

17. Drugs and Lactation Database (LactMed®). Wild Asparagus. Bethesda (MD): National Institute of Child Health and Human Development; last revised July 15, 2026.

These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

CLAVO HUASCA

Tynanthus panurensis (Bureau) Sandwith

Clavo Huasca is an aromatic woody vine native to the western and central Amazon region. Its accepted botanical name is Tynanthus panurensis (Bureau) Sandwith, and it belongs to the Bignoniaceae family. The species occurs naturally from southern Colombia through parts of Peru, Ecuador and Bolivia to northern Brazil.¹

Its Spanish common name reflects its distinctive aroma: clavo means “clove,” while huasca or waska refers to a vine. Amazonian communities have traditionally prepared its aromatic vine, bark, roots, sap or related plant material in decoctions and alcoholic macerations.

Clavo Huasca is best known for its traditional association with sensual vitality, physical strength and restorative wellbeing. It also appears in ethnobotanical records for soothing or calming use, memory-related use and ritual strengthening practices.²˒⁷–¹⁰

Unlike Shatavari, Saffron, Brahmi and several other Luminara botanicals, Clavo Huasca does not currently have controlled human clinical evidence supporting these outcomes. Its evidence base consists primarily of documented traditional use, phytochemical studies, laboratory research, one animal anti-inflammatory experiment and university research examining antioxidant, antimicrobial, quality-control and acute-toxicity questions.³–¹⁷

We believe that distinction should be made clear.


CLAVO HUASCA AT A GLANCE

Botanical name: Tynanthus panurensis (Bureau) Sandwith

Botanical family: Bignoniaceae

Older botanical synonym encountered in the literature: Schizopsis panurensis Bureau

Common names: Clavo Huasca, Clavohuasca, Cipó-cravo, clove vine

Growth form: Woody tropical liana or climbing vine

Part used in Luminara: Root

Ingredient form in Luminara: Root powder, not an extract

Luminara daily amount: 800 mg

Standardisation: None

Extract ratio: Not applicable to the supplied whole-root powder

Country of origin of Luminara’s ingredient: Brazil

Key compounds identified in other parts of the species: Eugenol; phenylpropanoid glycosides including verbascoside, isoverbascoside and leucosceptoside; an eugenol triglycoside; the flavonoid glycoside katchimoside; phenols; flavonoids; saponins; coumarins; anthraquinones and other plant constituents.³–⁵

These compounds have mostly been identified in the bark or aromatic cortex and in concentrated extracts. They have not been quantified in Luminara’s root powder. The presence or concentration of a compound in the bark or essential oil cannot automatically be assumed for the root powder.


HOW CLOSELY DOES LUMINARA’S CLAVO HUASCA MATCH THE RESEARCH?

Luminara’s ingredient matches the published literature in one fundamental respect: it is identified as the same botanical species, Tynanthus panurensis.

However, there are important differences between the formula ingredient and most of the available research.

Luminara contains:

• root;
• whole botanical powder;
• 800 mg daily;
• no extract ratio;
• no quantified phytochemical marker.

Most laboratory studies have investigated:

• bark or cortex rather than root;
• methanolic, hydroalcoholic or ethanolic extracts;
• isolated essential oil;
• concentrations applied directly to cells, enzymes or laboratory test systems;
• an extract administered by injection in an animal experiment.

One 2025 acute-toxicity thesis separately examined hydroethanolic extracts of the root, bark and leaves in mice.¹⁷ This provides limited root-specific safety information, but it does not establish human efficacy or equivalence to orally consumed root powder.

No published study located in our search tested 800 mg daily of Tynanthus panurensis root powder in people.

The accurate conclusion is therefore:

Luminara contains the same species used traditionally as Clavo Huasca, but the available laboratory and ethnobotanical research cannot be treated as direct clinical evidence for Luminara’s root powder.


TRADITIONAL USE

Clavo Huasca has a long and culturally significant history of use in Amazonian communities.

Published reviews and ethnobotanical surveys record uses or associations including:

• sensual vitality and aphrodisiac preparations;²˒⁶
• tonic and energising use;²˒⁵
• strengthening and restorative use;⁹
• soothing or calming use;⁷˒⁸
• memory-related use;⁸
• rheumatic or inflammatory complaints;²˒⁵
• inclusion in multi-herb preparations used for sexual potency or general vitality;⁶˒¹⁰
• use in traditional learning, initiation and dieta practices.⁹

These records document how the plant has been used and understood within particular cultures. They do not demonstrate that the plant has produced a clinically verified benefit in controlled human research.

Traditional preparations also differ substantially. They may use the vine stem, stem bark, root, sap or combinations with other plants, and may be prepared in water, alcohol or fermented beverages. A traditional multi-herb maceration is not chemically equivalent to Luminara’s encapsulated root powder.


WHAT HUMAN CLINICAL STUDIES HAVE INVESTIGATED

A broad search of PubMed, scientific journal databases, botanical reviews, institutional repositories and exact-name and synonym searches did not locate a controlled human clinical trial of Tynanthus panurensis alone.

We did not locate human trials assessing Clavo Huasca for:

• female libido or desire;
• female sexual function;
• arousal or vaginal lubrication;
• male erectile function;
• energy or fatigue;
• mood;
• stress;
• memory or cognition;
• pain;
• inflammation;
• rheumatic complaints;
• metabolic health;
• digestive health;
• menopause;
• menstrual wellbeing;
• safety, pharmacokinetics or drug interactions.

This absence of human evidence does not prove that the traditional uses are invalid. It means they have not yet been adequately tested in people.

Claims that Clavo Huasca has been “clinically proven” to increase libido, improve sexual performance, reduce inflammation or produce any other health outcome would not be supported by the presently available literature.


TRADITIONAL SENSUAL VITALITY

Clavo Huasca is widely associated in Amazonian traditional medicine with aphrodisiac beverages and sensual vitality.

It has been recorded as an ingredient in traditional multi-plant alcoholic preparations marketed or consumed for sexual potency, including preparations such as Siete Raíces and other regional mixtures.²˒⁶˒¹⁰

This is meaningful traditional evidence, but it has several limitations:

• the products contain multiple botanicals;
• recipes vary between healers, vendors and communities;
• the amount of Clavo Huasca may not be standardised;
• many preparations use bark rather than root;
• alcohol itself can alter extraction and subjective experience;
• traditional reputation does not establish a physiological effect in a clinical trial.

There are currently no controlled studies demonstrating that Clavo Huasca alone increases sexual desire in women or men.


PHOSPHODIESTERASE-5 RESEARCH

The most directly relevant modern experiment for sexual-function mechanisms was published in 2019.

Researchers analysed two traditional Amazonian male-enhancement beverages and several of their individual botanical ingredients. The study measured inhibition of phosphodiesterase type 5, or PDE5, in a laboratory enzyme assay. PDE5 is one of the biological targets involved in erectile physiology.⁶

At 200 micrograms per millilitre, the two complete traditional mixtures inhibited PDE5 by approximately 49.9% and 27.9%.⁶

The individual Tynanthus panurensis extract showed considerably lower activity: approximately 28.1% inhibition at 200 micrograms per millilitre and 23.0% at 100 micrograms per millilitre, according to the study data subsequently summarised in a review of medicinal-plant PDE5 inhibitors.⁶˒¹⁸

Another ingredient in the mixtures, Campsiandra angustifolia, was much more active in the same assay. The researchers concluded that several ingredients might contribute to the traditional preparation, but additional animal and human research was required.⁶

This study does not show that Clavo Huasca:

• works like a prescription PDE5 inhibitor;
• improves erections in people;
• improves female arousal;
• improves blood flow after oral supplementation;
• increases libido;
• produces the same effect at Luminara’s dose.

It was an in-vitro enzyme experiment using extracted plant material. Sexual desire is also a broader psychological and physiological experience that cannot be reduced to PDE5 activity.


FEMALE SEXUAL WELLBEING

No human study located in our search evaluated Tynanthus panurensis in women.

No study measured:

• the Female Sexual Function Index;
• female desire;
• arousal;
• lubrication;
• orgasm;
• satisfaction;
• sexual distress;
• intimate comfort.

It is therefore appropriate to describe Clavo Huasca as a botanical traditionally associated with sensual vitality.

It is not appropriate to present it as a clinically established female-libido ingredient.


ANIMAL SEXUAL-BEHAVIOUR RESEARCH

We did not locate a published sexual-behaviour experiment involving Tynanthus panurensis itself.

A different species, Tynanthus micranthus, has been studied in male mice for aphrodisiac-related effects. That research cannot be transferred to Tynanthus panurensis. Different species can contain different compounds in different concentrations and may produce different biological effects.¹⁹

The Tynanthus micranthus study is therefore deliberately excluded from the evidence rating for Luminara’s Clavo Huasca.


TRADITIONAL TONIC, ENERGY AND STRENGTHENING USE

A 2011 pharmacological paper described Tynanthus panurensis as traditionally used as a tonic and energiser.⁵

An ethnobotanical investigation of plants used in East-Central Peruvian Amazonian shamanic initiation recorded Tynanthus panurensis among plants used in strengthening practices. Participants described plantas con madre as plants used within strict dieta traditions to teach, guide or strengthen initiates.⁹

These accounts support the description of Clavo Huasca as a traditional strengthening or restorative botanical.

They do not establish that it reduces fatigue, increases physical performance, raises energy metabolism or improves exercise capacity in people.


SOOTHING, CALMING AND MEMORY-RELATED USE

Clavo Huasca has also appeared in ethnobotanical records that are less stimulating in character.

A survey of medicinal plants used in communities along the Rio Jauaperi in the Brazilian Amazon recorded Tynanthus panurensis stem bark as an orally used “soothing” remedy.⁷

A separate study of medicinal exudates used by river-dwelling communities along Brazil’s Unini River recorded sap from Tynanthus panurensis for calming and improving memory.⁸

These records are valuable because they show that traditional use is not uniform. Depending on the community, plant part and preparation, Clavo Huasca may be understood as strengthening, sensual, soothing or cognitively supportive.

No human clinical research has confirmed calming, anti-anxiety, sleep or memory effects.

The apparently different traditional uses may reflect:

• different plant parts;
• water versus alcohol preparations;
• different doses;
• multi-herb combinations;
• cultural context;
• variation in plant chemistry;
• differences between traditional concepts and modern clinical outcomes.


ANTIOXIDANT RESEARCH

Antioxidant activity is one of the better investigated laboratory areas for Tynanthus panurensis, but it remains preclinical.

In 2011, Morales and colleagues examined a methanol-water extract of the bark. The extract contained high measured concentrations of phenols and flavonoids and demonstrated activity in several laboratory antioxidant systems. It scavenged free radicals, inhibited lipid peroxidation and influenced the xanthine/xanthine-oxidase assay.⁵

A 2019 university thesis also tested ethanolic extracts of the bark and outer material using the DPPH laboratory assay. Antioxidant activity increased with concentration, and the researchers quantified phenols, flavonoids, tannins and anthocyanins.¹¹

These experiments demonstrate that concentrated bark extracts contain compounds capable of reacting in laboratory antioxidant tests.

They do not demonstrate that consuming Luminara:

• measurably increases antioxidant capacity in the body;
• prevents oxidative-stress-related disease;
• protects organs or tissues;
• slows ageing;
• produces the same effects from root powder.

No human antioxidant-biomarker study of Clavo Huasca was located.


INFLAMMATORY PATHWAYS

The 2011 Morales study also investigated inflammatory mechanisms.

In cell-based experiments, the bark extract reduced tumour-necrosis-factor-alpha production in stimulated HL-60 cells. It also affected superoxide production and lipid-peroxidation assays.⁵

In an animal experiment, researchers administered the bark extract intraperitoneally to rats at 1 mg per kilogram before inducing paw swelling with carrageenan. The extract significantly inhibited paw oedema during the first three hours. Indomethacin was used as a positive comparison.⁵

This is preliminary biological evidence, not a human clinical result.

The experiment differs from Luminara in several fundamental ways:

• bark extract was used rather than root powder;
• the material was extracted with methanol and water;
• it was injected into the abdomen rather than swallowed;
• the outcome was experimentally induced paw swelling in rats;
• the study did not evaluate women, menopause, pain or chronic inflammatory disease.

Clavo Huasca should not be described as clinically proven to reduce inflammation, treat pain or relieve rheumatic disease.


XANTHINE-OXIDASE RESEARCH

The Morales study reported inhibition in a xanthine/xanthine-oxidase laboratory system. At 200 micrograms per millilitre, the bark extract reduced uric-acid formation by approximately 40.8% and inhibited nitroblue-tetrazolium reduction by approximately 65.7%. Lower concentrations produced smaller effects.⁵

This does not establish that oral Clavo Huasca lowers blood uric acid or treats gout.

The assay is useful for identifying possible biochemical activity, but no animal uric-acid model or human trial was located.


ANTIBACTERIAL RESEARCH

The antibacterial evidence is limited and inconsistent.

A 2019 university thesis tested very high concentrations of ethanolic bark extract against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Small inhibition zones were observed against S. aureus at 1,300–1,700 mg/mL, while no inhibition zones were observed for E. coli or P. aeruginosa. The authors ultimately classified the organisms as resistant to the tested extract.¹²

A 2022 thesis tested separated fractions of ethanolic bark extract. At 1,300 mg/mL, two fractions produced inhibition zones against S. aureus, while other fractions were inactive. None of the fractions inhibited E. coli.¹³

These findings do not support a claim that Clavo Huasca:

• treats infections;
• acts as an antibiotic;
• supports the immune system through antimicrobial activity;
• produces an antibacterial effect after oral consumption.

The studies used highly concentrated bark extracts in laboratory systems and showed weak, selective or negative results.


USE IN TRADITIONAL INFECTIOUS-DISEASE PREPARATIONS

A 2020 ethnobotanical and antimicrobial survey of medicinal plants used in Loreto, Peru, recorded Tynanthus panurensis bark in alcoholic multi-herb preparations known as raíces.¹⁰

This documents inclusion in a traditional preparation. It does not establish that Tynanthus panurensis itself demonstrated clinically meaningful antimicrobial activity.

Traditional-use records and direct laboratory-efficacy results should not be treated as the same type of evidence.


PHYTOCHEMISTRY

The chemistry of Tynanthus panurensis has been investigated mainly in the bark and aromatic cortex.

EUGENOL-RICH AROMATIC OIL

A 2000 analysis of essential oils from Peruvian Amazonian plants reported that the hydrodistilled cortex oil of Tynanthus panurensis was composed almost entirely of eugenol—reported as 99.9% of the volatile oil in that sample.³

This finding helps explain the plant’s characteristic clove-like aroma.

It does not mean that:

• the whole plant is 99.9% eugenol;
• Luminara’s root powder is 99.9% eugenol;
• 800 mg of root powder supplies a known amount of eugenol;
• the biological effects of purified eugenol can be assigned to the finished formula.

The study measured the volatile oil obtained from cortex material, not the full dried botanical.

PHENYLPROPANOID GLYCOSIDES

A 2005 phytochemical study of methanolic bark extract isolated:

• a previously undescribed eugenol triglycoside;
• verbascoside;
• isoverbascoside;
• leucosceptoside;
• katchimoside, an apigenin C-glycoside.⁴

The study characterised these compounds using nuclear-magnetic-resonance and mass-spectrometry techniques and developed an LC-MS approach for quantitative analysis.⁴

Some of these compounds have shown biological activity when studied in isolation or in other plants. However, evidence about an isolated compound cannot establish the effect of Luminara’s Clavo Huasca powder unless the compound is present in a relevant amount and survives digestion and metabolism.

OTHER PHYTOCHEMICAL GROUPS

The 2011 bark-extract study reported saponins together with high concentrations of measured phenols and flavonoids.⁵ A genus review also catalogued reports of alkaloids, coumarins, anthraquinones and related constituents in Tynanthus research.²

A 2014 pharmacognostic thesis examined macroscopic and physicochemical features of Tynanthus panurensis bark and root material, including moisture, ash and solvent-soluble fractions.¹⁴

Luminara’s supplied ingredient is not standardised to eugenol, verbascoside, total phenols or any other marker. Its specific chemical profile therefore remains unknown.


QUALITY, IDENTITY AND PLANT-PART CONSIDERATIONS

Botanical identity and plant part matter particularly for Clavo Huasca.

The name cipó-cravo or “clove vine” is used for more than one aromatic Tynanthus species in South America. Research involving Tynanthus micranthus, Tynanthus polyanthus, Tynanthus guatemalensis or another species cannot be treated as evidence for Tynanthus panurensis.

Similarly, research on the bark cannot automatically be treated as research on the root.

A 2014 pharmacognostic study documented macroscopic and physicochemical features of root and bark samples, highlighting the need for appropriate botanical and quality specifications.¹⁴

For the internal substantiation record, stronger authentication than visual inspection alone would be preferable, such as:

• a qualified botanical identification;
• a reference voucher or authenticated raw-material source;
• chromatographic fingerprinting;
• microscopic authentication;
• or another validated identity method appropriate to the material.

This is a quality-control issue rather than proof of efficacy.


HEAVY-METAL RESEARCH

Wild botanical materials can vary according to soil and growing conditions.

A 2015 thesis measured metals in root, bark and leaves of Tynanthus panurensis collected from locations in the Loreto region. The study reported that cadmium exceeded the authors’ referenced maximum in the samples assessed, while lead remained below the cited limit.¹⁵

A broader 2016 doctoral study of twelve medicinal barks sold or used in Iquitos also reported Tynanthus panurensis among species exceeding the study’s cadmium threshold. All twelve barks in that investigation exceeded the authors’ cited arsenic limit.¹⁶

These findings do not mean that all Clavo Huasca is contaminated. They demonstrate why contaminant testing must be performed on each commercial batch rather than inferred from the botanical name.

The supplied Luminara raw-material document reported heavy-metal results within its stated limits for the batch tested. However, future production should rely on a current batch-specific certificate rather than an older document.


ACUTE-TOXICITY RESEARCH

A 2025 university thesis evaluated hydroethanolic extracts prepared separately from Tynanthus panurensis root, bark and leaves in female Balb/C mice. Doses of 25, 200 and 2,000 mg/kg were assessed.¹⁷

No animals died at the highest tested dose, leading the authors to classify the median lethal dose as greater than 2,000 mg/kg.¹⁷

That result suggests low acute lethality under the conditions of the experiment.

However, the same research reported observations that prevent the study from being interpreted as proof of complete safety:

• changes in behaviour, including irritability, passivity or sedation in some groups;
• altered respiratory observations;
• less favourable body-weight changes than the control group;
• some biochemical values outside reference ranges;
• vascular or tissue alterations in a proportion of the examined histological sections.¹⁷

The study was:

• conducted in mice rather than people;
• an acute study rather than a long-term exposure study;
• performed with hydroethanolic extracts rather than whole root powder;
• submitted as a university thesis rather than replicated peer-reviewed clinical research.

No chronic-toxicity, reproductive-toxicity, genotoxicity, pregnancy or human interaction studies of Tynanthus panurensis were located.


EVIDENCE STRENGTH


HOW WE RATE THE EVIDENCE

★★★★★ — Strong

Multiple high-quality human trials and/or systematic reviews with reasonably consistent findings, relevant preparations and meaningful replication.

★★★★☆ — Good

More than one relevant controlled human trial with encouraging or broadly consistent findings, but with limitations such as modest samples, proprietary extracts or limited independent replication.

★★★☆☆ — Emerging

At least one controlled human study showing a relevant benefit, with further confirmation required.

★★☆☆☆ — Preliminary

Limited, mixed or indirect human evidence, including combination studies or very small clinical investigations.

★☆☆☆☆ — Traditional or preclinical

Traditional use, laboratory research or animal evidence without adequate standalone human clinical confirmation.

Because no controlled human trial of Tynanthus panurensis was located, every current Clavo Huasca outcome remains within the one-star traditional or preclinical category. The strength and relevance within that category still differ substantially.


HEALTH AREA | EVIDENCE STRENGTH | CURRENT ASSESSMENT

Traditional sensual vitality | ★☆☆☆☆ | Repeated traditional association and use in multi-herb aphrodisiac preparations; no standalone human trial

Female libido or sexual function | ★☆☆☆☆ | Traditional reputation only; no female clinical evidence

PDE5 inhibition or erectile physiology | ★☆☆☆☆ | Low-to-moderate activity in one in-vitro bark-extract assay; no animal or human efficacy

Tonic, energy and strengthening use | ★☆☆☆☆ | Traditional and ethnobotanical evidence only

Soothing or calming use | ★☆☆☆☆ | Documented in ethnobotanical surveys; no clinical confirmation

Memory support | ★☆☆☆☆ | One ethnobotanical record involving sap; no cognitive study

Antioxidant activity | ★☆☆☆☆ | Bark extracts active in laboratory assays; no human biomarker evidence

Inflammatory pathways | ★☆☆☆☆ | Cell experiments and one injected bark-extract rat experiment

Pain or rheumatic support | ★☆☆☆☆ | Traditional use plus indirect preclinical inflammatory data; no human trial

Xanthine-oxidase activity | ★☆☆☆☆ | One laboratory assay; no evidence for blood uric acid or gout

Antibacterial activity | ★☆☆☆☆ | Weak, inconsistent and high-concentration laboratory evidence

Digestive wellbeing | ★☆☆☆☆ | Traditional reports only; no direct clinical study

Acute safety | ★☆☆☆☆ | One mouse thesis suggests low acute lethality but reports behavioural, biochemical and histological observations

Long-term human safety | ★☆☆☆☆ | Not established


WHAT THE KEY STUDIES FOUND


LECLERCQ ET AL., 2000³

Design: Phytochemical analysis of volatile oils from several Peruvian Amazonian plants.

Plant material: Tynanthus panurensis cortex.

Method: Hydrodistillation followed by gas chromatography and gas chromatography–mass spectrometry.

Key finding: Eugenol accounted for 99.9% of the analysed cortex essential oil.

Why it matters: It explains the characteristic clove-like aroma and identifies a major volatile constituent of the cortex oil.

Limitations: This was not an efficacy or safety study. Cortex essential oil is not equivalent to whole root powder, and the result cannot be used to calculate Luminara’s eugenol content.


PLAZA ET AL., 2005⁴

Design: Phytochemical isolation and LC-MS quantitative analysis.

Plant material: Methanolic bark extract.

Key findings: Researchers identified a new eugenol triglycoside together with verbascoside, isoverbascoside, leucosceptoside and katchimoside.

Why it matters: It provides the clearest detailed chemical characterisation of Tynanthus panurensis bark.

Limitations: It did not test a health outcome, and the compounds were not quantified in Luminara’s root powder.


MORALES ET AL., 2011⁵

Design: Laboratory antioxidant and inflammation-related experiments plus an animal paw-oedema model.

Plant material: Powdered bark extracted with methanol and water in a 4:1 ratio.

Key laboratory findings:

• high measured phenol and flavonoid content;
• radical-scavenging activity;
• inhibition of lipid peroxidation;
• activity in xanthine/xanthine-oxidase assays;
• reduced tumour-necrosis-factor-alpha production in stimulated cells.

Animal experiment: Rats received the extract intraperitoneally at 1 mg/kg before carrageenan-induced paw swelling.

Animal finding: Paw oedema was significantly inhibited during the first three hours.

Why it matters: It demonstrates genuine preclinical biological activity in bark extract.

Limitations: No humans; bark rather than root; concentrated extracted material; injection rather than oral dosing; short-term experimental inflammation rather than a clinical condition.


SCHMEDA-HIRSCHMANN ET AL., 2019⁶

Design: Chemical analysis and in-vitro PDE5 testing of two traditional Amazonian male-enhancement beverages and their individual plant ingredients.

Plant material: Extracts from traditional preparations and individual crude botanicals, including Tynanthus panurensis.

Key findings:

• the complete mixtures inhibited PDE5 in vitro;
• Tynanthus panurensis alone showed lower PDE5 inhibition than the most active botanical in the blends;
• no sildenafil adulteration was detected;
• the authors stated that further animal research was required.

Why it matters: This is the closest modern study to Clavo Huasca’s traditional sexual-vitality reputation.

Limitations: In-vitro enzyme assay; male erectile target rather than libido; no human participants; no female outcomes; multi-herb preparations; no equivalence to 800 mg root powder.


PEDROLLO ET AL., 2016⁷

Design: Ethnobotanical survey in five Rio Jauaperi river communities in the Brazilian Amazon.

Record for Clavo Huasca: Tynanthus panurensis stem bark was recorded as an orally used soothing remedy.

Why it matters: It provides peer-reviewed documentation of a calming traditional use.

Limitations: It records community use rather than measuring efficacy or safety.


LAGO ET AL., 2016⁸

Design: Ethnobotanical and chemical-classification study of medicinal exudates used by river-dwelling communities along the Unini River in Brazil.

Record for Clavo Huasca: Tynanthus panurensis sap was associated with calming and improving memory.

Why it matters: It documents an additional traditional nervous-system use and demonstrates that different preparations may be used for different purposes.

Limitations: No clinical outcome was measured, and sap is chemically different from root powder.


JAUREGUI ET AL., 2011⁹

Design: Ethnobotanical investigation involving healers, apprentices and herbalists in East-Central Peruvian Amazonian communities.

Record for Clavo Huasca: Bark and trunk decoction was used orally within the category of strengthening plants and in planta-con-madre or dieta traditions.

Why it matters: It documents the plant’s cultural role beyond simple commercial aphrodisiac language.

Limitations: The study examined traditional knowledge and ritual practice, not clinical efficacy.


ROUMY ET AL., 2020¹⁰

Design: Ethnobotanical inventory and laboratory antimicrobial evaluation of medicinal plants used in Loreto, Peru.

Record for Clavo Huasca: Tynanthus panurensis bark was documented in alcoholic multi-herb raíz preparations.

Why it matters: It confirms continuing use within regional multi-ingredient medicine.

Limitations: Inclusion in a traditional preparation is not evidence that Clavo Huasca alone produced antimicrobial or clinical benefit.


GONZALES TAMANI AND HOYOS MORENO, 2019¹¹

Design: University laboratory thesis.

Plant material: Bark and outer plant material extracted using ethanol with formic acid.

Key findings:

• concentration-dependent DPPH antioxidant activity;
• measured phenols, flavonoids, tannins and anthocyanins.

Why it matters: It adds laboratory support for antioxidant constituents.

Limitations: Non-clinical university thesis; bark rather than root powder; chemical assay rather than a health outcome.


CÁRDENAS RIVERA AND LÓPEZ ROJAS, 2019¹²

Design: In-vitro antibacterial university thesis.

Plant material: Ethanolic bark extract.

Microorganisms: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Key findings:

• small inhibition zones against S. aureus at extremely high extract concentrations;
• no inhibition zones against E. coli or P. aeruginosa;
• the authors classified the tested organisms as resistant to the extract under the study conditions.

Why it matters: It provides important negative and mixed evidence that should not be omitted.

Limitations: Very high laboratory concentrations; no relevance to oral dosing or infection treatment.


ROMERO VALLES, 2022¹³

Design: In-vitro antibacterial university thesis.

Plant material: Fractions of ethanolic bark extract.

Key findings:

• two fractions inhibited S. aureus at a very high tested concentration;
• two fractions were inactive;
• none of the fractions inhibited E. coli.

Why it matters: It suggests that any antibacterial activity may be restricted to particular extracted fractions and organisms.

Limitations: Laboratory-only evidence, very high concentrations and no relevance to human infection treatment.


RUÍZ AÑAPE AND SANTILLÁN RUÍZ, 2014¹⁴

Design: Pharmacognostic study of Tynanthus panurensis and another Amazonian species.

Plant material: Root and bark.

Key findings: Researchers documented macromorphological and physicochemical quality parameters, including foreign matter, moisture, ash and water- and alcohol-soluble extractives.

Why it matters: It contributes to raw-material identification and quality-control knowledge and includes root-specific measurements.

Limitations: It did not investigate efficacy or safety.


GARCÍA PAIMA AND URIBE GONZALES, 2015¹⁵

Design: Descriptive metal-content study.

Plant material: Root, bark and leaves collected in the Loreto region.

Key finding: Cadmium concentrations exceeded the authors’ cited maximum in the samples assessed, while lead was below the cited limit.

Why it matters: It demonstrates that contaminant levels can vary in wild material and supports batch-specific testing.

Limitations: Regional environmental samples do not predict the contaminant content of every commercial batch.


SOSA AMAY, 2016¹⁶

Design: Doctoral study measuring cadmium, lead, mercury and arsenic in twelve Amazonian medicinal barks.

Key findings relevant to Clavo Huasca:

• Tynanthus panurensis was among the barks exceeding the study’s cadmium threshold;
• none of the twelve species exceeded the cited lead threshold;
• all twelve barks exceeded the authors’ cited arsenic threshold.

Why it matters: It independently reinforces the need for contaminant control of wild-harvested medicinal barks.

Limitations: It involved bark samples from a particular market or region and does not establish contamination in Luminara’s tested root ingredient.


TENAZOA GOMEZ AND NUÑEZ SANCHEZ, 2025¹⁷

Design: Acute-toxicity university thesis in female Balb/C mice.

Plant material: Separate hydroethanolic extracts of root, bark and leaves.

Doses: 25, 200 and 2,000 mg/kg.

Key finding: No deaths occurred at 2,000 mg/kg, so the authors estimated the median lethal dose to be above that level.

Other observations: Behavioural, respiratory, weight, biochemical, vascular and tissue changes were reported in portions of the experimental groups or histological sections.

Why it matters: It is the only direct root-specific experimental safety research located and suggests low acute lethality.

Limitations: Mouse study; acute only; hydroethanolic extract rather than root powder; no chronic, reproductive or human safety conclusions.


CANSIAN ET AL., 2015²

Design: Review of chemistry and biological research across the Tynanthus genus.

Key contribution: The review brought together the limited traditional, chemical and pharmacological evidence available for Tynanthus species and identified significant research gaps.

Why it matters: It confirms that the scientific literature on Tynanthus panurensis is sparse and heavily preclinical.

Limitations: A review does not create new efficacy evidence, and studies involving other Tynanthus species cannot substantiate Luminara’s ingredient.


HOW CLAVO HUASCA MAY WORK

There is no established human mechanism for Clavo Huasca.

Several possible biological pathways have been suggested by chemical and laboratory studies.

PHENOLIC AND FLAVONOID ACTIVITY

Bark extracts contain phenolic and flavonoid compounds capable of reacting in antioxidant laboratory assays.⁵˒¹¹

This may contribute to some observed preclinical effects, but oral absorption, metabolism and effective human concentrations have not been established.

PHENYLPROPANOID GLYCOSIDES

Verbascoside, isoverbascoside, leucosceptoside and an eugenol glycoside have been identified in bark.⁴

These compounds have been studied in broader pharmacological literature, but their activity elsewhere cannot be assumed to represent the effect of Clavo Huasca root powder.

EUGENOL

The aromatic cortex essential oil in one sample was dominated by eugenol.³

Eugenol has known biological activity, but Luminara’s root powder has not been assayed for eugenol. It would be inappropriate to calculate or claim an eugenol dose based on the cortex-oil study.

PDE5 INHIBITION

A bark-derived preparation showed modest inhibition of PDE5 in vitro.⁶˒¹⁸

Whether relevant compounds are absorbed at sufficient concentrations after oral root-powder consumption is unknown. PDE5 inhibition also relates more directly to erectile physiology than to female desire or overall sexual wellbeing.

INFLAMMATORY AND OXIDATIVE-STRESS PATHWAYS

Laboratory and animal experiments suggest that concentrated bark extract can influence free-radical systems, lipid peroxidation, TNF-alpha production and acute inflammatory swelling.⁵

No human evidence has established that these mechanisms operate after consuming the root powder used in Luminara.


SAFETY AND RESPONSIBLE USE

Human safety data for Tynanthus panurensis are extremely limited.

No controlled human study was located that established:

• a safe therapeutic dose;
• long-term tolerability;
• medication interactions;
• effects during pregnancy;
• effects during breastfeeding;
• reproductive safety;
• liver or kidney safety during continued use;
• safety in hormone-sensitive conditions;
• safety in people using blood-pressure, anticoagulant, sedative, diabetes or sexual-function medicines.

One mouse study found no acute deaths at hydroethanolic-extract doses up to 2,000 mg/kg, but reported behavioural, biochemical and histological observations that require further investigation.¹⁷ Low acute mortality is not equivalent to proof of long-term human safety.

Because traditional records include both energising and calming uses, it is not possible to predict reliably whether the botanical could feel stimulating, sedating or neutral in an individual.

People who are pregnant, breastfeeding, taking prescription medication or managing a medical condition should consult a qualified healthcare professional before using Luminara.

Any unusual reaction should prompt discontinuation and appropriate professional advice.


PLAIN-ENGLISH SUMMARY

Clavo Huasca is a culturally significant Amazonian vine with a long traditional association with sensual vitality, strength and restoration.

Ethnobotanical studies also record soothing, calming, memory-related and ritual strengthening uses.⁷–⁹ Its bark contains interesting compounds, including eugenol-rich aromatic oil and several phenylpropanoid glycosides.³˒⁴ Concentrated bark extracts have demonstrated antioxidant and inflammation-related activity in laboratory and animal experiments.⁵

However, no controlled human clinical trial of Tynanthus panurensis alone was located.

The closest modern sexual-function research is an in-vitro PDE5 experiment involving traditional multi-herb male-enhancement preparations. Clavo Huasca alone produced relatively modest enzyme inhibition, and the study did not test sexual desire, female sexual function or outcomes in people.⁶

Luminara contains 800 mg daily of Tynanthus panurensis root powder. Most published chemical and biological research has used extracted bark or cortex, so direct equivalence cannot be claimed.

Clavo Huasca should therefore be presented as:

• a traditional Amazonian sensual-vitality botanical;
• a traditional strengthening and restorative ingredient;
• a botanical with interesting early phytochemical and preclinical research;
• an ingredient whose clinical efficacy has not yet been established.

It should not be described as clinically proven to increase libido, improve arousal, enhance erections, reduce inflammation, treat pain, fight infection or deliver any other medical outcome.

Within Luminara, Clavo Huasca contributes traditional and cultural depth to the formula, while other ingredients provide the stronger human clinical evidence for mood, stress, sexual wellbeing and hormonal transitions.


REFERENCES

1. Royal Botanic Gardens, Kew. Tynanthus panurensis (Bureau) Sandwith. Plants of the World Online. Accessed 1 August 2026.

2. Cansian FC, Zortéa Merino FJ, Dias JFG, Zanin SMW, Miguel OG, Miguel MD. Chemical review and studies related to species from the genus Tynanthus (Bignoniaceae). Brazilian Journal of Pharmaceutical Sciences. 2015;51(3):515–523. doi:10.1590/S1984-82502015000300003.

3. Leclercq PA, Delgado HS, Garcia J, Hidalgo JE, Cerrutti T, Mestanza M, Ríos F, Nina E, Nonato L, Alvarado R, Menéndez R. Aromatic plant oils of the Peruvian Amazon. Part 2: Cymbopogon citratus (DC) Stapf., Renealmia sp., Hyptis recurvata Poit. and Tynanthus panurensis (Bur.) Sandw.. Journal of Essential Oil Research. 2000;12(1):14–18. doi:10.1080/10412905.2000.9712030.

4. Plaza A, Montoro P, Benavides A, Pizza C, Piacente S. Phenylpropanoid glycosides from Tynanthus panurensis: characterization and LC-MS quantitative analysis. Journal of Agricultural and Food Chemistry. 2005;53(8):2853–2858. doi:10.1021/jf0479867. PMID: 15826030.

5. Morales L, Acero N, Galán A, Perez-García C, Alguacil LF, Muñoz-Mingarro D. Bioactive properties of Tynanthus panurensis (Bureau) Sanwith bark extract, the Amazonian “Clavo Huasca”. Journal of Medicinal Food. 2011;14(9):939–943. doi:10.1089/jmf.2010.0171. PMID: 21488753.

6. Schmeda-Hirschmann G, Burgos-Edwards A, Theoduloz C, Jiménez-Aspee F, Vargas-Arana G. Male sexual enhancers from the Peruvian Amazon. Journal of Ethnopharmacology. 2019;229:167–179. doi:10.1016/j.jep.2018.10.007.

7. Pedrollo CT, Kinupp VF, Shepard G Jr, Heinrich M. Medicinal plants at Rio Jauaperi, Brazilian Amazon: ethnobotanical survey and environmental conservation. Journal of Ethnopharmacology. 2016;186:111–124. doi:10.1016/j.jep.2016.03.055. PMID: 27058631.

8. Lago JHG, Tezoto J, Yazbek PB, Cassas F, Santos JFL, Rodrigues E. Exudates used as medicine by the “caboclos river-dwellers” of the Unini River, AM, Brazil – classification based in their chemical composition. Revista Brasileira de Farmacognosia. 2016;26(3):379–384. doi:10.1016/j.bjp.2016.03.001.

9. Jauregui X, Clavo ZM, Jovel EM, Pardo-de-Santayana M. “Plantas con madre”: plants that teach and guide in the shamanic initiation process in the East-Central Peruvian Amazon. Journal of Ethnopharmacology. 2011;134(3):739–752. doi:10.1016/j.jep.2011.01.042. PMID: 21295130.

10. Roumy V, Ruiz Macedo JC, Bonneau N, Samaillie J, Azaroual N, Arévalo Encinas L, Rivière C, Hennebelle T, Sahpaz S, Anthérieu S, Pinçon C, Neut C, Siah A, Gutierrez-Choquevilca AL, Ruiz L. Plant therapy in the Peruvian Amazon (Loreto) in case of infectious diseases and its antimicrobial evaluation. Journal of Ethnopharmacology. 2020;249:112411. doi:10.1016/j.jep.2019.112411. PMID: 31751651.

11. Gonzales Tamani CM, Hoyos Moreno LG. Actividad antioxidante y determinación de compuestos fenólicos de la corteza y cáscara de Tynanthus panurensis (Clavo Huasca). Bachelor’s thesis. Universidad Nacional de la Amazonía Peruana; 2019.

12. Cárdenas Rivera CK, López Rojas AL. Actividad antibacteriana in vitro del extracto etanólico de la corteza de Tynanthus panurensis (Clavo Huasca) frente a Staphylococcus aureus, Escherichia coli y Pseudomonas aeruginosa. Bachelor’s thesis. Universidad Nacional de la Amazonía Peruana; 2019.

13. Romero Valles DM. Actividad antibacteriana in vitro de las fracciones del extracto etanólico de la corteza de Tynanthus panurensis (Clavo Huasca). Bachelor’s thesis. Universidad Nacional de la Amazonía Peruana; 2022.

14. Ruíz Añape MA, Santillán Ruíz N. Características farmacognósticas de las especies amazónicas Maytenus macrocarpa (R. & P.) Briq., y Tynanthus panurensis (Bur.) Sandw. Iquitos - 2012. Bachelor’s thesis. Universidad Nacional de la Amazonía Peruana; 2014.

15. García Paima TR, Uribe Gonzales RB. Evaluación de metales de la especie Tynanthus panurensis (Clavo Huasca), de uso etnoterapéutico en la Región Loreto. Bachelor’s thesis. Universidad Nacional de la Amazonía Peruana; 2015.

16. Sosa Amay FE. Evaluación de metales pesados en recursos terapéuticos vegetales de la ciudad de Iquitos. Doctoral thesis. Universidad Nacional de Trujillo; 2016. Repository record: handle 20.500.14414/7726.

17. Tenazoa Gomez JD, Nuñez Sanchez BL. Toxicidad aguda del extracto hidroetanólico de Tynantus panurensis (clavo huasca) en Mus musculus cepa Balb C. Bachelor’s thesis. Universidad Nacional de la Amazonía Peruana; 2025.

18. Anand Ganapathy A, Hari Priya VM, Kumaran A. Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review. Journal of Ethnopharmacology. 2021;267:113536. doi:10.1016/j.jep.2020.113536. PMID: 33137431.

19. Cansian FC, Zortéa Merino FJ, Lângaro Amaral VL, Salvador RA, Campos PM, Montrucchio DP, Miguel OG, Miguel MD. Aphrodisiac properties of Tynanthus micranthus Corr. & Mello ex. Schum in male mice. African Journal of Pharmacy and Pharmacology. 2014;8(47):1200–1204. doi:10.5897/AJPP2014.4149. [Different Tynanthus species; included only to substantiate the exclusion discussed in the Evidence Centre.]


These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

DAMIANA

TURNERA DIFFUSA WILLD. EX SCHULT.

Damiana is an aromatic shrub native to Mexico, Central America, the Caribbean and parts of South America. It belongs to the Passifloraceae family and has a long history of traditional use for sensual vitality, nervous-system wellbeing, physical energy and digestive comfort.¹–³

Its leaves contain a chemically diverse mixture of flavonoids, terpenoids, phenolic compounds, arbutin, volatile constituents and cyanogenic glycosides. Investigations have identified compounds including apigenin, acacetin, pinocembrin, luteolin and quercetin derivatives, arbutin and a number of Damiana-specific compounds.⁴–⁶

The modern evidence is much more nuanced than the common description of Damiana as an “aphrodisiac.”

One published observational human study has evaluated a standalone Damiana leaf extract in women experiencing reduced sexual desire. It reported improvements in overall female sexual function, all six Female Sexual Function Index domains and sexual distress after eight weeks. However, it had no placebo group, only 35 of 70 enrolled women were included in the reported evaluable analysis, and it used a different extract and dose from Luminara.⁷

Damiana has also appeared in human trials of multi-ingredient formulas for female and male sexual function, menopausal wellbeing, appetite and weight management. Some reported benefits, while one important cancer-survivor trial did not find improved sexual function. Because these products contained several active ingredients, none establishes Damiana’s independent effect.⁸–²¹

A much larger preclinical literature has investigated sexual behaviour, nitric-oxide and smooth-muscle pathways, aromatase, mood-related activity, metabolism, liver and kidney models, neurological pathways, pain, inflammation, antioxidants, skin biology, antimicrobial activity and safety.²²–⁷⁷ These findings explain scientific interest in the plant, but laboratory and animal results are not equivalent to demonstrated benefits in people.


DAMIANA AT A GLANCE

Botanical name: Turnera diffusa Willd. ex Schult.
Botanical family: Passifloraceae
Older family name often used in studies: Turneraceae
Common name: Damiana; Mexican Damiana
Part used in Luminara: Leaf
Ingredient form: Leaf extract powder
Luminara daily amount: 500 mg
Supplier-specified extract ratio: 4:1
Country of origin: China
Identity method on the supplied specification: TLC
Chemical standardisation: None stated
Extraction solvent: Not stated
Carrier or excipient content: Not stated

The supplier document describes a Turnera diffusa leaf extract with a 4:1 ratio. It is a specification sheet rather than a batch-specific certificate showing actual production-batch results. It does not identify the extraction solvent, native extract ratio, carrier percentage or a quantified chemical marker.

A 4:1 ratio is sometimes interpreted as four parts dried botanical used to produce one part extract. If confirmed as the native dry-extract ratio with no relevant dilution, 500 mg could nominally represent material derived from 2,000 mg of dried leaf. The current document does not provide enough information to make that equivalence claim publicly.

The accurate description is therefore 500 mg of a 4:1 Damiana leaf extract—not a clinically proven or directly study-matched dose.


HOW CLOSELY DOES LUMINARA’S DAMIANA MATCH THE HUMAN RESEARCH?

The 2021 standalone human study and Luminara use the same species and plant part: Turnera diffusa leaf.⁷

The study used 675 mg daily of a traditional herbal medicinal product made from dry Damiana leaf extract. Available product information describes the extract as approximately 5–7:1 and produced with 90% ethanol.⁷

Luminara provides 500 mg daily of a supplier-specified 4:1 extract, with no solvent or marker stated.

Direct equivalence cannot be claimed because:

• the daily extract mass differs;
• the extraction ratio differs;
• the extraction solvent is not known to match;
• neither preparation has been shown to have the same flavonoid or marker profile;
• the human study was observational rather than randomised and placebo controlled.

A new randomised, double-blind, placebo-controlled trial registered in 2026 is testing 500 mg daily of a standardised Turnera diffusa extract for eight weeks in healthy adults reporting low sexual desire. Planned measures include the Female Sexual Function Index, Sexual Desire Inventory, male sexual-function measures and safety. Results had not been published when this review was completed on 1 August 2026.⁶⁷

The trial’s nominal 500 mg dose matches Luminara, but it uses a proprietary standardised extract. A matching milligram number does not establish compositional equivalence, and an ongoing trial provides no evidence of effectiveness.


BOTANICAL IDENTITY MATTERS

“Damiana” is sometimes applied incorrectly to other plants, particularly Turnera ulmifolia, known as false Damiana.

A pharmacognostic investigation showed that T. diffusa could be distinguished from false Damiana using morphology, fluorescence, scanning-electron microscopy, HPTLC and UPLC.⁴

Species substitution matters because related plants can differ in chemistry, traditional use, biological activity and safety.

Luminara’s supplier specification identifies Turnera diffusa and lists TLC as the identity method. A current batch-specific chromatographic fingerprint and actual conformity result would provide stronger substantiation.


TRADITIONAL USE

Damiana has a long history in Mexican, Central American and Caribbean herbal practice. Traditional uses and associations include:

• sensual vitality and aphrodisiac use;
• sexual desire;
• nervous tension and emotional relaxation;
• low mood;
• energy and restorative use;
• menstrual and reproductive wellbeing;
• digestive discomfort;
• urinary and general tonic use.¹–³

Traditional preparations include teas, infusions, tinctures, liqueurs and other extracts.

Traditional use documents historical practice. It does not establish a particular clinical benefit in a controlled human trial.


HUMAN CLINICAL EVIDENCE

STANDALONE DAMIANA IN WOMEN WITH REDUCED SEXUAL DESIRE

The most directly relevant published human evidence is a 2021 prospective, multicentre, non-interventional study of a traditional Damiana leaf-extract medicine.⁷

Seventy women were enrolled. The published evaluable analysis included 35 women with a mean age of 46.1 years who took 675 mg daily for eight weeks.

Significant improvements were reported in:

• total Female Sexual Function Index score;
• desire;
• arousal;
• lubrication;
• orgasm;
• satisfaction;
• pain;
• Female Sexual Distress Scale–Revised score.

Quality of life showed a favourable trend.⁷

This matters because it evaluated Damiana alone and used validated female sexual-function measures.

Its limitations are substantial:

• no placebo or untreated group;
• no randomisation or blinding;
• only 35 of 70 enrolled women were included in the reported evaluable analysis;
• expectation, behavioural change, natural fluctuation and regression to the mean cannot be excluded;
• the extract differs from Luminara’s;
• causation cannot be established.

Evidence-based conclusion: Early observational human evidence suggests that one specific Damiana leaf extract may support overall female sexual function and reduce sexual distress. Randomised placebo-controlled confirmation is required.

ONGOING RANDOMISED STANDALONE TRIAL

ISRCTN12819093 was registered in 2026 as a prospective, randomised, double-blind, placebo-controlled study of 500 mg daily of standardised Turnera diffusa extract versus placebo for eight weeks in adults with low sexual desire.⁶⁷

No results were available by 1 August 2026. Trial registration is not evidence of benefit.

CONFERENCE AND UNPUBLISHED EVIDENCE

A 2011 conference poster was later cited as an eight-week investigation of a 60% ethanol Damiana extract in men with mild erectile concerns.⁶⁸ A sufficiently detailed peer-reviewed report was not located. It is recorded internally but not used to substantiate a clinical claim.

Manufacturer materials have also referred to a consumer study of a branded Damiana extract. No complete peer-reviewed publication was located, so those marketing results are excluded from the evidence rating.


FEMALE SEXUAL FUNCTION: MULTI-INGREDIENT HUMAN STUDIES

These studies are indirect evidence only.

ARGINMAX, 2001

A double-blind placebo-controlled study of 77 women evaluated a combination of L-arginine, ginseng, ginkgo, Damiana, vitamins and minerals. After four weeks, 73.5% of the active group reported improved overall sexual satisfaction compared with 37.2% receiving placebo.⁸

The result applies to the formula, not Damiana alone.

ARGINMAX BY MENOPAUSAL STATUS, 2006

A randomised double-blind placebo-controlled study included 108 premenopausal, perimenopausal and postmenopausal women. Benefits varied by menopause status, with improvements reported in desire, satisfaction and other domains in selected subgroups.⁹

Damiana’s independent contribution cannot be determined.

ARGINMAX IN FEMALE CANCER SURVIVORS, 2015

A 12-week randomised placebo-controlled trial in female cancer survivors did not find a significant sexual-function benefit. Overall quality of life was better in the active group at 12 weeks.¹⁰

This negative sexual-function result is important and prevents the combination literature from being presented as uniformly positive.

LIBICARE, 2019

An uncontrolled pilot study enrolled 29 postmenopausal women aged 45–65. Participants took a formula containing fenugreek, Damiana, ginkgo and tribulus for approximately two months. Total FSFI and all domains except pain improved, and 86.2% recorded an improved total score. Selected testosterone and sex-hormone-binding-globulin values also changed.¹¹

The study was small, uncontrolled and multi-ingredient. A later randomised Libicare trial was registered but withdrawn without confirmatory results.⁶⁹


MALE SEXUAL FUNCTION: MULTI-INGREDIENT HUMAN STUDIES

A small 1998 open-label ArginMax pilot in men reported improvements in erection maintenance and satisfaction among completers.¹²

A 2012 randomised, double-blind, placebo-controlled study evaluated VigRx Plus in 78 men with mild-to-moderate erectile dysfunction. The active multi-herb formula improved erectile and secondary IIEF domains compared with placebo, while sperm parameters and testosterone did not meaningfully change.¹³

Neither study isolates Damiana.


MENOPAUSAL WELLBEING: COMBINATION EVIDENCE

A 2011 randomised, double-blind, placebo-controlled study evaluated Lady 4 in 120 women aged 45–60. The formula contained evening primrose oil, Damiana, ginseng and royal jelly. After four weeks, the active formula improved Menopause Rating Scale scores more than placebo.¹⁴

No standalone human study was located testing Damiana for:

• hot flushes or night sweats;
• menopausal vaginal dryness;
• menopausal mood or sleep;
• PMS;
• menstrual discomfort;
• “hormone balance.”

Damiana should not be presented as a clinically established menopause or hormonal-support ingredient.


APPETITE AND WEIGHT-MANAGEMENT COMBINATION STUDIES

Damiana is one component of YGD or Zotrim, a mixture of yerba mate, guarana and Damiana.

A 2001 study reported delayed gastric emptying, greater fullness and weight loss with the mixture.¹⁵

Uncontrolled consumer and prospective studies reported reductions in weight, BMI, waist or hip measurements and changes in hunger, snacking and satiety.¹⁶˒¹⁷

A randomised double-blind within-participant study in overweight women found acute changes in energy intake and selected appetite measures after the mixture, with or without inulin.¹⁸

A small crossover study in overweight or obese women reported reduced food intake and increased GLP-1 measures.¹⁹ A related conference abstract may represent preliminary or overlapping work.²⁰

All of these studies used yerba mate and guarana with Damiana. They do not show that Damiana alone suppresses appetite, raises GLP-1 or causes weight loss.

Luminara is not a weight-management product.


EVIDENCE FROM ANIMAL AND LABORATORY RESEARCH

SEXUAL BEHAVIOUR

Damiana fluid extract improved selected sexual-behaviour measures in sexually sluggish or impotent male rats but had little effect in already potent rats.²²

An aqueous extract restored sexual behaviour in a proportion of sexually exhausted male rats.²³

A later rat study suggested that nitric-oxide signalling contributed to prosexual effects.²⁴

These are specialised male-animal models, not evidence of female or human benefit.

SMOOTH MUSCLE AND PDE5

Dichloromethane and methanol extracts relaxed pre-contracted guinea-pig corpus-cavernosum tissue in vitro.²⁵

A 2010 conference study reported PDE5 inhibition by Damiana extracts and fractions.²⁶

A 2026 laboratory study of a proprietary standardised extract identified 49 compounds and reported reduced PDE5 expression, aromatase inhibition and a moderate nitric-oxide increase in experimental models.²⁷

None demonstrates that Luminara works like sildenafil, increases libido or produces clinically meaningful genital blood-flow effects.

AROMATASE AND HORMONE-RELATED PATHWAYS

Methanolic leaf extract and isolated compounds including pinocembrin and acacetin inhibited aromatase in vitro. Selected constituents also showed estrogen-receptor activity in laboratory assays.²⁸

An earlier screen reported progesterone-receptor binding but did not establish a clear functional hormone effect.²⁹

These studies do not show that Damiana balances hormones, raises testosterone or lowers oestrogen in people.

ANXIETY, MOOD AND ADAPTOGENIC RESEARCH

Homeopathic Damiana preparations produced anxiety-related behavioural changes in mice, but homeopathic dilutions are not comparable with a botanical extract.³⁰

Methanolic extracts and isolated apigenin produced anxiolytic-like and analgesic effects in animal models.³¹

A 2019 mouse study reported acute anxiolytic-like effects; a single dose did not produce an antidepressant-like effect, while repeated high-dose administration reduced immobility in a forced-swim test.²¹

A 2011 adaptogenic study produced mixed results and did not establish a broad adaptogenic effect.³²

Acacetin 7-methyl ether isolated from Damiana selectively inhibited human MAO-B in vitro.³³

No controlled human study of Damiana alone for anxiety, mood, stress resilience or cognition was located.

METABOLIC RESEARCH

Teuhetenone A isolated from Damiana produced acute glucose-related effects in animal models.³⁴

Studies of Damiana extracts in diabetic animals have produced mixed results. Some organ or antioxidant outcomes improved, while hyperglycaemia was not consistently corrected.³⁵

A 2021 screen found no meaningful alpha-glucosidase, alpha-amylase or intestinal-glucose-absorption inhibition, although rat glucose area under the curve decreased.³⁶

A 2023 diabetic-rat study reported improved glucose, insulin and male reproductive measures.³⁷

No human standalone evidence supports a blood-glucose or diabetes claim.

DIGESTIVE RESEARCH

Arbutin isolated from Damiana produced gastroprotective effects in rat models of aspirin- and ethanol-induced injury.³⁸

This is isolated-compound animal evidence, not proof of digestive benefit from Luminara.

LIVER RESEARCH

Aqueous and ethanolic Damiana extracts have been studied in chemically induced rat liver-injury models.³⁹–⁴¹

In cultured human hepatic-stellate cells, Damiana extract reduced selected profibrotic, extracellular-matrix and mitochondrial markers.⁴²

A hepatodamianol-rich preparation and isolated hepatodamianol have also been studied in liver-cell and animal models.⁴³˒⁴⁴

No human liver trial was located. Preclinical hepatoprotection does not prove clinical benefit or eliminate safety concerns.

KIDNEY AND MALE REPRODUCTIVE RESEARCH

Rat studies reported protection against amitriptyline-associated kidney injury and against testicular damage caused by pesticides, chromium or amitriptyline.⁴⁵–⁴⁷

These induced toxic-injury models do not establish human kidney, testosterone or fertility benefits.

NEUROLOGICAL RESEARCH

Damiana was evaluated with other botanicals for hippocampal apoptosis in aged rats.⁴⁸

In human neuroblastoma cells, Damiana extract inhibited selected CNS enzymes and delayed glutamate-related excitotoxicity.⁴⁹

Additional studies investigated neurotoxicity, neuroinflammation, antiglycation, tyrosinase and Damiana phyto-phospholipid nanostructures.⁵⁰–⁵²

No human cognitive or neuroprotective benefit has been established.

PAIN AND INFLAMMATION

Apigenin isolated from Damiana produced analgesic effects in animals.³¹

Damiana leaf and stem-bark essential oils showed antinociceptive and anti-inflammatory activity in animal models.⁵³

These preparations are not equivalent to Luminara’s leaf extract.

ANTIOXIDANT CHEMISTRY

Studies have examined:

• wild versus cultivated material;⁵⁴
• conventional and ultrasound extraction;⁵⁵
• microwave-assisted extraction;⁵⁶
• total phenolics and antioxidant assays;⁵⁷
• ultrasound-assisted polyphenol recovery;⁵⁸
• natural variability of essential oils and antioxidants;⁵⁹
• microwave, ultrasound and conventional extraction across botanicals;⁶⁰
• antioxidant activity alongside vascular testing.⁶¹

The research demonstrates antioxidant-active chemistry and major variation with source and extraction. No human antioxidant-biomarker benefit was located.

VASCULAR RESEARCH: A NEGATIVE FINDING

A 2021 rat-aortic-ring study found antioxidant activity but no meaningful vasorelaxation from methanolic Damiana extract under the study conditions.⁶¹

This is important because the evidence should not be simplified into a general claim that Damiana “improves circulation.”

SKIN RESEARCH

Damiana leaf extract influenced AP-1 and Nrf2/ARE signalling in ultraviolet-stressed human keratinocytes and dermal fibroblasts.⁶²

Experimental research has also examined transdermal penetration of Damiana essential oil.⁷⁰

No oral human skin benefit has been demonstrated.

ANTIMICROBIAL RESEARCH

Studies have tested Damiana extracts, essential oils and isolated compounds against urinary pathogens, fungal enzymes, Staphylococcus aureus, mycobacteria and other organisms.⁶³–⁶⁶˒⁷¹

Results vary by preparation, organism and concentration. No human infection study was located. Damiana should not be described as an antibiotic or antifungal treatment.

CYTOTOXICITY

Methanolic Damiana extract has shown cytotoxicity in breast-cancer cell lines.⁷²

Other extracts and constituents have been tested in multiple-myeloma cells, and hydroethanolic extract has been evaluated for effects on astrocyte cell death.⁷³˒⁷⁴

Cell cytotoxicity is not evidence that Damiana treats cancer. It can also represent a safety signal.


HERB–DRUG INTERACTION RESEARCH

A 2023 laboratory screen found that Damiana leaf extract activated pregnane-X receptor and aryl-hydrocarbon receptor and inhibited CYP3A4 and CYP1A2.⁷⁵

These are theoretical interaction signals. Laboratory concentrations do not prove a clinically significant interaction at Luminara’s dose, but they support caution for people taking prescription medicines—especially medicines with narrow therapeutic ranges or substantial CYP3A4 or CYP1A2 metabolism.


SAFETY

The standalone women’s study lasted only eight weeks and was not controlled.⁷

A systematic review of reported human harm found no Damiana case reports and only one clinical trial reporting adverse events, but concluded that adverse-event reporting quality was poor. Limited reports of harm do not prove safety.⁷⁶

In mice, aqueous extract up to 1,000 mg/kg daily for 28 days caused no deaths or major behavioural toxicity, but slight liver vascular congestion appeared at the highest dose.²¹

In rats, a single oral ethanolic-extract dose of 5,000 mg/kg and repeated doses up to 1,000 mg/kg for four weeks produced no major measured toxicity.⁷⁷

A 2011 study found no obvious acute toxicity after a very high oral dose, while intraperitoneal dosing caused substantial mortality—showing that route and preparation matter.³²

No adequate human pregnancy or breastfeeding study was located. Damiana contains biologically active constituents, including cyanogenic glycosides and compounds with enzyme and hormonal activity in laboratory models.⁶˒²⁸

Anyone who is pregnant, breastfeeding, taking prescription medication, preparing for surgery, using hormonal therapy or managing a medical condition should consult a qualified healthcare professional before using Luminara.


EVIDENCE STRENGTH

RATING METHOD

★★★★★ — Strong: Multiple high-quality human trials and/or systematic reviews with consistent findings and relevant preparations.

★★★★☆ — Good: More than one relevant controlled human trial, with some limitations.

★★★☆☆ — Emerging: At least one controlled human study showing a relevant benefit.

★★☆☆☆ — Preliminary: Limited, observational, mixed or indirect human evidence.

★☆☆☆☆ — Traditional or preclinical: Traditional use, laboratory research or animal evidence without adequate standalone clinical confirmation.

Health area | Evidence strength | Current assessment
Overall female sexual function | ★★☆☆☆ | One standalone uncontrolled observational study; randomised trial ongoing
Female sexual desire | ★★☆☆☆ | Improvement in one observational study; no completed standalone placebo-controlled trial
Female arousal | ★★☆☆☆ | Observational standalone finding plus indirect combination evidence
Vaginal lubrication | ★★☆☆☆ | Observational finding; no controlled standalone confirmation
Orgasm and satisfaction | ★★☆☆☆ | Observational standalone and indirect combination evidence
Sexual distress | ★★☆☆☆ | Improved in one observational study
Male sexual function | ★☆☆☆☆ | Animal, tissue, conference and multi-ingredient human evidence
Menopausal symptoms | ★☆☆☆☆ | One multi-ingredient trial; no standalone Damiana study
Appetite and weight management | ★☆☆☆☆ | Combination evidence only
Anxiety and mood | ★☆☆☆☆ | Traditional and animal evidence only
Adaptogenic activity | ★☆☆☆☆ | Mixed animal evidence
Nitric oxide, smooth muscle and PDE5 | ★☆☆☆☆ | Preclinical mechanisms only
Aromatase and hormonal effects | ★☆☆☆☆ | Laboratory evidence only
Metabolic support | ★☆☆☆☆ | Mixed animal and isolated-compound evidence
Digestive effects | ★☆☆☆☆ | Isolated-compound animal evidence
Liver and kidney protection | ★☆☆☆☆ | Cell and animal evidence
Fertility and testicular protection | ★☆☆☆☆ | Male-animal models
Neuroprotection and cognition | ★☆☆☆☆ | Cell and animal evidence
Pain and inflammation | ★☆☆☆☆ | Animal, essential-oil and isolated-compound evidence
Antioxidant activity | ★☆☆☆☆ | Extensive laboratory chemistry; no human biomarker evidence
Skin and photoageing | ★☆☆☆☆ | Cell and transdermal evidence
Antimicrobial activity | ★☆☆☆☆ | Variable laboratory evidence
Short-term human tolerability | ★★☆☆☆ | Limited standalone observational and combination-trial experience
Long-term human safety | ★☆☆☆☆ | Not established
Herb–drug interaction potential | ★☆☆☆☆ | In-vitro CYP and receptor signal warrants caution


PLAIN-ENGLISH SUMMARY

Damiana is a traditional Mexican and Central American leaf botanical best known for sensual vitality.

The strongest direct human evidence is one eight-week observational study of a specific Damiana leaf extract in women with reduced sexual desire. Overall sexual function, every measured sexual-function domain and sexual distress improved. Because there was no placebo group and only 35 of 70 enrolled women were included in the reported evaluable analysis, this is preliminary rather than definitive evidence.⁷

A placebo-controlled standalone trial was registered in 2026, but no results were available by 1 August 2026.⁶⁷

Several multi-ingredient sexual-function formulas containing Damiana have been studied. Some produced positive outcomes, while one trial in female cancer survivors found no sexual-function benefit. Those studies cannot determine Damiana’s individual contribution.⁸–¹⁴

Animal and laboratory studies support plausible traditional mechanisms involving sexual behaviour, nitric oxide, smooth muscle, PDE5 and aromatase.²²–²⁹ A substantial preclinical literature also spans mood, metabolism, liver and kidney models, neurological pathways, inflammation, antioxidants, skin and antimicrobial activity. None establishes that Luminara produces each effect in people.

Luminara provides 500 mg daily of a supplier-specified 4:1 Turnera diffusa leaf extract. The specification does not state the solvent, carrier, chemical marker or actual batch assay. It is not known to be equivalent to the 675 mg, approximately 5–7:1 hydroethanolic extract used in the published women’s study.

Most accurate positioning: Damiana contributes its long traditional association with sensual vitality, supported by early observational human evidence and a substantial preclinical research base. Direct placebo-controlled evidence for Damiana alone remains incomplete.


REFERENCES

1. Royal Botanic Gardens, Kew. Turnera diffusa Willd. ex Schult.. Plants of the World Online. Accessed 1 August 2026.

2. Szewczyk K, Zidorn C. Ethnobotany, phytochemistry, and bioactivity of the genus Turnera (Passifloraceae) with a focus on damiana—Turnera diffusa. J Ethnopharmacol. 2014;152(3):424-443. doi:10.1016/j.jep.2014.01.019. PMID: 24468305.

3. Parra-Naranjo A, Delgado-Montemayor C, Salazar-Aranda R, Waksman-Minsky N. Bioactivity of the Genus Turnera: A Review of the Last 10 Years. Pharmaceuticals (Basel). 2023;16(11):1573. doi:10.3390/ph16111573. PMID: 38004438.

4. Joshi VC, Rao AS, Wang YH, Avula B, Khan IA. Taxonomic Clarification on Turnera diffusa Ward and its Demarcation from “False Damiana” using Fluorescence, Scanning Electron Microscopy, HPTLC and UPLC. Planta Med. 2009;75:P-16. doi:10.1055/s-2009-1216454.

5. Piacente S, Camargo E, Zampelli A, Gracioso J, Souza Brito A, Pizza C, Vilegas W. Flavonoids and Arbutin from Turnera diffusa. Z Naturforsch C. 2002;57(11-12):983-985. doi:10.1515/znc-2002-11-1204.

6. Zhao J, Pawar RS, Ali Z, Khan IA. Phytochemical investigation of Turnera diffusa. J Nat Prod. 2007;70(2):289-292. doi:10.1021/np060253r. PMID: 17284070.

7. Rotmann AR, Mordhorst N, Klein T, Kassen A. Nicht-Interventionelle Studie zum Einfluss eines Damiana-Präparates auf die Verbesserung der Symptomatik des Mangels oder Verlusts von sexuellem Verlangen bei Frauen. Z Phyther. 2021;42(5):241-248. doi:10.1055/a-1256-7034.

8. Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001;27(5):541-549. doi:10.1080/713846828. PMID: 11554217.

9. Ito TY, Polan ML, Whipple B, Trant AS. The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status. J Sex Marital Ther. 2006;32(5):369-378. doi:10.1080/00926230600834901. PMID: 16959660.

10. Greven KM, et al. Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. J Community Support Oncol. 2015;13(3):87-94. doi:10.12788/jcso.0114. PMID: 26287032.

11. Palacios S, Soler E, Ramírez M, Lilue M, Khorsandi D, Losa F. Effect of a multi-ingredient based food supplement on sexual function in women with low sexual desire. BMC Womens Health. 2019;19(1):58. doi:10.1186/s12905-019-0755-9. PMID: 31039769.

12. Ito T, Kawahara K, Das A, Strudwick W. The effects of ArginMax, a natural dietary supplement for enhancement of male sexual function. Hawaii Med J. 1998;57(12):741-744. PMID: 9893389.

13. Shah GR, Chaudhari MV, Patankar SB, Pensalwar SV, Sabale VP, Sonawane NA. Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study. BMC Complement Altern Med. 2012;12:155. doi:10.1186/1472-6882-12-155. PMID: 22978405.

14. Yakoot M, Salem A, Omar AM. Effectiveness of a herbal formula in women with menopausal syndrome. Forsch Komplementmed. 2011;18(5):264-268. doi:10.1159/000333430. PMID: 22105039.

15. Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Diet. 2001;14(3):243-250. doi:10.1046/j.1365-277X.2001.00290.x. PMID: 11424516.

16. Ruxton CHS. Efficacy of Zotrim: A herbal weight loss preparation. Nutrition & Food Science. 2004;34(1):25-28. doi:10.1108/00346650410516199.

17. Ruxton CHS, Kirkwood L, McMillan B, St John D, Evans CEL. Effectiveness of a herbal supplement (Zotrim™) for weight management. British Food Journal. 2007;109(6):416-428. doi:10.1108/00070700710753481.

18. Harrold JA, Hughes GM, O'Shiel K, Quinn E, Boyland EJ, Williams NJ, Halford JCG. Acute effects of a herb extract formulation and inulin fibre on appetite, energy intake and food choice. Appetite. 2013;62:84-90. doi:10.1016/j.appet.2012.11.018. PMID: 23207186.

19. Celestino MMM, Gomes AC, Botelho PB, Gambero A, Mesquita LM, Vilegas W, Ribeiro ML, Mota JF. South American herbal extracts reduce food intake through modulation of gastrointestinal hormones in overweight and obese women. J Funct Foods. 2017;35:555-563. doi:10.1016/j.jff.2017.06.015.

20. Hughes GM, et al. Experimental study to investigate the impact of a patented herb extract formulation Yerbe Maté, Guarana and Damiana (YGD; Zotrim®) on food intake and appetite ratings in women. Appetite. 2011;57(2):550. doi:10.1016/j.appet.2011.05.048.

21. Dorantes-Barron AM, et al. Neurobehavioral and toxicological effects of an aqueous extract of Turnera diffusa Willd (Turneraceae) in mice. J Ethnopharmacol. 2019;236:50-62. doi:10.1016/j.jep.2019.02.036.

22. Arletti R, et al. Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual behavior of male rats. Psychopharmacology (Berl). 1999;143(1):15-19. doi:10.1007/s002130050913. PMID: 10227074.

23. Estrada-Reyes R, Ortiz-López P, Gutiérrez-Ortíz J, Martínez-Mota L. Turnera diffusa Wild (Turneraceae) recovers sexual behavior in sexually exhausted males. J Ethnopharmacol. 2009;123(3):423-429. doi:10.1016/j.jep.2009.03.032. PMID: 19501274.

24. Estrada-Reyes R, Carro-Juárez M, Martínez-Mota L. Pro-sexual effects of Turnera diffusa Wild (Turneraceae) in male rats involves the nitric oxide pathway. J Ethnopharmacol. 2013;146(1):164-172. doi:10.1016/j.jep.2012.12.025. PMID: 23298455.

25. Hnatyszyn O, et al. Argentinian plant extracts with relaxant effect on the smooth muscle of the corpus cavernosum of Guinea pig. Phytomedicine. 2003;10(8):669-674. doi:10.1078/0944-7113-00261. PMID: 14692728.

26. Feistel B, Walbroel B, Benedek B. Damiana (Turnera diffusa Willd.)—A traditionally used aphrodisiac as modern PDE-5 inhibitor. Planta Med. 2010;76:P002. doi:10.1055/s-0030-1264300.

27. Benito-Vázquez I, et al. Flavonoid Composition and Molecular Basis of the Potential Sexual-Enhancing Properties of a Turnera diffusa Extract (Liboost®). Pharmaceuticals (Basel). 2026;19(4):597. doi:10.3390/ph19040597. PMID: 42075853.

28. Zhao J, Dasmahapatra AK, Khan SI, Khan IA. Anti-aromatase activity of the constituents from damiana (Turnera diffusa). J Ethnopharmacol. 2008;120(3):387-393. doi:10.1016/j.jep.2008.09.016. PMID: 18948180.

29. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med. 1998;217(3):369-378. doi:10.3181/00379727-217-44247. PMID: 9492350.

30. Kumar S, Sharma A. Anti-anxiety Activity Studies on Homoeopathic Formulations of Turnera aphrodisiaca Ward. Evid Based Complement Alternat Med. 2005;2(1):117-119. doi:10.1093/ecam/neh069. PMID: 15864356.

31. Kumar S, Madaan R, Sharma A. Pharmacological evaluation of Bioactive Principle of Turnera aphrodisiaca. Indian J Pharm Sci. 2008;70(6):740-744. doi:10.4103/0250-474X.49095. PMID: 21369434.

32. Bezerra AG, Mendes FR, Tabach R, Carlini EA. Effects of a hydroalcoholic extract of Turnera diffusa Willd. ex Schult., Turneraceae, in tests for adaptogenic activity. Rev Bras Farmacogn. 2011;21(1):121-127. doi:10.1590/S0102-695X2011005000019.

33. Chaurasiya ND, Zhao J, Pandey P, Doerksen RJ, Muhammad I, Tekwani BL. Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). Molecules. 2019;24(4):810. doi:10.3390/molecules24040810. PMID: 30813423.

34. Parra-Naranjo A, et al. Acute Hypoglycemic and Antidiabetic Effect of Teuhetenone A Isolated from Turnera diffusa. Molecules. 2017;22(4):599. doi:10.3390/molecules22040599. PMID: 28397755.

35. Esquivel-Gutiérrez ER, et al. Effects of damiana (Turnera diffusa; var. diffusa and var. aphrodisiaca) on diabetic rats. Acta Universitaria. 2018;28(6):84-92. doi:10.15174/au.2018.1761.

36. Adame-Miranda SJ, Granados-Guzmán G, Silva-Mares DA, Acevedo-Fernández JJ, Waksman-Minsky N, Salazar-Aranda R. Evaluation of antihyperglycemic activity of plants in northeast mexico. Cell Mol Biol. 2021;67(1):212-218. doi:10.14715/cmb/2021.67.1.30.

37. Kumar GG, Kilari EK, Nelli G, Salleh NB. Oral administration of Turnera diffusa willd. ex Schult. extract ameliorates steroidogenesis and spermatogenesis impairment in the testes of rats with type-2 diabetes mellitus. J Ethnopharmacol. 2023;314:116638. doi:10.1016/j.jep.2023.116638. PMID: 37187362.

38. Taha MM, Salga MS, Ali HM, Abdulla MA, Abdelwahab SI, Hadi AH. Gastroprotective activities of Turnera diffusa Willd. ex Schult. revisited: Role of arbutin. J Ethnopharmacol. 2012;141(1):273-281. doi:10.1016/j.jep.2012.02.030. PMID: 22374081.

39. Bathula NK, Chowdhury B. Hepatoprotective activity of ethanolic and aqueous extract of Turnera aphrodisiaca leaves against CCl4-induced liver injury in rats. Int J Basic Clin Pharmacol. 2019;8(8):1758-1765. doi:10.18203/2319-2003.ijbcp20193174.

40. Bathula NK, Chowdhury B. Pharmacological Evaluation of Turnera aphrodisiaca Leaves for Hepatoprotective Activity in Albino Rats. Nat Volatiles Essent Oils. 2021;8(6):5275-5283.

41. Hasan AF, Mutar TF, Tousson EM, Felemban SG. Therapeutic Effects of Turnera diffusa Extract Against Amitriptyline-Induced Toxic Hepatic Inflammation. OnLine J Biol Sci. 2021;21(2):395-408. doi:10.3844/ojbsci.2021.395.408.

42. Rodríguez-Rodríguez DR, Lozano-Sepulveda SA, Delgado-Montemayor C, Waksman N, Cordero-Perez P, Rivas-Estilla AM. Turnera diffusa extract attenuates profibrotic, extracellular matrix and mitochondrial markers in activated human hepatic stellate cells (HSC). Ann Hepatol. 2021;22:100281. doi:10.1016/j.aohep.2020.10.009. PMID: 33220464.

43. Delgado-Montemayor C, et al. Development of a Hepatoprotective Herbal Drug from Turnera diffusa. Evid Based Complement Alternat Med. 2022;2022:5114948. doi:10.1155/2022/5114948.

44. Delgado-Montemayor C, Perez-Meseguer J, Salazar-Aranda R, Cordero-Perez P, Waksman N. Hepatodamianol as hepatoprotective constituent of Turnera diffusa. Pak J Pharm Sci. 2023;36(5):1553-1559. doi:10.36721/PJPS.2023.36.5.REG.1553-1559.1.

45. Hasan AF, Hameed HM, Tousson E, Massoud A, Atta F, Youssef H, Hussein Y. Role of Oral Supplementation of Damiana (Turnera diffusa) Reduces the Renal Toxicity, Apoptosis and DNA Damage Associated with Amitriptyline Administration in Rats. Biomed Pharmacol J. 2022;15(3):1245-1253. doi:10.13005/bpj/2460.

46. El-Demerdash FM, Jebur AB, Nasr HM, Hamid HM. Modulatory effect of Turnera diffusa against testicular toxicity induced by fenitrothion and/or hexavalent chromium in rats. Environ Toxicol. 2019;34(3):330-339. doi:10.1002/tox.22688. PMID: 30578656.

47. Tousson E, Hafez E, Zaki S, Gad A, Elgharabawy RM. Evaluation of the testicular protection conferred by damiana (Turnera diffusa Willd.) against amitriptyline-induced testicular toxicity, DNA damage and apoptosis in rats. Biomed Pharmacother. 2020;132:110819. doi:10.1016/j.biopha.2020.110819. PMID: 33035829.

48. Bezerra AG, Smaili SS, Lopes GS, Carlini EA. Effects of Panax ginseng, Turnera diffusa and Heteropterys tomentosa extracts on hippocampal apoptosis of aged rats. Einstein (São Paulo). 2013;11(2):163-167. doi:10.1590/S1679-45082013000200005. PMID: 23843055.

49. Bernardo J, Ferreres F, Gil-Izquierdo Á, Valentão P, Andrade PB. Medicinal species as MTDLs: Turnera diffusa Willd. Ex Schult inhibits CNS enzymes and delays glutamate excitotoxicity in SH-SY5Y cells via oxidative damage. Food Chem Toxicol. 2017;106(Pt A):466-476. doi:10.1016/j.fct.2017.06.014. PMID: 28606766.

50. Vélez-Huerta J, et al. Neuroprotective activity of Datura inoxia and Turnera diffusa extracts in an in vitro model of neurotoxicity. Pharmacogn Mag. 2022;18(78):470-475. doi:10.4103/pm.pm_543_21.

51. Bernardo J, et al. Trichilia catigua and Turnera diffusa extracts: In vitro inhibition of tyrosinase, antiglycation activity and effects on enzymes and pathways engaged in the neuroinflammatory process. J Ethnopharmacol. 2021;271:113865. doi:10.1016/j.jep.2021.113865. PMID: 33485975.

52. Bernardo J, et al. Trichilia catigua and Turnera diffusa phyto-phospholipid nanostructures: Physicochemical characterization and bioactivity in cellular models of induced neuroinflammation and neurotoxicity. Int J Pharm. 2022;620:121774. doi:10.1016/j.ijpharm.2022.121774. PMID: 35489602.

53. Lawal OA, et al. Anti-nociceptive Property, Anti-inflammatory Activity and Constituents of Essential Oils from the Leaves and Stem Bark of Turnera diffusa Wild (Passifloraceae) Growing in Nigeria. J Biol Act Prod Nat. 2020;10(6):473-483. doi:10.1080/22311866.2020.1865837.

54. Soriano-Melgar LAA, et al. Antioxidant and trace element content of damiana (Turnera diffusa Willd) under wild and cultivated conditions in semi-arid zones. Ind Crops Prod. 2012;37(1):321-327. doi:10.1016/j.indcrop.2011.12.017.

55. Wong-Paz JE, Muñiz-Márquez DB, Aguilar-Zárate P, Rodríguez-Herrera R, Aguilar CN. Microplate Quantification of Total Phenolic Content from Plant Extracts Obtained by Conventional and Ultrasound Methods. Phytochem Anal. 2014;25(5):439-444. doi:10.1002/pca.2512. PMID: 24692153.

56. Wong-Paz JE, et al. Microwave-Assisted Extraction of Phenolic Antioxidants from Semiarid Plants. Am J Agric Biol Sci. 2014;9(3):299-310. doi:10.3844/ajabssp.2014.299.310.

57. Wong-Paz JE, et al. Total phenolic content, in vitro antioxidant activity and chemical composition of plant extracts from semiarid Mexican region. Asian Pac J Trop Med. 2015;8(2):104-111. doi:10.1016/S1995-7645(14)60299-6.

58. Wong Paz JE, Muñiz Márquez DB, Martínez Ávila GCG, Belmares Cerda RE, Aguilar CN. Ultrasound-assisted extraction of polyphenols from native plants in the Mexican desert. Ultrason Sonochem. 2015;22:474-481. doi:10.1016/j.ultsonch.2014.06.001. PMID: 25012563.

59. Urbizu-González AL, et al. Natural variability of essential oil and antioxidants in the medicinal plant Turnera diffusa. Asian Pac J Trop Med. 2017;10(2):121-125. doi:10.1016/j.apjtm.2017.01.013. PMID: 28237475.

60. Tsaltaki C, Katsouli M, Kekes T, Chanioti S, Tzia C. Comparison study for the recovery of bioactive compounds from Tribulus terrestris, Panax ginseng, Gingko biloba, Lepidium meyenii, Turnera diffusa and Withania somnifera by using microwave-assisted, ultrasound-assisted and conventional extraction methods. Ind Crops Prod. 2019;142:111875. doi:10.1016/j.indcrop.2019.111875.

61. Aguirre-Crespo FJ, et al. Vasorelaxant and antioxidant activity of some medicinal plants from Campeche, Mexico. Pharmacogn Mag. 2021;17(73):23-30. doi:10.4103/pm.pm_291_20.

62. Kim M, Ha L-K, Oh S, Fang M, Zheng S, Bellere AD, Jeong J, Yi T-H. Antiphotoaging Effects of Damiana (Turnera diffusa) Leaves Extract via Regulation AP-1 and Nrf2/ARE Signaling Pathways. Plants (Basel). 2022;11(11):1486. doi:10.3390/plants11111486. PMID: 35684259.

63. Angulo Escalante MA, Báez-Parra KM, Soto-Beltrán M, López-Cuevas O, Basilio Heredia J, Alcaraz-Meléndez L. Actividad Antimicrobiana in vitro de extractos metánolicos y hexánicos de Turnera diffusa contra patógenos comunes de vías urinarias. Rev Bio Cienc. 2019;6:e670. doi:10.15741/revbio.06.nesp.e670.

64. Tapia-Quirós P, Martínez-Téllez MA, Ávila-Quezada GD, Vargas-Arispuro I. Inhibition of fungal endo-1,3-β-glucanase by phenols isolated from Turnera diffusa: an alternative for conventional antifungals. Rev Mex Fitopatol. 2020;38(1):160-169. doi:10.18781/r.mex.fit.1911-3.

65. Snowden R, et al. A comparison of the anti-Staphylococcus aureus activity of extracts from commonly used medicinal plants. J Altern Complement Med. 2014;20(5):375-382. doi:10.1089/acm.2013.0036. PMID: 24635487.

66. Barrios Martínez SX, Stashenko EE, Ocazionez Jimenez RE, Fuentes Lorenzo JL. Antibacterial activity of essential oils of plants growing in Colombia and its effect on the activity of β-lactam antibiotics. Rev Cubana Farm. 2021;54(4):e627.

67. ISRCTN Registry. Prospective, randomised, double-blind clinical trial to evaluate the effect of a dietary supplement (Turnera diffusa) in healthy subjects who report low sexual desire. ISRCTN12819093. Registered 19 January 2026. doi:10.1186/ISRCTN12819093.

68. Feistel B, Walbroel B. Traditional aphrodisiaca Turnera diffusa WILLD. – new human aspects. Conference poster. 15th International Congress PHYTOPHARM 2011; 25-27 July 2011; Nuremberg, Germany. Cited in Rotmann et al., 2021.

69. ClinicalTrials.gov. Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels (VITAL). NCT04188600. Withdrawn; enrollment 0.

70. Carreño H, Stashenko EE, Escobar P. Essential Oils Distilled from Colombian Aromatic Plants and Their Constituents as Penetration Enhancers for Transdermal Drug Delivery. Molecules. 2023;28(6):2872. doi:10.3390/molecules28062872.

71. Bueno J, Escobar P, Martínez JR, Leal SM, Stashenko EE. Composition of Three Essential Oils, and their Mammalian Cell Toxicity and Antimycobacterial Activity against Drug Resistant-Tuberculosis and Nontuberculous Mycobacteria Strains. Nat Prod Commun. 2011;6(11):1743-1748. doi:10.1177/1934578X1100601143.

72. Avelino-Flores MC, Cruz-López MC, Jiménez-Montejo FE, Reyes-Leyva J. Cytotoxic Activity of the Methanolic Extract of Turnera diffusa Willd on Breast Cancer Cells. J Med Food. 2015;18(3):299-305. doi:10.1089/jmf.2013.0055. PMID: 25299247.

73. Willer J, Jöhrer K, Greil R, Zidorn C, Çiçek SS. Cytotoxic Properties of Damiana (Turnera diffusa) Extracts and Constituents and A Validated Quantitative UHPLC-DAD Assay. Molecules. 2019;24(5):855. doi:10.3390/molecules24050855. PMID: 30823394.

74. Bezerra AG, Negri G, Duarte-Almeida JM, Smaili SS, Carlini EA. Phytochemical analysis of hydroethanolic extract of Turnera diffusa Willd and evaluation of its effects on astrocyte cell death. Einstein (São Paulo). 2016;14(1):56-63. doi:10.1590/S1679-45082016AO3386. PMID: 27074236.

75. Husain I, et al. Screening of medicinal plants for possible herb-drug interactions through modulating nuclear receptors, drug-metabolizing enzymes and transporters. J Ethnopharmacol. 2023;301:115822. doi:10.1016/j.jep.2022.115822. PMID: 36223846.

76. Dwyer L, Breakspear I. Systematic review of harm from case reports and clinical trials of the oral use of Arctostaphylos uva-ursi, Turnera diffusa and Achillea millefolium. Aust J Herbal Naturopathic Med. 2020;32(4):142-151. doi:10.33235/ajhnm.32.4.142-151.

77. Bathula NK, Chowdhury B. Assessment of acute and subacute oral toxicity elicited by ethanolic extract of Turnera aphrodisiaca leaves in albino rats. Asian J Pharm Clin Res. 2020;13(7):144-148. doi:10.22159/ajpcr.2020.v13i7.37409.


These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

BRAHMI

Bacopa monnieri (L.) Wettst.

Brahmi is a small creeping wetland herb with a long history in Ayurveda as a medhya rasayana—a traditional class of restorative botanicals associated with memory, learning, mental clarity and healthy ageing.

The name “Brahmi” requires care. In different regions and products it may refer to Bacopa monnieri, Centella asiatica, or occasionally a combination of the two. Luminara uses Bacopa monnieri. Research involving Centella asiatica is not evidence for Luminara’s Brahmi ingredient.¹–³

Bacopa contains dammarane-type triterpenoid saponins collectively described as bacosides and bacopasides, together with alkaloids, flavonoids, sterols and other plant compounds. The term “bacosides” is itself not a single chemical: different analytical methods and proprietary extracts can measure different mixtures of bacoside A components, bacopasides and related saponins.⁴–⁷

Brahmi is among the more extensively studied herbs in Luminara. Human clinical research has investigated memory, learning, information processing, attention, executive function, stress reactivity, fatigue, mood, sleep, children with attention or behavioural concerns, mild cognitive impairment, dementia, Parkinson’s disease and several biological markers.⁸–³⁹

The overall evidence is not uniformly positive.

Reviews of the clinical literature have found the most consistent cognitive benefit in memory—especially delayed recall or the rate of forgetting after regular supplementation for approximately eight to twelve weeks. Evidence for attention, processing speed, working memory and executive function is less consistent and depends on the test, population and extract.⁴¹–⁴⁷

Recent trials reinforce that mixed picture. A 2024 study reported broad improvements across several memory and cognitive measures, anxiety, sleep and biological markers, while a rigorous 2025 trial found no advantage over placebo for its primary cognitive outcomes but did find reduced stress reactivity and task-related fatigue.³³˒³⁴

Brahmi should therefore be presented as a botanical with meaningful human evidence for memory and emerging evidence for stress-related mental wellbeing—not as a guaranteed cognitive enhancer or a treatment for a neurological or psychiatric condition.

BRAHMI AT A GLANCE

Botanical name: Bacopa monnieri (L.) Wettst.

Botanical family: Plantaginaceae

Traditional system: Ayurveda

Traditional category: Medhya rasayana

Common names: Brahmi, Bacopa, water hyssop

Part used in Luminara: Not stated on the supplied certificate of analysis

Ingredient form in Luminara: Bacopa monnieri extract

Luminara daily amount: 300 mg

Supplier specification: Not less than 20% bacosides

Raw-material batch assay result: 20.20% bacosides by ultraviolet spectrophotometry

Calculated bacosides from the raw-material assay: Approximately 60.6 mg per 300 mg daily amount

Identity result: Positive by thin-layer chromatography

Manufacture date on the supplied CoA: 2 June 2025

Expiry date on the supplied CoA: 1 June 2028

The 60.6 mg figure is a calculation based on the raw-material assay result:

300 mg × 20.20% = 60.6 mg.

It does not replace finished-product potency testing and should not be described as an independently verified amount in every finished bottle unless the production batch and finished capsules are confirmed to use this exact raw material at the declared quantity.

The supplied CoA does not state:

• the plant part;
• extraction ratio;
• extraction solvent;
• carrier or excipient percentage;
• the individual bacoside profile;
• whether the ultraviolet method measures the same constituents as proprietary clinical assays;
• country of origin.

These omissions matter when comparing Luminara with clinical research.

HOW CLOSELY DOES LUMINARA’S BRAHMI MATCH THE CLINICAL RESEARCH?

Luminara’s ingredient aligns with many human trials in several useful ways:

• it is identified as Bacopa monnieri;
• it is an extract rather than unstandardised herb powder;
• it is standardised to bacosides;
• the daily extract amount is 300 mg, which is one of the most frequently studied adult doses;
• its raw-material assay indicates approximately 60.6 mg of measured bacosides per daily amount.

However, direct clinical equivalence cannot be claimed.

Human studies have used several chemically distinct preparations, including:

• CDRI 08 or KeenMind, commonly described as a high-bacoside proprietary extract;
• BacoMind, a proprietary full-spectrum extract;
• Bacognize, a proprietary standardised extract;
• Bacumen;
• B-Lit, standardised to 30% bacosides;
• other extracts standardised to 20%, 30%, 40% or approximately 50–55% bacosides;
• extracts measured with different ultraviolet, HPLC or proprietary analytical methods;
• doses ranging from approximately 125 mg to 600 mg daily.

A 300 mg daily dose of one extract is not automatically equivalent to 300 mg of another.

For example:

• a 300 mg extract standardised to 30% bacosides nominally provides 90 mg of the measured bacoside fraction;
• Luminara’s raw material assayed at 20.20%, nominally providing 60.6 mg by its UV method;
• a proprietary extract described as approximately 55% bacosides may report a considerably higher percentage, but the assay definition may not match either of those methods.

It would be misleading to rank the extracts simply by percentage without confirming:

• which bacosides were measured;
• the reference standard;
• the analytical method;
• the extraction ratio and solvent;
• the native extract content;
• the plant part;
• the full chemical fingerprint.

The accurate conclusion is:

Luminara uses a clinically familiar 300 mg daily amount of Bacopa monnieri extract and a meaningful bacoside standardisation. It is broadly relevant to the clinical literature, but equivalence to any proprietary study extract has not been established.

TRADITIONAL USE

Ayurvedic texts describe Brahmi as a medhya rasayana associated with intellect, memory, learning and mental composure.¹–³

Traditional uses have included support for:

• memory and learning;
• concentration and intellectual performance;
• calm mental energy;
• emotional balance;
• healthy sleep;
• resilience during mental strain;
• longevity and healthy ageing;
• neurological wellbeing.

Traditional practice has used fresh plant material, juice, powders, decoctions, medicated ghee and multi-herb preparations.

These preparations differ from a modern standardised extract. Traditional use provides cultural and historical context; it is not equivalent to controlled clinical evidence.

WHAT HUMAN CLINICAL STUDIES HAVE INVESTIGATED

MEMORY, LEARNING AND RECALL IN HEALTHY ADULTS

Memory is the area in which Bacopa’s human evidence is most consistent.

Several randomised, double-blind, placebo-controlled trials have reported improvements in one or more measures of:

• delayed word recall;
• new-learning retention;
• memory consolidation;
• resistance to forgetting;
• paired-associate learning;
• logical memory;
• visual-information processing;
• working-memory or memory-span tasks.⁸–¹⁸

The results are not identical across studies, and some tests have shown no difference. The benefit also tends to emerge after repeated supplementation rather than immediately.

A systematic review of randomised controlled trials concluded that memory free recall was the domain showing the clearest recurring benefit. Bacopa improved nine of seventeen free-recall measures in the included trials, while evidence across other cognitive domains was sparse or inconsistent.⁴¹

A meta-analysis subsequently reported potential improvement in cognition, particularly speed of attention, but highlighted small samples, heterogeneity and differences between extracts.⁴²

More recent reviews continue to describe the evidence as promising but variable, with memory and learning generally more convincing than broad claims of improved intelligence or all-domain cognition.⁴³–⁴⁷

STOUGH ET AL., 2001

In one of the landmark modern trials, 46 healthy adults received 300 mg daily of a standardised Bacopa extract or placebo for twelve weeks.⁸

Bacopa was associated with improvements in:

• the speed of visual-information processing;
• learning rate;
• memory consolidation;
• delayed recall.

State-anxiety scores also improved.

The study did not demonstrate an immediate stimulant-like effect. Its findings support the concept that benefits may develop gradually with repeated use.

ROODENRYS ET AL., 2002

A twelve-week placebo-controlled study in 76 adults aged 40–65 found that Bacopa reduced the rate at which newly learned information was forgotten.⁹

Other cognitive outcomes were less consistently affected.

This is important because “memory improvement” can reflect different processes. In this study, retention or resistance to forgetting appeared more responsive than every aspect of learning or attention.

RAGHAV ET AL., 2006

A randomised placebo-controlled trial in people with age-associated memory impairment reported improvements in mental control, logical memory and paired-associate learning after Bacopa supplementation.¹⁰

The population already had subjective or age-related memory concerns, so the findings should not be assumed to apply identically to all healthy adults.

STOUGH ET AL., 2008

A larger placebo-controlled study in 107 healthy adults found improvements in memory accuracy or consolidation after ninety days of a standardised Bacopa extract.¹¹

Not every cognitive task improved, reinforcing that the effect is selective rather than universal.

CALABRESE ET AL., 2008

Fifty-four adults aged sixty-five or older received 300 mg of standardised Bacopa extract or placebo daily for twelve weeks.¹²

Compared with placebo, the Bacopa group showed improvement in:

• delayed word recall;
• a Stroop-based measure of cognitive processing;
• selected anxiety and depression scores.

No meaningful benefit was found in several other measures, including divided attention, a digit-based task, broader mood measures or blood pressure.

Digestive complaints were more common with Bacopa.

MORGAN AND STEVENS, 2010

A randomised placebo-controlled trial in older adults reported improvements in selected memory measures after twelve weeks of Bacopa supplementation.¹³

As in other trials, effects were more apparent in memory than across every measure of attention or executive performance.

PETH-NUI ET AL., 2012

Sixty healthy older adults received Bacopa or placebo for twelve weeks.¹⁴

The researchers reported improvements in selected measures of:

• attention;
• cognitive processing;
• working memory.

Changes in cholinergic and monoamine-related markers were also investigated.

The trial was small, and its biomarker findings should not be interpreted as proof of a specific mechanism in every consumer.

KUMAR ET AL., 2016

A six-week placebo-controlled study in sixty medical students evaluated 150 mg of Bacopa twice daily.¹⁵

Selected memory measures improved. The study’s young, academically engaged population and relatively short duration limit generalisation to older adults or women experiencing hormonal changes.

ACUTE COGNITIVE EFFECTS

Bacopa is often marketed as though it produces immediate focus.

The human evidence does not support a reliable caffeine-like acute effect.

An acute crossover study using 320 mg and 640 mg of a proprietary extract reported selected improvements in sustained cognitive performance, mood and stress-related responses over several hours.¹⁶

Another acute study reported changes in stress reactivity and cortisol under demanding cognitive conditions.¹⁷

These were small studies using concentrated proprietary extracts. Most of the stronger memory literature involves regular use for eight to twelve weeks.

RECENT COGNITIVE TRIALS: WHY THE EVIDENCE REMAINS MIXED

ERAIAH ET AL., 2024

A randomised, double-blind, placebo-controlled study enrolled eighty healthy adults and tested 300 mg daily of an extract standardised to 30% total bacosides for twelve weeks.³³

Seventy-four participants completed the study.

The researchers reported improvements in several measures of:

• memory;
• learning;
• working memory;
• attention-related performance;
• anxiety;
• sleep quality.

Changes in cortisol and brain-derived neurotrophic factor were also reported.

However:

• sustained attention and planning did not improve;
• the extract supplied approximately 90 mg of its measured bacoside fraction, compared with approximately 60.6 mg calculated from Luminara’s raw-material assay;
• the study involved a particular standardised extract and industry involvement;
• replication by independent researchers remains important.

LOPRESTI ET AL., 2025

A twelve-week randomised, double-blind, placebo-controlled trial enrolled 101 adults aged 40–70 who reported memory or attention concerns.³⁴

Participants received 300 mg daily of Bacumen or placebo.

The study found no significant advantage over placebo for its primary cognitive outcomes, including:

• verbal learning;
• attention;
• working memory.

However, Bacopa was associated with:

• lower stress reactivity during laboratory testing;
• less task-related stress;
• less task-related fatigue.

Digestive complaints and headaches were reported more often in the Bacopa group.

This high-quality negative cognitive result is central to an honest evidence assessment. It shows that 300 mg of Bacopa does not consistently improve cognition in every population or with every extract.

ATTENTION, PROCESSING SPEED AND EXECUTIVE FUNCTION

Evidence for attention and executive function is less consistent than the evidence for memory.

Positive findings have included:

• faster visual-information processing;⁸
• selected Stroop performance;¹²
• aspects of attention and working memory in older adults;¹⁴
• fewer errors and greater cognitive flexibility in children;²⁴
• attention and language measures in mild cognitive impairment;³⁵
• speed-of-attention findings in meta-analysis.⁴²

Null findings have included:

• divided attention;¹²
• sustained attention and planning in a recent adult trial;³³
• primary attention outcomes in the 2025 Bacumen trial;³⁴
• broad cognitive outcomes in some older-adult and neurological studies.²⁹˒³⁶˒³⁸

The appropriate conclusion is that Bacopa may support selected attention or processing tasks, but it is not established as a universal concentration enhancer.

STRESS REACTIVITY, CORTISOL AND MENTAL FATIGUE

Bacopa is traditionally regarded as calming rather than strongly stimulating.

Several human studies have investigated stress-related outcomes.

An acute crossover study found that a proprietary Bacopa extract influenced mood, cognitive performance and cortisol responses during laboratory stress.¹⁷

The 2025 Bacumen trial did not improve its primary cognitive outcomes but did reduce stress reactivity and task-related fatigue.³⁴

A 2026 randomised, double-blind, placebo-controlled study enrolled fifty adults experiencing non-chronic stress. Participants received a proprietary Bacopa extract or placebo for twelve weeks.³⁷

The study reported improvements in:

• perceived stress;
• anxiety scores;
• mood disturbance;
• serum cortisol;
• subjective sleep quality;
• actual sleep time and sleep efficiency measured by actigraphy.

Forty-four participants completed the study. The trial was small, used an enhanced proprietary extract and was reported in a lower-profile journal with industry involvement. It is encouraging but should be treated as emerging evidence requiring independent replication.

Together, these studies support cautious language that Bacopa has been investigated for stress-related mental wellbeing and fatigue. They do not establish that it treats anxiety disorders, burnout or chronic stress-related disease.

MOOD, ANXIETY AND EMOTIONAL WELLBEING

Anxiety or mood measures have improved in some adult trials, including:

• state anxiety in the 2001 healthy-adult study;⁸
• anxiety and depression scores in older adults;¹²
• anxiety in the 2024 adult study;³³
• mood and anxiety outcomes in the 2026 stress study.³⁷

Other trials have found:

• no broad mood benefit;
• improvements limited to selected quality-of-life domains;
• no effect in neurological populations;
• results that were secondary rather than primary outcomes.²⁹˒³⁴˒³⁶˒³⁸

A small 2020 study added 600 mg daily of Bacopa to existing treatment in people with anhedonia. Improvements were reported over four weeks, but the study was not a large placebo-controlled standalone trial and cannot establish Bacopa as a treatment for depression or anhedonia.³⁰

The responsible conclusion is that Bacopa may support emotional wellbeing or calmness in some populations, while clinical psychiatric claims are not justified.

SLEEP

The human sleep evidence is mixed.

LOPRESTI ET AL., 2021

One hundred adults with self-reported poor sleep received 150 mg of Bacognize twice daily or placebo for twenty-eight days.³¹

Bacopa did not improve the primary insomnia measure more than placebo.

It was associated with greater improvements in:

• emotional wellbeing;
• general health;
• pain-related quality-of-life measures;
• selected salivary stress-related markers.

This is an important negative sleep study.

DELFIN ET AL., 2024

A triple-blind placebo-controlled trial in sixty-two people with mild cognitive impairment tested 160 mg of Bacopa twice daily for two months.³⁵

The researchers reported selected cognitive benefits, but sleep quality did not improve compared with placebo.

ERAIAH ET AL., 2024 AND THE 2026 B-LIT TRIAL

The 2024 healthy-adult trial reported improved sleep-related measures,³³ and the 2026 B-Lit study reported both subjective and actigraphy-derived sleep improvements.³⁷

Because two other controlled trials did not find a sleep advantage, the evidence should be rated as mixed rather than consistently positive.

Bacopa should not be described as a clinically established sleep treatment.

CHILDREN, ATTENTION AND ADHD-RELATED RESEARCH

Bacopa has been investigated in children with inattention, hyperactivity or ADHD-related concerns.

This is disease- or diagnosis-adjacent research and must not be converted into a claim that Luminara treats ADHD.

DAVE ET AL., 2014

An open-label study gave 225 mg daily of a standardised Bacopa extract to thirty-one children aged six to twelve with ADHD symptoms for six months.²²

Improvements were reported in:

• restlessness;
• impulsivity;
• attention-related concerns;
• self-control;
• learning problems.

There was no placebo group, so maturation, expectancy, concurrent support and reporting effects cannot be excluded.

KEAN ET AL., 2022

A stronger fourteen-week randomised, double-blind, placebo-controlled study enrolled 112 boys aged six to fourteen with high levels of inattention or hyperactivity.²⁴

The Bacopa extract did not significantly improve the primary behavioural outcomes of inattention or hyperactivity.

However, improvements were reported in selected measures of:

• cognitive flexibility;
• executive function;
• error rates;
• interpersonal problems;
• sleep routine.

This is mixed evidence: selected cognitive and functional outcomes improved, but the central ADHD-related behavioural targets did not.

OTHER CHILD EVIDENCE

A schoolchild study used Bacopa with micronutrients, so the contribution of Bacopa could not be isolated.²³

The current evidence is insufficient to claim that Bacopa treats ADHD or reliably reduces hyperactivity.

MILD COGNITIVE IMPAIRMENT AND AGE-RELATED MEMORY CONCERNS

Bacopa has been studied in people with subjective memory concerns, age-associated memory impairment or mild cognitive impairment.

Positive findings have included:

• selected logical or paired-associate memory outcomes;¹⁰
• attention and verbal-memory outcomes in an elderly trial;¹⁸
• attention, language and overall Montreal Cognitive Assessment scores in a 2024 MCI trial.³⁵

However, many cognitive domains in the MCI trial did not differ, both groups improved over time and sleep did not improve.

The evidence is too limited and heterogeneous to state that Bacopa prevents progression to dementia.

ALZHEIMER’S DISEASE AND DEMENTIA

A 2022 systematic review evaluated randomised and quasi-randomised trials of Bacopa in mild cognitive impairment or Alzheimer’s dementia.⁴³

Five studies involving approximately 286 participants were included. Doses, products, comparators and treatment periods varied substantially. Some studies used Bacopa alone, while others used multi-herb formulations.

The review found:

• individual studies reported selected statistically significant outcomes;
• all included studies had important risks of bias;
• sample sizes were small;
• the overall certainty of evidence was very low;
• the results could not be pooled reliably.

An open-label uncontrolled study in people with Alzheimer’s disease reported cognitive and quality-of-life improvements after six months of 600 mg daily, but without a control group it cannot establish efficacy.²⁵

A comparative phase-2 study assessed Bacopa against donepezil in Alzheimer’s disease or mild cognitive impairment. The evidence did not establish that Bacopa was equivalent or superior to approved therapy.²⁶

Other studies have used Bacopa within multi-herb or multi-nutrient products, making attribution impossible.²⁰˒²¹˒²⁸

A 2026 protocol describes a planned placebo-controlled study in amnestic mild cognitive impairment or early Alzheimer’s disease. It is a protocol, not a result.⁴⁰

Luminara must not be marketed as preventing or treating Alzheimer’s disease, dementia or mild cognitive impairment.

PARKINSON’S DISEASE

A 2023 pilot study assigned twenty people with Parkinson’s disease to Bacopa at 225 mg or 450 mg daily or matching placebo conditions for ninety days.²⁹

No significant differences were found in:

• Parkinson’s symptoms;
• emotional function;
• social function.

The study reported exploratory correlations and percentage changes, but the main clinical outcomes were not improved significantly.

This does not support a Parkinson’s disease claim.

BIOLOGICAL MARKERS AND MECHANISTIC HUMAN RESEARCH

Human studies have explored biological markers including:

• cortisol;¹⁷˒³³˒³⁷
• brain-derived neurotrophic factor;³³˒³⁶
• NF-kB and CREB signalling-related markers;³⁶
• inflammatory or oxidative-stress markers in combination products;²⁰
• cholinergic or monoamine-related markers;¹⁴
• metabolomic profiles of Bacopa constituents.³⁹
• brain microstructure during combined cognitive training and Bacopa supplementation.³²

These studies help generate hypotheses.

They do not prove that Luminara:

• increases BDNF in a clinically meaningful way;
• prevents neuronal loss;
• reverses neuroinflammation;
• protects against dementia;
• produces the same biomarker changes as a proprietary extract.

RELEVANCE TO WOMEN’S HORMONAL TRANSITIONS

No controlled human trial located in this evidence review specifically tested Bacopa for:

• premenstrual syndrome;
• menstrual-cycle symptoms;
• perimenopausal hot flushes;
• night sweats;
• vaginal dryness;
• menopause-related hormone changes;
• female sexual function.

Brahmi’s role in Luminara is therefore not as a direct hormonal or vasomotor ingredient.

Its relevance is broader and complementary:

• memory and learning;
• mental clarity;
• stress-related fatigue;
• emotional wellbeing;
• cognitive demands that may feel more difficult during periods of poor sleep or hormonal change.

We should not imply that Bacopa corrects the hormonal causes of brain fog or treats menopause.

EVIDENCE STRENGTH

HOW WE RATE THE EVIDENCE

★★★★★ — Strong

Multiple high-quality human trials and/or systematic reviews with reasonably consistent findings, relevant preparations and meaningful replication.

★★★★☆ — Good

More than one relevant controlled human trial with broadly consistent findings, but with limitations such as modest samples, extract heterogeneity or incomplete independent replication.

★★★☆☆ — Emerging

At least one controlled human study showing a relevant benefit, with mixed findings or further confirmation required.

★★☆☆☆ — Preliminary

Limited, inconsistent or indirect human evidence, including open-label studies, combination products or disease-population research at high risk of bias.

★☆☆☆☆ — Traditional or preclinical

Traditional use, laboratory research or animal evidence without adequate human confirmation.

The rating reflects the body of evidence—not a guarantee that an individual will experience the outcome.

HEALTH AREA | EVIDENCE STRENGTH | CURRENT ASSESSMENT

Memory learning and delayed recall | ★★★★☆ | The most consistent human outcome across multiple trials and reviews; extract and test differences remain

Memory retention or reduced forgetting | ★★★★☆ | Positive findings in several controlled studies

Visual-information processing | ★★★☆☆ | Positive in selected trials; not consistently reproduced

Attention and processing speed | ★★★☆☆ | Meta-analytic and individual positive findings, but several null trials and tasks

Working memory | ★★★☆☆ | Positive in selected studies; no consistent benefit across all populations

Executive function and cognitive flexibility | ★★★☆☆ | Emerging adult and child findings with mixed primary outcomes

Stress reactivity | ★★★☆☆ | Positive acute and twelve-week controlled findings; proprietary extracts and small studies

Mental fatigue during cognitive tasks | ★★★☆☆ | Positive in the 2025 controlled trial; limited replication

General anxiety or emotional wellbeing | ★★★☆☆ | Secondary benefits in several studies, but mixed and not a treatment for anxiety disorders

Sleep quality | ★★☆☆☆ | Mixed controlled evidence: two negative trials and two positive recent trials

Children’s cognitive flexibility and executive function | ★★★☆☆ | Positive selected outcomes in a placebo-controlled study

ADHD-related inattention and hyperactivity | ★★☆☆☆ | Open-label positives but primary behavioural outcomes negative in the stronger RCT

Age-associated memory concerns | ★★★☆☆ | Several small controlled trials with selected benefits

Mild cognitive impairment | ★★☆☆☆ | One recent small RCT with selective cognitive effects; overall evidence limited

Alzheimer’s disease or dementia | ★☆☆☆☆ | Very-low-certainty evidence and high risk of bias; no treatment claim

Parkinson’s disease | ★☆☆☆☆ | Small pilot found no significant clinical benefit

Anhedonia or clinical mood disorders | ★★☆☆☆ | Very small preliminary augmentation research

Biological markers and neuroplasticity | ★★☆☆☆ | Human exploratory findings are inconsistent and extract-specific

Menopause or PMS symptoms | ★☆☆☆☆ | No direct human evidence located

Short-term tolerability | ★★★☆☆ | Generally acceptable in trials, with gastrointestinal effects relatively common

Long-term safety | ★★☆☆☆ | Limited data beyond several months and across diverse extracts

Extract match to Luminara | ★★☆☆☆ | Same species, standardised bacosides and common 300 mg dose; plant part and chemical equivalence unresolved

WHAT THE KEY STUDIES FOUND

STOUGH ET AL., 2001⁸

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Forty-six healthy adults.

Intervention: Standardised Bacopa extract, 300 mg daily, or placebo.

Duration: Twelve weeks.

Key findings: Improvements were reported in visual-information processing, learning rate, memory consolidation and delayed recall. State-anxiety scores also improved.

Why it matters: This is a landmark controlled study supporting chronic—not immediate—memory effects.

Limitations: Small sample, one proprietary extract and multiple cognitive outcomes.

ROODENRYS ET AL., 2002⁹

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Seventy-six adults aged 40–65.

Duration: Twelve weeks.

Key finding: Bacopa reduced the rate of forgetting newly acquired information.

Findings not consistently demonstrated: Broad improvement across all memory, attention or cognitive measures.

Why it matters: It supports retention as a potentially responsive cognitive process.

Limitations: Selective outcome and modest sample.

RAGHAV ET AL., 2006¹⁰

Design: Randomised, double-blind, placebo-controlled trial.

Population: Adults with age-associated memory impairment.

Key findings: Mental control, logical memory and paired-associate learning improved.

Limitations: Population had existing memory concerns, and extract comparability to Luminara is not established.

STOUGH ET AL., 2008¹¹

Design: Randomised, double-blind, placebo-controlled trial.

Participants: One hundred and seven healthy adults.

Duration: Ninety days.

Key findings: Improvements in selected memory-accuracy or consolidation measures.

Limitations: Not every cognitive domain improved.

CALABRESE ET AL., 2008¹²

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Fifty-four healthy adults aged sixty-five or older.

Intervention: Standardised Bacopa extract, 300 mg daily.

Duration: Twelve weeks.

Key findings: Better delayed word recall and selected Stroop performance, with lower anxiety and depression scores.

Null findings: No clear benefit for divided attention, a digit-based task, broad mood or blood pressure.

Safety: Gastrointestinal complaints were more common with Bacopa.

Why it matters: It provides older-adult evidence while demonstrating selective rather than universal benefit.

MORGAN AND STEVENS, 2010¹³

Design: Randomised, double-blind, placebo-controlled trial.

Population: Older adults without dementia.

Duration: Twelve weeks.

Key findings: Selected memory outcomes improved.

Limitations: Small study and varied cognitive endpoints.

PETH-NUI ET AL., 2012¹⁴

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Sixty healthy older adults.

Duration: Twelve weeks.

Key findings: Selected attention, working-memory and processing outcomes improved, with exploratory neurotransmitter-related findings.

Limitations: Small sample and biomarker findings requiring replication.

KUMAR ET AL., 2016¹⁵

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Sixty medical students.

Intervention: 150 mg twice daily.

Duration: Six weeks.

Key findings: Selected memory measures improved.

Limitations: Young specialised population, short intervention and limited generalisability.

DOWNEY ET AL., 2013¹⁶

Design: Randomised, double-blind, placebo-controlled acute crossover study.

Participants: Seventeen healthy adults.

Interventions: Acute doses of a proprietary Bacopa extract.

Key findings: Selected cognitive-performance and mood effects occurred over several hours.

Limitations: Very small acute study; does not establish a reliable immediate effect for Luminara.

BENSON ET AL., 2014¹⁷

Design: Double-blind, placebo-controlled acute crossover study.

Population: Healthy adults undergoing a cognitive stress test.

Key findings: Dose-related changes in mood, task performance and cortisol/stress reactivity were reported.

Limitations: Acute proprietary-extract study and modest sample.

ERAIAH ET AL., 2024³³

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Eighty healthy adults; seventy-four completed.

Intervention: Bacopa extract, 300 mg daily, standardised to 30% total bacosides.

Duration: Twelve weeks.

Key findings: Improvements were reported in several memory, learning and cognitive outcomes, anxiety, sleep and selected cortisol and BDNF measures.

Null findings: Sustained attention and planning did not improve.

Why it matters: It is a broad recent positive trial at the same nominal daily extract mass as Luminara.

Limitations: Its measured bacoside amount was approximately 90 mg daily, its extract differs chemically from Luminara and independent replication is needed.

LOPRESTI ET AL., 2025³⁴

Design: Randomised, double-blind, placebo-controlled trial.

Participants: One hundred and one adults aged 40–70 with self-reported memory or attention concerns.

Intervention: Bacumen, 300 mg daily, or placebo.

Duration: Twelve weeks.

Key findings: Reduced laboratory stress reactivity and task-related fatigue or stress.

Primary null findings: No advantage over placebo for verbal learning, attention or working memory.

Safety: Digestive complaints and headaches were more frequent in the Bacopa group.

Why it matters: It is a rigorous recent study showing stress-related benefits without cognitive benefit.

Limitations: One proprietary extract and self-selected population.

LOPRESTI ET AL., 2021³¹

Design: Randomised, double-blind, placebo-controlled trial.

Participants: One hundred adults with self-reported poor sleep.

Intervention: Bacognize, 150 mg twice daily.

Duration: Twenty-eight days.

Primary finding: Sleep did not improve more than placebo on the Bergen Insomnia Scale.

Other findings: Emotional wellbeing, general health, pain-related symptoms and selected salivary stress markers improved.

Why it matters: It prevents sleep evidence from being presented as uniformly positive.

Limitations: Four weeks may be shorter than the period used in many cognitive trials.

B-LIT STRESS AND SLEEP TRIAL, 2026³⁷

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Fifty adults with non-chronic stress; forty-four completed.

Duration: Twelve weeks.

Key findings: The proprietary extract improved perceived stress, anxiety, mood disturbance, cortisol, subjective sleep quality and selected actigraphy measures.

Safety: Fourteen mild adverse events were reported in eight participants and were assessed as unrelated.

Why it matters: It provides new placebo-controlled stress and objective sleep data.

Limitations: Small, proprietary enhanced extract, industry involvement and need for independent replication.

KEAN ET AL., 2022²⁴

Design: Randomised, double-blind, placebo-controlled trial.

Participants: One hundred and twelve boys aged six to fourteen with high levels of inattention or hyperactivity.

Duration: Fourteen weeks.

Primary null finding: Inattention and hyperactivity behaviour did not improve significantly.

Positive secondary findings: Fewer cognitive errors, greater cognitive flexibility or executive performance, improved interpersonal problems and improved sleep routine.

Why it matters: It is the strongest child study and shows a mixed result rather than simple ADHD improvement.

DELFIN ET AL., 2024³⁵

Design: Triple-blind, randomised, placebo-controlled trial.

Participants: Sixty-two people with mild cognitive impairment and dementia risk factors.

Intervention: 160 mg twice daily.

Duration: Two months.

Key findings: Selected attention and language measures and average MoCA score favoured Bacopa.

Null finding: Sleep did not improve.

Limitations: Small sample, short duration, multiple cognitive domains and both groups improved over time.

BASHEER ET AL., 2022⁴³

Design: Systematic review of randomised and quasi-randomised studies in mild cognitive impairment and Alzheimer’s disease.

Studies: Five studies involving approximately 286 participants.

Conclusion: Individual trials reported selected benefits, but the studies were small, heterogeneous and at high risk of bias. Overall certainty was very low.

Why it matters: It is the best summary of disease-population evidence and does not support a treatment claim.

SANTOS ET AL., 2023²⁹

Design: Small Parkinson’s disease pilot.

Participants: Twenty people.

Interventions: 225 mg or 450 mg daily or matching placebo conditions.

Duration: Ninety days.

Finding: No significant improvement in Parkinson’s symptoms, emotional function or social function.

Why it matters: It is a clinically relevant negative result.

Limitations: Very small and allocation procedures were not fully robust.

HOW BRAHMI MAY WORK

No single mechanism has been established as the explanation for Bacopa’s human effects.

Research has proposed several interacting pathways.

BACOSIDES AND BACOPASIDES

Bacopa contains dammarane-type triterpenoid saponins collectively called bacosides or bacopasides.⁴–⁷

Bacoside A is not one pure molecule but a mixture of related saponins. Different extracts and test methods can define “total bacosides” differently.

This is why Luminara’s 20.20% UV result cannot automatically be compared with a proprietary extract described as 30%, 50% or 55% using another method.

CHOLINERGIC SIGNALLING

Animal and laboratory research suggests that Bacopa may influence acetylcholine synthesis, acetylcholinesterase activity and cholinergic communication.²˒⁴⁸–⁵¹

The cholinergic system contributes to attention and memory.

Human evidence does not establish that Bacopa acts like an approved cholinesterase-inhibiting medicine or that it treats dementia.

SYNAPTIC PLASTICITY, CREB AND BDNF

Preclinical research suggests possible effects on synaptic growth, dendritic branching, CREB signalling and brain-derived neurotrophic factor.⁵²–⁵⁴

Human BDNF findings are inconsistent. The 2024 adult trial reported a favourable change, while a 2023 human study found no serum BDNF effect but reported changes in NF-kB and CREB-related measures.³³˒³⁶

Biomarker changes do not automatically translate into noticeable memory improvement.

ANTIOXIDANT AND INFLAMMATORY PATHWAYS

Laboratory and animal studies indicate that Bacopa can influence:

• lipid peroxidation;
• reactive oxygen species;
• antioxidant enzymes;
• inflammatory cytokines;
• NF-kB-related signalling.²˒⁴⁷–⁵⁶

These pathways may be relevant to neuroprotection, but no evidence shows that Luminara prevents neurodegenerative disease through antioxidant activity.

MONOAMINE, GABA AND STRESS PATHWAYS

Preclinical studies suggest modulation of serotonin, dopamine, noradrenaline and GABA-related pathways.²˒⁴⁷˒⁵⁷–⁵⁹

Human cortisol and stress-reactivity findings suggest possible effects on the stress response, but the clinical mechanism remains uncertain.

AMYLOID, TAU AND NEURODEGENERATION MODELS

Bacopa and isolated bacosides have been studied in cell and animal models involving:

• amyloid accumulation;
• tau-related changes;
• neurotoxicity;
• mitochondrial function;
• cerebral blood flow;
• neuroinflammation.⁴⁷˒⁵²–⁶²

These experiments do not establish that Bacopa prevents or treats Alzheimer’s or Parkinson’s disease in humans.

SAFETY AND RESPONSIBLE USE

Bacopa has generally been tolerated in short-term human trials, but adverse effects are not absent.

The most frequently reported effects are gastrointestinal and can include:

• nausea;
• abdominal cramps;
• increased stool frequency;
• diarrhoea;
• digestive discomfort.

Headache, fatigue or other mild symptoms have also been reported in some trials.¹²˒³¹˒³⁴˒³⁷

A United States National Library of Medicine liver-safety review has not identified Bacopa as a common established cause of clinically apparent liver injury, although supplement quality, combinations and under-reporting remain limitations.⁶¹

Laboratory and preclinical literature raises theoretical interaction considerations involving:

• cholinergic medicines;
• medicines affecting heart rate;
• thyroid function;
• CYP enzymes;
• sedatives or other central-nervous-system medicines;
• medicines used for dementia or psychiatric conditions.²˒⁶¹

These potential interactions are not all proven clinically.

Pregnancy and breastfeeding safety have not been adequately established.

Anyone who is pregnant, breastfeeding, taking prescription medication, preparing for surgery or managing a medical condition should consult a qualified healthcare professional before using Luminara.

Particular caution is appropriate for people with:

• clinically slow heart rate;
• gastrointestinal conditions worsened by increased motility;
• thyroid conditions or thyroid medication;
• cholinergic medication use;
• complex neurological or psychiatric treatment.

PLAIN-ENGLISH SUMMARY

Brahmi—Bacopa monnieri—is one of the most researched herbs in Luminara.

Its strongest human evidence relates to memory, particularly delayed recall, learning retention and resistance to forgetting after regular supplementation for roughly eight to twelve weeks.⁸–¹⁵˒⁴¹–⁴⁷

Evidence for attention, working memory, processing speed and executive function is promising but more mixed. Some studies report improvements, while others—including a rigorous 2025 trial—find no cognitive advantage over placebo.¹²˒¹⁴˒²⁴˒³³–³⁵

Stress-related outcomes may be an important part of Brahmi’s role. Controlled studies have reported lower stress reactivity, task-related fatigue, perceived stress, anxiety and cortisol with certain proprietary extracts.¹⁷˒³⁴˒³⁷

Sleep results are inconsistent. A 2021 trial and a 2024 mild-cognitive-impairment trial found no sleep benefit, while two other recent studies reported improvements.³¹˒³³˒³⁵˒³⁷

Research in children, mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease and clinical mood conditions remains limited, mixed or at high risk of bias. Bacopa should not be presented as treating ADHD, dementia, Parkinson’s disease, depression or another medical condition.²²–³⁰˒⁴⁰˒⁴³

Luminara provides 300 mg daily of Bacopa monnieri extract. The supplied raw-material batch assayed at 20.20% bacosides by UV, corresponding nominally to approximately 60.6 mg of measured bacosides in the daily amount. The CoA does not state the plant part, extraction ratio, solvent, carrier content or detailed bacoside profile, so direct equivalence to proprietary clinical extracts cannot be claimed.

The most accurate positioning is:

Brahmi provides meaningful human evidence for memory and learning, with emerging support for mental clarity, stress-related wellbeing and fatigue. Its effects are gradual, selective and dependent on the extract and population rather than universal.

REFERENCES

1. Royal Botanic Gardens, Kew. Bacopa monnieri (L.) Wettst.. Plants of the World Online. Accessed 1 August 2026.

2. Walker EA, Pellegrini MV. Bacopa monnieri. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Chapter first posted 17 March 2023. PMID: 36943953.

3. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313-326. doi:10.1089/rej.2013.1431. PMID: 23772955.

4. Sivaramakrishna C, Rao CV, Trimurtulu G, Vanisree M, Subbaraju GV. Triterpenoid glycosides from Bacopa monnieri. Phytochemistry. 2005;66(23):2719-2728. doi:10.1016/j.phytochem.2005.09.016. PMID: 16293276.

5. Chakravarty AK, Garai S, Masuda K, Nakane T, Kawahara N. Bacopasides III-V: three new triterpenoid glycosides from Bacopa monnieri. Chem Pharm Bull (Tokyo). 2003;51(2):215-217. doi:10.1248/cpb.51.215. PMID: 12576661.

6. Deepak M, Amit A. The need for establishing identities of 'bacoside A and B', the putative major bioactive saponins of Indian medicinal plant Bacopa monnieri. Phytomedicine. 2004;11(2-3):264-268. doi:10.1078/0944-7113-00351. PMID: 15070183.

7. Mathur D, Goyal K, Koul V, Anand A. The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera). Front Pharmacol. 2016;7:44. doi:10.3389/fphar.2016.00044. PMID: 26973531.

8. Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481-484. doi:10.1007/s002130100815. PMID: 11498727.

9. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279-281. doi:10.1016/S0893-133X(01)00419-5. PMID: 12093601.

10. Raghav S, Singh H, Dalal PK, Srivastava JS, Asthana OP. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Indian J Psychiatry. 2006;48(4):238-242. doi:10.4103/0019-5545.31555. PMID: 20703343.

11. Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, Wesnes K, Nathan PJ. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-1634. doi:10.1002/ptr.2537. PMID: 18683852.

12. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707-713. doi:10.1089/acm.2008.0018. PMID: 18611150.

13. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753-759. doi:10.1089/acm.2009.0342. PMID: 20590480.

14. Peth-Nui T, Wattanathorn J, Muchimapura S, Tong-Un T, Piyavhatkul N, Rangseekajee P, Ingkaninan K, Vittaya-Areekul S. Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evid Based Complement Alternat Med. 2012;2012:606424. doi:10.1155/2012/606424. PMID: 23320031.

15. Kumar N, Abichandani LG, Thawani V, Gharpure KJ, Naidu MUR, Venkat Ramana G. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2016;2016:4103423. doi:10.1155/2016/4103423. PMID: 27803728.

16. Downey LA, Kean J, Nemeh F, Lau A, Poll A, Gregory R, Murray M, Rourke J, Patak B, Pase MP, Zangara A, Lomas J, Scholey A, Stough C. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2013;27(9):1407-1413. doi:10.1002/ptr.4864. PMID: 23281132.

17. Benson S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A. An acute, double-blind, placebo-controlled crossover study of Bacopa monnieri on stress reactivity and mood. Phytother Res. 2014;28(4):551-559. doi:10.1002/ptr.5029. PMID: 23788517.

18. Barbhaiya HC, Desai RP, Saxena VS, Pravina K, Wasim P, Geetharani P, Allan JJ, Venkateshwarlu K, Amit A. Efficacy and Tolerability of BacoMind® on Memory Improvement in Elderly Participants - A Double Blind Placebo Controlled Study. J Pharmacol Toxicol. 2008;3(6):425-434. doi:10.3923/jpt.2008.425.434.

19. Pravina K, Ravindra KR, Goudar KS, Vinod DR, Joshua AJ, Wasim P, Venkateshwarlu K, Saxena VS, Amit A. Safety evaluation of BacoMind in healthy volunteers: a phase I study. Phytomedicine. 2007;14(5):301-308. doi:10.1016/j.phymed.2007.03.010. PMID: 17442556.

20. Sadhu A, Upadhyay P, Agrawal A, Ilango K, Karmakar D, Singh GPI, Dubey GP. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. Clin Drug Investig. 2014;34(12):857-869. doi:10.1007/s40261-014-0235-9. PMID: 25316430.

21. Crosta F, Stefani A, Melani F, Fabrizzi P, Nizzardo A, Grassi D, Bocale R, Necozione S, Lombardi F, Castelli V, et al. Improvement of Executive Function after Short-Term Administration of an Antioxidants Mix Containing Bacopa, Lycopene, Astaxanthin and Vitamin B12: The BLAtwelve Study. Nutrients. 2021;13(1):56. doi:10.3390/nu13010056. PMID: 33375429.

22. Dave UP, Dingankar SR, Saxena VS, Joseph JA, Bethapudi B, Agarwal A, Kudiganti V. An open-label study of a standardized Bacopa monnieri extract in children with attention-deficit hyperactivity disorder. Adv Mind Body Med. 2014;28(2):10-15. PMID: 24682000.

23. Mitra-Ganguli T, Kalita S, Bhushan S, Stough C, Kean J, Wang N, Sethi V, Khadilkar A. A Randomized, Double-Blind Study Assessing Changes in Cognitive Function in Indian School Children Receiving a Combination of Bacopa monnieri and Micronutrient Supplementation vs. Placebo. Front Pharmacol. 2017;8:678. doi:10.3389/fphar.2017.00678. PMID: 29204115.

24. Kean JD, Kaufman J, Lomas J, Goh A, White D, Simpson D, et al. Effects of Bacopa monnieri (CDRI 08®) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2022;36(2):996-1012. doi:10.1002/ptr.7372. PMID: 35041248.

25. Goswami S, Saoji A, Kumar N, Thawani V, Tiwari M, Thawani M. Effect of Bacopa monnieri on Cognitive functions in Alzheimer's disease patients. Int J Collab Res Intern Med Public Health. 2011;3(4):285-293.

26. Prabhakar S, et al. Efficacy of Bacopa Monnieri (Brahmi) and Donepezil in Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Double-Blind Parallel Phase 2b Study. Ann Indian Acad Neurol. 2020;23(6):767-773. doi:10.4103/aian.AIAN_610_19. PMID: 33688125.

27. Mishra M, Mishra AK, Mishra U. Brahmi (Bacopa monnieri Linn) in the treatment of dementias - a pilot study. Future Healthc J. 2019;6(Suppl 1):s69. doi:10.7861/futurehosp.6-1-s69. PMID: 31363591.

28. Cicero AFG, Bove M, Colletti A, Rizzo M, Fogacci F, Giovannini M, Borghi C. Short-Term Impact of a Combined Nutraceutical on Cognitive Function, Perceived Stress and Depression in Young Elderly with Cognitive Impairment: A Pilot, Double-Blind, Randomized Clinical Trial. J Prev Alzheimers Dis. 2017;4(1):12-15. doi:10.14283/jpad.2016.110.

29. dos Santos AF, Souza MMQ, Amaral EC, Albuquerque ER, Bortoloti DS, Gasparotto Junior A, Lourenço ELB, Lovato ECW, Lívero FADR. Bacopa monnieri in Patients with Parkinson's Disease: A Pilot Study. J Med Food. 2023;26(2):114-119. doi:10.1089/jmf.2022.0106. PMID: 36800346.

30. Micheli L, Spitoni S, Di Cesare Mannelli L, Bilia AR, Ghelardini C, Pallanti S. Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. Phytother Res. 2020;34(9):2331-2340. doi:10.1002/ptr.6684. PMID: 32236999.

31. Lopresti AL, Smith SJ, Ali S, Metse A, Kalns J, Drummond PD. Effects of a Bacopa monnieri extract (Bacognize®) on stress, fatigue, quality of life and sleep in adults with self-reported poor sleep: A randomised, double-blind, placebo-controlled study. J Funct Foods. 2021;85:104671. doi:10.1016/j.jff.2021.104671.

32. McPhee GM, Downey LA, Wesnes KA, Stough C. The Neurocognitive Effects of Bacopa monnieri and Cognitive Training on Markers of Brain Microstructure in Healthy Older Adults. Front Aging Neurosci. 2021;13:638109. doi:10.3389/fnagi.2021.638109. PMID: 33692683.

33. Eraiah MM, Shekhar HC, Joshua L, Thomas JV. Effect of Bacopa monnieri Extract on Memory and Cognitive Skills in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Study. J Psychiatry Cogn Behav. 2024;8:168. doi:10.29011/2574-7762.000068.

34. Lopresti AL, Smith SJ. The Effects of a Bacopa monnieri Extract (Bacumen®) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Drug Investig. 2025;45(12):967-982. doi:10.1007/s40261-025-01492-1. PMID: 41091332.

35. Delfan M, et al. Evaluating the effects of Bacopa monnieri on cognitive performance and sleep quality of patients with mild cognitive impairment: A triple-blinded, randomized, placebo-controlled trial. Explore (NY). 2024;20(5):102990. doi:10.1016/j.explore.2024.02.008. PMID: 38538390.

36. Keegan AP, Stough C, Paris D, Luis CA, Abdullah L, Ait-Ghezala G, Crawford F, Mullan M. Bacopa monnieri supplementation has no effect on serum brain-derived neurotrophic factor levels but beneficially modulates nuclear factor kappa B and cyclic AMP response element-binding protein levels in healthy elderly subjects. J Clin Transl Res. 2023;9(1):50-58. PMID: 37032999.

37. Gowda SS, Joshua L, Thomas JV. Efficacy and Safety of Bacopa monnieri Extract for Stress Management and Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial. Curr Res Cmpl Alt Med. 2026;10:280. doi:10.29011/25772201.100280. Trial registration: CTRI/2025/05/087114.

38. Young LM, Gauci S, Arnoldy L, Martin L, Perry N, White DJ, Meyer D, Lassemillante AC, Ogden E, Silber B, Scholey A, Pipingas A. Investigating the Effects of a Multinutrient Supplement on Cognition, Mood and Biochemical Markers in Middle-Aged Adults with 'Optimal' and 'Sub-Optimal' Diets: A Randomized Double Blind Placebo Controlled Trial. Nutrients. 2022;14(23):5079. doi:10.3390/nu14235079.

39. Minale G, Saesong T, Temkitthawon P, et al. Characterization of Metabolites in Plasma, Urine and Feces of Healthy Participants after Taking Brahmi Essence for Twelve Weeks Using LC-ESI-QTOF-MS Metabolomic Approach. Molecules. 2021;26(10):2944. doi:10.3390/molecules26102944.

40. Dwivedi A, Anjali A, Narzari H, Kumar Y, Sharma HP, Dubey A, Nilima N, Rajan R, Singh MB, Vishnu VY, Bhatia R, Sharma G, Gupta A. Efficacy of Bacopa monnieri (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial. JMIR Res Protoc. 2026;15:e82891. doi:10.2196/82891. PMID: 41740144.

41. Pase MP, Kean J, Sarris J, Neale C, Scholey AB, Stough C. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647-652. doi:10.1089/acm.2011.0367. PMID: 22747190.

42. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Scholfield CN. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528-535. doi:10.1016/j.jep.2013.11.008. PMID: 24252493.

43. Basheer A, Agarwal A, Mishra B, Gupta A, Srivastava MVP, Kirubakaran R, Vishnu V. Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials. Interact J Med Res. 2022;11(2):e38542. doi:10.2196/38542. PMID: 35612544.

44. Valotto Neto LJ, Reverete de Araujo M, Moretti Junior RC, Mendes Machado N, Joshi RK, dos Santos Buglio D, Barbalho Lamas C, Direito R, Fornari Laurindo L, Tanaka M, Barbalho SM. Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis. Antioxidants (Basel). 2024;13(4):393. doi:10.3390/antiox13040393. PMID: 38671841.

45. Cave AE, Chang DH, Münch GW, Steiner-Lim GZ. A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment. Syst Rev. 2023;12(1):143. doi:10.1186/s13643-023-02301-6. PMID: 37592293.

46. Gościniak A, Stasiłowicz-Krzemień A, Szeląg M, Pawlak J, Skiera I, Kwiatkowska H, Nowak N, Bernady K, Trzaskoma P, Zimak-Krótkopad O, Cielecka-Piontek J. Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability. Nutrients. 2025;17(11):1939. doi:10.3390/nu17111939. PMID: 40507208.

47. Brimson JM, Brimson S, Prasanth MI, Thitilertdecha P, Malar DS, Tencomnao T. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. Sci Rep. 2021;11(1):596. doi:10.1038/s41598-020-80045-2. PMID: 33436817.

48. Das A, Shanker G, Nath C, Pal R, Singh S, Singh HK. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav. 2002;73(4):893-900. doi:10.1016/S0091-3057(02)00940-1.

49. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol. 2010;127(1):26-31. doi:10.1016/j.jep.2009.09.056.

50. Holcomb LA, Dhanasekaran M, Hitt AR, Young KA, Riggs M, Manyam BV. Bacopa monniera extract reduces amyloid levels in PSAPP mice. J Alzheimers Dis. 2006;9(3):243-251. doi:10.3233/JAD-2006-9303. PMID: 16914834.

51. Vollala VR, Upadhya S, Nayak S. Enhancement of basolateral amygdaloid neuronal dendritic arborization following Bacopa monniera extract treatment in adult rats. Clinics (Sao Paulo). 2011;66(4):663-671. doi:10.1590/S1807-59322011000400023. PMID: 21655763.

52. Saraf MK, Prabhakar S, Khanduja KL, Anand A. Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice. Evid Based Complement Alternat Med. 2011;2011:236186. doi:10.1093/ecam/neq038. PMID: 21607013.

53. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi). Indian J Pharmacol. 1997;29(5):359-365.

54. Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005;12(4):305-317. doi:10.1016/j.phymed.2003.12.008.

55. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000;14(3):174-179. doi:10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3.0.CO;2-O. PMID: 10815010.

56. Charles PD, Ambigapathy G, Geraldine P, Akbarsha MA, Rajan KE. Bacopa monniera leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: implications in memory formation. J Ethnopharmacol. 2011;134(1):55-61. doi:10.1016/j.jep.2010.11.045. PMID: 21129470.

57. Le XT, Pham HTN, Do PT, Fujiwara H, Tanaka K, Li F, Van Nguyen T, Nguyen KM, Matsumoto K. Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems. Neurochem Res. 2013;38(10):2201-2215. doi:10.1007/s11064-013-1129-6. PMID: 23949198.

58. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol. 2008;120(1):112-117. doi:10.1016/j.jep.2008.07.039. PMID: 18755259.

59. Saini N, Singh D, Sandhir R. Neuroprotective effects of Bacopa monnieri in experimental model of dementia. Neurochem Res. 2012;37(9):1928-1937. doi:10.1007/s11064-012-0811-4. PMID: 22700087.

60. Rai D, Bhatia G, Palit G, Pal R, Singh S, Singh HK. Adaptogenic effect of Bacopa monniera (Brahmi). Pharmacol Biochem Behav. 2003;75(4):823-830. doi:10.1016/S0091-3057(03)00156-4. PMID: 12957224.

61. National Institute of Diabetes and Digestive and Kidney Diseases. Bacopa monnieri. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Library of Medicine. Last updated 24 April 2024. Bookshelf ID: NBK603563.

62. Russo A, Izzo AA, Borrelli F, Renis M, Vanella A. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytother Res. 2003;17(8):870-875. doi:10.1002/ptr.1061. PMID: 13680815.

63. Singh RH, Singh L. Studies on the anti-anxiety effect of the Medhya rasayana drug Brahmi (Bacopa monniera Wettst.). Res Ayurveda Siddha. 1980;1:133-148.

64. Rauf K, Subhan F, Al-Othman AM, Khan I, Zarrelli A, Shah MR. Preclinical profile of bacopasides from Bacopa monnieri (BM) as an emerging class of therapeutics for management of chronic pains. Curr Med Chem. 2013;20(8):1028-1037. doi:10.2174/0929867311320080006. PMID: 23210787.

These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

JUJUBE

Ziziphus jujuba Mill.

Jujube is the edible fruit of a small tree in the Rhamnaceae family. It is also known as Chinese date, red date, Da Zao or Hong Zao.

The fruit has been consumed as food and used in East Asian, Persian and other traditional systems for nourishment, digestive wellbeing, physical restoration and emotional calm. Its chemistry includes carbohydrates and fibre together with polysaccharides, phenolic compounds, flavonoids, triterpenic acids, cyclic nucleotides, vitamins and minerals.¹–³

Jujube requires an unusually important evidence distinction:

THE FRUIT IS NOT THE SAME INGREDIENT AS THE MEDICINAL SEED.

Luminara contains a 10:1 jujube fruit extract.

Most of the direct modern human research commonly used to support “jujube for sleep” has investigated:

• the seed of Ziziphus jujuba;
• Ziziphus jujuba var. spinosa;
• Ziziphus spinosa seed;
• or multi-herb formulas centred on Ziziphi Spinosae Semen, known as Suan Zao Ren.

Those seed preparations contain and are often standardised around compounds such as spinosin and jujosides. Luminara’s fruit extract has not been assayed for those compounds, and seed findings cannot automatically be assigned to the fruit.²˒²⁵–³¹

Human fruit research does exist, but it focuses mainly on:

• constipation and bowel function;⁴˒¹⁷˒²¹
• lipid, glucose, insulin and blood-pressure measures in people with metabolic conditions;⁶˒⁷˒¹⁰˒¹²˒¹⁴˒²⁰˒²²
• postprandial glycaemic responses as a food;¹¹˒²³
• neonatal jaundice;⁵
• toxic elements in human milk;⁹
• topical nipple fissures;¹³
• pulmonary-tuberculosis treatment support;¹⁵
• chronic urticaria;¹⁸˒¹⁹
• a multi-herb skin-brightening syrup;¹⁶
• and a recent trial in women with polycystic ovary syndrome.²⁴

These studies are scientifically relevant, but most involved whole dried fruit, fruit infusions, syrups, pastes, lotions or much larger fruit-equivalent amounts than Luminara’s 300 mg extract.

The most accurate interpretation is therefore:

Jujube fruit has meaningful human research in digestive and metabolic areas. The direct sleep evidence belongs mainly to the seed and cannot be treated as proof that Luminara’s fruit extract improves sleep.


JUJUBE AT A GLANCE

Intended botanical identity: Ziziphus jujuba Mill.

Botanical family: Rhamnaceae

Common names: Jujube, Chinese date, red date, Da Zao, Hong Zao

Part used in Luminara: Fruit

Ingredient form in Luminara: Fruit extract

Luminara daily amount: 300 mg

Supplier-specified extract ratio: 10:1

Nominal dried-fruit equivalent if the ratio is confirmed as a true native drug-extract ratio: 3,000 mg

Chemical standardisation: None stated

Identity method on supplied CoA: Thin-layer chromatography

Batch number: HB-DZ20240109

Manufacture date: 9 January 2024

Expiry date: 8 January 2027

The supplier document is a current batch certificate showing a positive identity result and acceptable results against its listed physical, microbial, pesticide and heavy-metal specifications.

However, it does not state:

• the Latin botanical species;
• the fruit tissue used, such as whole fruit, pulp or another fraction;
• the extraction solvent;
• whether 10:1 is the native drug-extract ratio;
• the carrier or excipient percentage;
• the country of origin;
• a chemical marker or chromatographic fingerprint;
• the actual amount of polysaccharides, phenolics, triterpenic acids, spinosin or jujubosides.

Until the supplier confirms the native extraction ratio and carrier status, it is safer to describe the ingredient as:

300 mg of a 10:1 jujube fruit extract.

The public page should not state that it “delivers 3,000 mg of fruit” as an established equivalence unless that calculation is supported by the supplier’s technical documentation.


HOW CLOSELY DOES LUMINARA’S JUJUBE MATCH THE HUMAN RESEARCH?

Luminara aligns with the fruit literature in one important way: it uses the fruit rather than the seed.

The match remains limited for several reasons.

Many fruit studies used:

• 15–30 grams of dried fruit each day;⁷˒¹²˒¹⁴˒²⁰˒²²
• a fruit infusion prepared from 10 grams per 100 mL, consumed three times daily;¹⁰
• liquid extracts or syrups dosed by body weight;⁴˒⁵˒¹⁷˒²¹
• jujube paste;¹⁷
• 15 grams daily of a hydroalcoholic extract in the PCOS study;²⁴
• topical fruit lotion;¹³
• multi-herb syrups or oxymels;¹⁶˒¹⁹
• dried fruit as a food providing a defined carbohydrate load.¹¹˒²³

If Luminara’s 10:1 ratio represents a true undiluted native extract, 300 mg would be nominally derived from approximately 3 grams of fruit.

That remains:

• one-fifth of a 15-gram study amount;
• one-tenth of the 30-gram amount used in several cardiometabolic trials;
• chemically different from a fruit syrup, paste, infusion or whole dried fruit;
• not known to contain the same fibre, sugars or full food matrix.

Fibre and food structure may be important to bowel and postprandial-glycaemic effects. A concentrated extract cannot be assumed to reproduce the physiological behaviour of thirty grams of whole dried fruit.

No located human study tested:

• 300 mg daily of a 10:1 jujube fruit extract;
• an extract demonstrated to be chemically equivalent to Luminara’s ingredient;
• Luminara’s exact botanical combination.

The accurate conclusion is:

Luminara uses the same plant part as the human fruit studies, but its dose and preparation are not clinically matched to them.


FRUIT VERSUS SEED: THE CRITICAL DISTINCTION

Jujube fruit and jujube seed are physically and chemically different botanical materials.

FRUIT

The fruit is an edible food and traditional tonic. It contains:

• polysaccharides;
• soluble and insoluble carbohydrates;
• phenolic acids;
• flavonoids;
• triterpenic acids;
• cyclic nucleotides;
• vitamins and minerals;
• variable fibre and sugar depending on processing.²˒³

Human fruit studies have focused mainly on bowel, metabolic, dermatological and adjunctive medical outcomes.

SEED

The medicinal seed is known in Chinese medicine as Suan Zao Ren or Ziziphi Spinosae Semen.

Seed research commonly involves:

• Ziziphus jujuba var. spinosa;
• Ziziphus spinosa;
• seed granules or seed capsules;
• multi-herb insomnia formulas;
• spinosin, jujubosides or related seed markers.

Standalone controlled human seed studies have reported improved subjective sleep outcomes in small samples, including postmenopausal women and adults with insomnia.²⁵˒²⁶

A wider formula literature exists for Suanzaoren Decoction, Zao Ren An Shen and other seed-centred products, but those formulas contain additional herbs and cannot establish the effect of jujube fruit—or even seed alone.²⁷–³¹

Luminara’s CoA does not quantify spinosin or jujubosides and does not identify seed material.

Therefore, it would be scientifically misleading to use the seed sleep trials as direct evidence that Luminara’s jujube fruit extract improves sleep.


TRADITIONAL USE

Jujube fruit has been used traditionally as both a food and restorative botanical.

Traditional associations have included:

• nourishment during weakness or recovery;
• digestive comfort and bowel regularity;
• appetite and general vitality;
• support during physical fatigue;
• emotional calm;
• harmonising stronger herbs in traditional formulas;
• respiratory and throat comfort;
• support during convalescence;
• healthy ageing.

In Chinese herbal practice, the sweet fruit is often described as nourishing and harmonising.

In Persian traditional medicine, fruit preparations have been used in areas including bowel function, skin and inflammatory complaints.

Traditional use varies according to:

• fresh versus dried fruit;
• whole fruit, pulp, syrup or decoction;
• dose;
• cultivar;
• whether other herbs are included.

Traditional use does not establish that a 300 mg 10:1 extract produces every historical outcome.


WHAT HUMAN CLINICAL STUDIES HAVE INVESTIGATED


SLEEP AND EMOTIONAL CALM

No controlled human sleep trial of a standalone jujube fruit extract was located.

This is the single most important finding for Luminara’s Evidence Centre.

Jujube is frequently promoted online as a sleep herb, but the clinical evidence commonly cited belongs to the seed.

JUJUBE SEED IN POSTMENOPAUSAL WOMEN

A double-blind randomised clinical trial investigated a jujube seed capsule in postmenopausal women and reported an improvement in Pittsburgh Sleep Quality Index scores compared with placebo.²⁵

This study is relevant to women in the menopausal stage, but it does not substantiate Luminara because:

• the medicinal seed was used;
• Luminara uses fruit;
• the seed preparation and marker content are not matched;
• the study addressed sleep quality, not broader menopause symptoms;
• it does not show that fruit has the same activity.

ZIZIPHUS SPINOSA SEED GRANULES

A 2021 randomised, placebo-controlled crossover feasibility study enrolled twelve adults with insomnia. Participants received 2 grams daily of encapsulated Ziziphus spinosa seed granules or placebo during four-week treatment periods.²⁶

Subjective sleep quality on the PSQI improved during seed treatment compared with placebo.

However:

• the trial was extremely small;
• it primarily established feasibility;
• several sleep outcomes were not clearly superior;
• it used seed granules rather than fruit extract.

SEED-CENTRED FORMULAS

Trials and systematic reviews have investigated formulas including:

• Suanzaoren Tang or Suanzaoren Decoction;²⁷˒²⁸
• Zao Ren An Shen;²⁹
• other Chinese patent medicines containing Ziziphi Spinosae Semen.³⁰˒³¹

Some report improved subjective insomnia outcomes.

These formulas usually contain several active botanicals. Their findings cannot be assigned to jujube fruit, and often cannot be assigned to the seed alone.

CURRENT CONCLUSION FOR SLEEP

Evidence level for jujube seed and seed-centred formulas: emerging but preparation-specific.

Evidence level for Luminara’s jujube fruit extract: traditional or preclinical only.

The public copy should not describe Luminara’s jujube as clinically proven—or human-clinically supported—for sleep.


CONSTIPATION AND BOWEL FUNCTION

Fruit-specific human evidence is strongest in constipation.

NAFTALI ET AL., 2008

A controlled twelve-week clinical trial investigated a liquid Ziziphus jujuba extract in adults with chronic idiopathic constipation.⁴

Thirty-seven participants with prolonged intestinal transit time were included:

• eighteen received the jujube preparation;
• nineteen received placebo.

The study reported:

• reduced transit time;
• lower constipation-symptom severity;
• improved quality-of-life measures.

However, sixteen of nineteen placebo participants withdrew because of severe constipation, compared with two of eighteen receiving jujube. This unusually high and unequal attrition substantially complicates interpretation.

The preparation was a liquid extract of incompletely reported composition and is not matched to Luminara.

YOUSEFI ET AL., 2023

A randomised clinical trial compared jujube paste with polyethylene glycol for maintenance treatment of functional constipation in children.¹⁷

The study reported that both interventions were effective, with selected advantages for jujube in stool consistency or acceptability.

Limitations include:

• paediatric disease population;
• paste rather than extract;
• short follow-up;
• no relevance to an ordinary adult supplement claim;
• incomplete equivalence to the 10:1 extract.

KEIHANIAN ET AL., 2025

A double-blind randomised clinical trial compared jujube syrup with polyethylene glycol in children aged two to ten with functional constipation.²¹

Ninety children were eligible, and sixty-two completed follow-up.

Compared with polyethylene glycol, the jujube-syrup group had greater improvements in:

• therapeutic response score;
• defecation frequency;
• encopresis;
• pain;
• medication adherence.

The study did not identify liver or kidney injury over the follow-up period, and self-limiting adverse effects occurred only in the polyethylene-glycol group.

This is encouraging clinical evidence for that paediatric syrup.

It does not establish that Luminara’s much smaller extract amount:

• treats constipation;
• acts as a laxative;
• reproduces syrup or whole-fruit effects;
• is appropriate for children.

CURRENT CONCLUSION FOR DIGESTIVE REGULARITY

Several human fruit studies support biological plausibility for bowel and transit effects.

The evidence is still not a clean match to Luminara because the studies involve medical populations, different preparations and potentially fibre-rich products.

The safest general wording would be:

“Jujube fruit has been investigated in human studies of bowel function and digestive regularity.”

It should not be marketed as treating chronic or paediatric constipation.


CARDIOMETABOLIC RESEARCH

Several randomised trials have examined jujube fruit in people with type 2 diabetes, metabolic syndrome, dyslipidaemia, obesity or related risk factors.

This is a substantial fruit-specific human literature, but it presents three major challenges for Luminara:

• most participants had diagnosed medical conditions;
• most interventions used 15–30 grams of dried fruit or large infusions;
• findings are mixed across glucose, lipids, blood pressure, inflammation and oxidative stress.

SABZGHABAEE ET AL., 2013

A triple-masked placebo-controlled trial enrolled eighty-six obese adolescents with dyslipidaemia.⁶

Jujube fruit was generally tolerated, and the researchers reported potentially favourable lipid effects.

The small changes, short duration, paediatric population and disease-risk context limit relevance to Luminara.

MOSTAFA AND LABBAN, 2013

An intervention study investigated different daily amounts of jujube powder and reported changes in lipid and anthropometric measures.⁷

The study was published in a lower-profile journal and had methodological limitations. It should be treated as supporting evidence rather than a foundation for a claim.

YAZDANPANAH ET AL., 2017

A randomised controlled trial enrolled adults with type 2 diabetes.¹⁰

Participants consumed a fruit infusion prepared from 10 grams of jujube in 100 mL of boiling water three times daily for twelve weeks.

The study investigated:

• fasting and postprandial glucose;
• HbA1c;
• lipid profile;
• antioxidant status.

The findings were mixed. Later reviews of the trial note that glucose and oxidative-stress outcomes were not consistently improved. Some participants were reportedly excluded after hypotension.

This study should not be summarised as simple proof that jujube lowers glucose.

IRANNEJAD NIRI ET AL., 2021

A randomised controlled trial investigated 30 grams daily of dried fruit for twelve weeks in people with type 2 diabetes.¹²

Compared with control, the intervention produced improvements in selected measures including:

• insulin;
• HOMA-IR;
• ApoB100;
• high-sensitivity C-reactive protein;
• weight or body-mass-index change.

Plasma glucose did not show a consistently significant improvement.

The product was whole dried fruit at one hundred times Luminara’s extract mass and approximately ten times its possible dried-fruit equivalent.

FARHADNEJAD ET AL., 2022

A randomised controlled trial enrolled forty-eight adults with type 2 diabetes; forty completed the intervention.¹⁴

Participants consumed 30 grams daily of dried jujube for twelve weeks.

The study assessed:

• glucose;
• lipids;
• anthropometric measures;
• systemic inflammatory markers.

Selected cardiometabolic and inflammatory improvements were reported.

Again, this was a medical population consuming a whole-food quantity.

PARASTOUEI ET AL., 2024

A parallel randomised controlled trial enrolled sixty people with metabolic syndrome and provided 30 grams of dried jujube powder or placebo.²⁰

The study reported improvements in selected outcomes including:

• waist circumference;
• triglycerides;
• HDL cholesterol;
• stress scores.

Other outcomes were not uniformly improved.

The presence of a mental-health or stress score in this study does not establish that Luminara’s extract is a clinical calming ingredient. The population, dose and food matrix differ substantially.

FARHADNEJAD ET AL., 2025

A randomised controlled trial investigated 30 grams daily of dried fruit for twelve weeks in forty-eight adults with type 2 diabetes and excess weight.²²

Compared with control, jujube reduced:

• plasma insulin by up to approximately 4.6 mIU/L;
• systolic blood pressure by up to approximately 7 mmHg;
• diastolic blood pressure by up to approximately 5 mmHg;
• HOMA-IR.

The study did not find significant between-group improvements in:

• total antioxidant capacity;
• malondialdehyde;
• carboxymethyl lysine, an advanced-glycation-end-product marker.

This important null evidence prevents the trial from being described as broadly antioxidant.

META-ANALYTIC EVIDENCE

A 2025 systematic review and meta-analysis examined jujube-fruit trials involving lipids, glycaemic measures and liver markers.³²

The review reported pooled improvements in some lipid or anthropometric measures but emphasised:

• few eligible trials;
• small samples;
• clinical and methodological heterogeneity;
• variable doses and products;
• limited certainty for several outcomes.

The meta-analysis does not solve the product-match problem.

CURRENT CONCLUSION FOR METABOLIC OUTCOMES

Fruit research in diagnosed metabolic populations is scientifically meaningful.

It does not justify claims that Luminara:

• treats diabetes;
• reduces blood pressure;
• lowers cholesterol;
• reverses insulin resistance;
• prevents cardiovascular disease.

The evidence is best retained in the complete research record rather than used as a primary consumer claim.


POSTPRANDIAL GLYCAEMIC RESPONSE AS A FOOD

Dried jujube has been studied as a food in healthy adults.

ZHU ET AL., 2018

A randomised crossover study tested dried fruits, including dried jujube, in eleven healthy participants.¹¹

The researchers measured postprandial glucose responses when the dried fruits were consumed alone or in meals.

This was food research rather than supplementation research. The outcome depended on:

• available carbohydrate;
• fruit sugars;
• fibre;
• meal composition;
• whether nuts or rice were included.

COOKING AND PRELOAD STUDY, 2025

A later randomised food study in fourteen healthy participants compared cooked and uncooked air-dried jujube and tested a small jujube preload before a rice meal.²³

Cooking increased the postprandial glycaemic response when jujube was consumed as the principal carbohydrate source, while the preload approach altered the subsequent rice response.

This is useful negative and contextual evidence:

Jujube is a carbohydrate-containing dried fruit, and its metabolic effect is not inherently glucose-lowering in every eating pattern.

A 300 mg concentrated extract cannot be assumed to behave like these whole-food portions.


PCOS, FERTILITY AND REPRODUCTIVE RESEARCH

A 2026 randomised controlled trial compared:

• jujube hydroalcoholic extract;
• metformin;
• myo-inositol;
• placebo;

in infertile women with polycystic ovary syndrome.²⁴

The jujube group reportedly consumed 15 grams daily for twelve weeks.

The trial reported improvements in selected:

• fasting glucose;
• lipid measures;
• insulin-resistance indices.

Jujube did not significantly increase pregnancy occurrence compared with metformin or myo-inositol.

One participant reportedly experienced mild constipation.

This is relevant modern research in younger women, but it does not support claiming that Luminara:

• treats PCOS;
• improves fertility;
• induces ovulation;
• increases pregnancy rates;
• replaces metformin or myo-inositol;
• broadly balances hormones.

The extract amount was also far larger than Luminara’s 300 mg ingredient.


STRESS AND MENTAL-HEALTH OUTCOMES

The strongest fruit-specific mental-health result comes from the 2024 metabolic-syndrome trial, which reported improvement in a stress score alongside selected metabolic outcomes.²⁰

That result is insufficient to establish a direct stress claim because:

• stress was one of several outcomes;
• the population had metabolic syndrome;
• 30 grams of dried fruit powder was used;
• the trial does not establish an anxiolytic or sedative mechanism;
• no replication with fruit extract was located.

The human sleep evidence remains seed-based.

Jujube fruit may appropriately be described as traditionally associated with nourishment and calm, but direct clinical evidence for anxiety, mood or sleep from the fruit is limited.


SKIN RESEARCH

TOPICAL NIPPLE FISSURES

A double-blind clinical trial recruited one hundred primiparous breastfeeding women with nipple fissures.¹³

Jujube-fruit lotion was applied topically and compared with breast milk over fourteen days.

The fruit lotion produced faster improvement in fissure severity and pain.

This is direct human evidence for a topical fruit preparation.

It has no direct relevance to oral Luminara supplementation.

MULTI-HERB SKIN-BRIGHTENING SYRUP

A 2022 randomised double-blind trial enrolled forty-six participants who consumed a syrup or placebo twice daily for eight weeks.¹⁶

The syrup was not jujube alone. It contained extracts of:

• Ziziphus jujuba;
• Berberis vulgaris;
• Rhus coriaria;
• Prunus domestica;
• Rosa damascena.

Skin-brightening outcomes improved with the complete syrup.

The effect cannot be attributed specifically to jujube, and it does not establish an oral skin benefit for Luminara.


HUMAN MILK AND BREASTFEEDING RESEARCH

A randomised controlled trial examined whether maternal jujube-fruit consumption altered lead, cadmium and arsenic concentrations in human milk.⁹

The findings were selective rather than uniformly positive. Later reviews highlighted a sharper reduction in cadmium, while consistent reductions across all tested elements were not established.

This study:

• does not show that jujube detoxifies the body;
• does not establish clinical benefit to an infant;
• does not establish the safety of Luminara during breastfeeding;
• used fruit consumption rather than Luminara’s multi-herb formula.

Breastfeeding women should seek qualified professional advice before using Luminara.


NEONATAL JAUNDICE

A clinical trial enrolled 121 newborns receiving phototherapy for jaundice.⁵

The intervention group received jujube-fruit extract at 1 mL/kg three times daily in addition to phototherapy.

An early reduction in bilirubin was reported compared with phototherapy plus distilled water.

This is highly population-specific medical research in newborns.

It cannot support a general liver, detoxification or jaundice claim for Luminara.


PULMONARY-TUBERCULOSIS TREATMENT SUPPORT

A small randomised double-blind placebo-controlled pilot trial investigated jujube syrup alongside standard anti-tuberculosis treatment.¹⁵

The study reported fewer cases of medicine-associated hepatotoxicity and improvements in selected cough or quality-of-life outcomes.

Limitations include:

• pilot sample;
• disease population;
• adjunctive use with several medicines;
• syrup preparation;
• uncertain generalisability;
• no equivalence to Luminara.

It does not establish that jujube protects the liver generally or that Luminara prevents medicine-related liver injury.


CHRONIC URTICARIA

Two recent trials have examined jujube preparations as add-ons in chronic spontaneous urticaria.

ZARE ET AL., 2023

A double-blind randomised trial enrolled sixty-four patients whose symptoms had not responded adequately to standard-dose second-generation antihistamines.¹⁸

Jujube syrup was added to conventional treatment.

Improvements in urticaria-related outcomes were reported.

The study was disease-specific and does not support an immune, antihistamine or allergy-treatment claim for Luminara.

SHIRAZI ET AL., 2024

A randomised double-blind placebo-controlled study enrolled ninety-two participants with chronic spontaneous urticaria.¹⁹

Participants received jujube oxymel or placebo alongside cetirizine.

Oxymel is a preparation made with acidic and sweet components, commonly vinegar and honey, and is not equivalent to a dry fruit extract.

This study should remain in the research record but cannot substantiate Luminara.


EVIDENCE STRENGTH

HOW WE RATE THE EVIDENCE

★★★★★ — Strong

Multiple high-quality human trials and systematic reviews with consistent findings, relevant preparations and meaningful independent replication.

★★★★☆ — Good

More than one relevant controlled human trial with broadly consistent findings, but with limitations such as modest samples, preparation differences or incomplete replication.

★★★☆☆ — Emerging

At least one controlled human study showing a relevant benefit, with further confirmation or better product matching required.

★★☆☆☆ — Preliminary

Limited, mixed, indirect or disease-population evidence, including different preparations, combination products or small trials.

★☆☆☆☆ — Traditional or preclinical

Traditional use, laboratory research, animal evidence or human evidence involving the wrong plant part.

The rating describes the evidence for the specific Luminara ingredient—not merely whether another part of the same plant has been studied.

HEALTH AREA | EVIDENCE STRENGTH | CURRENT ASSESSMENT

Fruit-specific bowel function and digestive regularity | ★★★☆☆ | Several controlled adult and paediatric studies, but medical populations, syrups/pastes and dose mismatch

Chronic or paediatric constipation treatment | ★★☆☆☆ | Clinical evidence exists, but it is a disease claim inappropriate for Luminara

Sleep support from jujube fruit | ★☆☆☆☆ | No controlled standalone fruit trial located

Sleep support from jujube seed | ★★★☆☆ | Small controlled standalone seed studies and broader formula evidence, but wrong plant part for Luminara

Postmenopausal sleep from Luminara’s fruit | ★☆☆☆☆ | Positive postmenopausal study used seed, not fruit

Traditional calm and restorative use | ★☆☆☆☆ | Traditional evidence; little direct fruit-specific clinical confirmation

Stress-related wellbeing from fruit | ★★☆☆☆ | One metabolic-syndrome trial reported a stress-score improvement at 30 g/day

Metabolic and lipid outcomes | ★★★☆☆ | Multiple fruit trials and a meta-analysis, but diagnosed populations, high food doses and mixed outcomes

Insulin resistance | ★★★☆☆ | Several trials reported selected improvements; glucose findings inconsistent

Blood pressure | ★★☆☆☆ | Positive in a recent T2D trial, not consistent across all studies

Antioxidant biomarkers | ★★☆☆☆ | Laboratory plausibility, but recent controlled human markers were null

Postprandial glycaemic response | ★★☆☆☆ | Small whole-food studies show context-dependent responses, including increased response after cooking

PCOS-related metabolic outcomes | ★★☆☆☆ | One recent disease-population trial at 15 g/day; no treatment or fertility claim

Pregnancy occurrence or fertility | ★☆☆☆☆ | No superiority over active comparators demonstrated

Topical nipple-fissure support | ★★★☆☆ | One controlled topical study; not relevant to oral Luminara

Oral skin brightening | ★★☆☆☆ | One multi-herb syrup trial; jujube contribution cannot be isolated

Human-milk toxic elements | ★★☆☆☆ | One selective and mixed controlled study

Neonatal jaundice | ★★☆☆☆ | One medical trial in newborns; no general product claim

Tuberculosis-treatment support | ★★☆☆☆ | One small adjunctive pilot; no liver-protection claim

Chronic urticaria | ★★☆☆☆ | Two disease-specific add-on trials using syrup or oxymel

Short-term fruit tolerability | ★★★☆☆ | Generally acceptable in the located trials; preparation and dose varied

Long-term extract safety | ★★☆☆☆ | Limited data for concentrated extracts

Clinical match to Luminara’s 300 mg 10:1 extract | ★☆☆☆☆ | No matching human study and incomplete supplier characterisation


WHAT THE KEY STUDIES FOUND

NAFTALI ET AL., 2008⁴

Design: Controlled twelve-week clinical trial.

Population: Adults with chronic idiopathic constipation and prolonged transit time.

Participants: Thirty-seven.

Intervention: Liquid Ziziphus jujuba extract or placebo.

Key findings:

• intestinal transit time improved;
• symptom severity improved;
• quality-of-life measures improved.

Major limitation: Sixteen of nineteen placebo participants withdrew because of severe constipation, compared with two of eighteen receiving jujube. This very unequal dropout makes the magnitude of effect difficult to interpret.

Product limitation: Liquid extract composition and equivalence to Luminara are not established.

EBRAHIMI ET AL., 2011⁵

Design: Randomised clinical trial.

Participants: One hundred and twenty-one newborns aged two to fourteen days with jaundice.

Intervention: Fruit extract at 1 mL/kg three times daily plus phototherapy, or phototherapy with distilled water.

Finding: Greater early bilirubin reduction was reported.

Limitations: Newborn medical population, phototherapy co-treatment, short-term disease outcome and no relevance to ordinary supplementation.

SABZGHABAEE ET AL., 2013⁶

Design: Triple-masked randomised placebo-controlled trial.

Participants: Eighty-six obese adolescents with dyslipidaemia.

Intervention: Jujube fruit preparation.

Finding: The fruit was generally tolerated and may have produced favourable lipid changes.

Limitations: Short, paediatric, disease-risk population and limited clinical relevance to Luminara.

MOSTAFA AND LABBAN, 2013⁷

Design: Human dietary intervention.

Intervention: Different daily amounts of jujube powder.

Outcomes: Lipids and anthropometric measures.

Finding: Within-study improvements were reported.

Limitations: Methodological and reporting quality, modest study status and no extract matching.

KELISHADI ET AL., 2016⁹

Design: Randomised controlled trial.

Population: Lactating mothers.

Intervention: Jujube-fruit consumption or control.

Outcomes: Lead, cadmium and arsenic in human milk.

Finding: Selective changes, with later reviews highlighting a greater decline in cadmium.

Null or uncertain findings: No consistent reduction across every tested toxic element.

Limitation: Does not establish detoxification, infant benefit or breastfeeding safety of Luminara.

YAZDANPANAH ET AL., 2017¹⁰

Design: Randomised controlled trial.

Population: Adults with type 2 diabetes.

Intervention: Infusion made from 10 grams of fruit per 100 mL, three times daily.

Duration: Twelve weeks.

Outcomes: Glycaemic measures, lipids and antioxidant status.

Finding: Selected outcomes changed.

Null and safety findings: Glucose and oxidative-stress findings were not consistently positive; later evidence summaries note withdrawals associated with hypotension.

Limitation: Very large fruit amount, disease population and preparation mismatch.

ZHU ET AL., 2018¹¹

Design: Randomised crossover feeding study.

Participants: Eleven healthy adults.

Intervention: Dried jujube and other dried-fruit test meals.

Outcome: Postprandial glucose.

Finding: Dried jujube produced a measurable food-based glycaemic response that changed according to meal composition.

Limitation: Whole-food carbohydrate study, not extract efficacy.

SHAHRAHMANI ET AL., 2018¹³

Design: Double-blind controlled trial.

Participants: One hundred primiparous breastfeeding women.

Intervention: Topical jujube-fruit lotion or breast milk.

Duration: Fourteen days.

Finding: The fruit lotion improved nipple-fissure severity and pain more quickly.

Limitation: Topical outcome cannot support an oral supplement claim.

IRANNEJAD NIRI ET AL., 2021¹²

Design: Randomised controlled trial.

Population: Adults with type 2 diabetes.

Intervention: Thirty grams of dried fruit daily.

Duration: Twelve weeks.

Key findings:

• lower insulin;
• improved HOMA-IR;
• lower ApoB100;
• lower hs-CRP;
• selected anthropometric improvements.

Null finding: No consistent significant plasma-glucose benefit.

Limitation: Whole-food dose approximately ten times the possible fruit equivalent of Luminara’s ingredient.

MADDAHI ET AL., 2022¹⁵

Design: Pilot randomised double-blind placebo-controlled trial.

Population: People receiving treatment for pulmonary tuberculosis.

Intervention: Jujube-fruit syrup as an add-on.

Findings: Fewer cases of drug-associated hepatotoxicity and improvements in selected cough or quality-of-life outcomes.

Limitations: Small pilot, disease and medication context, syrup mismatch and no general liver-protection conclusion.

FARHADNEJAD ET AL., 2022¹⁴

Design: Randomised controlled trial.

Participants: Forty-eight people with type 2 diabetes; forty completed.

Intervention: Thirty grams of dried jujube daily.

Duration: Twelve weeks.

Finding: Selected cardiometabolic and inflammatory measures improved.

Limitations: Disease population, food dose and no extract equivalence.

AAFI ET AL., 2022¹⁶

Design: Randomised double-blind controlled study.

Participants: Forty-six.

Intervention: Twice-daily multi-herb “jujube syrup.”

Duration: Eight weeks.

Finding: Facial-skin brightening measures improved.

Critical limitation: The syrup also contained barberry, sumac, plum and rose. The result cannot be assigned to jujube alone.

YOUSEFI ET AL., 2023¹⁷

Design: Randomised clinical trial.

Population: Children with functional constipation.

Intervention: Jujube paste or polyethylene glycol.

Duration: Four weeks.

Finding: Both interventions were effective, with selected stool or acceptability advantages for jujube.

Limitations: Paediatric medical condition, paste preparation and no relevance to a general supplement claim.

ZARE ET AL., 2023¹⁸

Design: Double-blind randomised trial.

Participants: Sixty-four people with chronic spontaneous urticaria inadequately controlled by standard-dose antihistamine.

Intervention: Add-on jujube syrup.

Finding: Urticaria-related outcomes improved.

Limitations: Disease treatment, concurrent antihistamine, syrup and no relevance to ordinary immune support.

SHIRAZI ET AL., 2024¹⁹

Design: Randomised double-blind placebo-controlled trial.

Participants: Ninety-two people with chronic spontaneous urticaria.

Intervention: Thirty millilitres of jujube oxymel three times daily plus cetirizine, followed by cetirizine alone.

Finding: Clinical urticaria outcomes improved during the add-on period.

Limitations: Oxymel includes additional ingredients and is not comparable with dry fruit extract.

PARASTOUEI ET AL., 2024²⁰

Design: Parallel randomised controlled trial.

Participants: Sixty people with metabolic syndrome.

Intervention: Thirty grams of dried jujube powder daily or placebo.

Finding: Selected improvements in waist circumference, triglycerides, HDL cholesterol and stress scores.

Limitations: Medical population, whole-food quantity, imperfect blinding and multiple outcomes.

KEIHANIAN ET AL., 2025²¹

Design: Double-blind randomised comparative trial.

Population: Children aged two to ten with functional constipation.

Eligible participants: Ninety; sixty-two completed follow-up.

Intervention: Jujube syrup or polyethylene glycol.

Findings favouring jujube:

• therapeutic response;
• defecation frequency;
• encopresis;
• pain;
• adherence.

Safety: No liver or kidney injury was detected during the study; no adverse events were reported in the jujube group.

Limitations: Paediatric medical treatment, syrup dosing and no equivalence to Luminara.

FARHADNEJAD ET AL., 2025²²

Design: Randomised controlled trial.

Participants: Forty-eight adults with type 2 diabetes and excess weight.

Intervention: Thirty grams of dried fruit daily.

Duration: Twelve weeks.

Findings:

• lower plasma insulin;
• lower HOMA-IR;
• lower systolic and diastolic blood pressure.

Null findings:

• total antioxidant capacity;
• malondialdehyde;
• carboxymethyl lysine.

Why it matters: It supplies both positive cardiometabolic and negative antioxidant evidence.

Limitation: Disease population and high whole-fruit dose.

COOKING AND PRELOAD STUDY, 2025²³

Design: Randomised controlled food-response experiments.

Participants: Fourteen healthy adults.

Interventions: Cooked or uncooked air-dried jujube and a jujube preload before rice.

Finding: Cooking increased glycaemic response when jujube was consumed as the main carbohydrate source, while a smaller preload changed the subsequent meal response.

Why it matters: Jujube’s food effects depend on processing, amount and meal context.

Limitation: Not an extract study.

MASHHADI ET AL., 2026²⁴

Design: Randomised controlled comparative trial.

Population: Infertile women with PCOS.

Interventions:

• jujube hydroalcoholic extract, 15 grams daily;
• metformin;
• myo-inositol;
• placebo.

Duration: Twelve weeks.

Findings: Selected glucose, lipid and insulin-resistance outcomes improved.

Null finding: Jujube did not significantly increase pregnancy occurrence compared with metformin or myo-inositol.

Safety: One mild constipation report in the jujube arm.

Limitations: Diagnosed PCOS and infertility population, extremely different dose and no disease or fertility claim for Luminara.

MAHMOUDI ET AL., 2020²⁵

Design: Double-blind randomised clinical trial.

Population: Postmenopausal women.

Intervention: Jujube seed capsule or placebo.

Finding: Subjective sleep quality improved.

Critical limitation: Seed, not fruit.

SHERGIS ET AL., 2021²⁶

Design: Randomised placebo-controlled crossover feasibility trial.

Participants: Twelve adults with insomnia.

Intervention: Two grams daily of Ziziphus spinosa seed granules.

Duration: Four weeks per treatment period.

Finding: PSQI sleep-quality scores improved compared with placebo.

Limitations: Tiny feasibility sample, seed rather than fruit and not every sleep outcome improved.

BIRLING ET AL., 2022²⁹

Design: Double-blind randomised placebo-controlled trial.

Participants: Eighty-five people with insomnia.

Intervention: Zao Ren An Shen capsule.

Duration: Four weeks.

Finding: Zao Ren An Shen was safe, acceptable and tolerable, but did not significantly outperform placebo for insomnia severity or the measured secondary efficacy outcomes.

Critical limitation: Multi-herb seed-centred formula, not fruit and not seed alone.


HOW JUJUBE FRUIT MAY WORK

No single mechanism has been established for Luminara’s fruit extract.

Potential pathways depend heavily on the outcome being studied.

POLYSACCHARIDES AND FIBRE-RELATED EFFECTS

Fruit polysaccharides and fibre may influence:

• stool bulk;
• water retention;
• fermentation;
• intestinal transit;
• gut-microbial activity.

These pathways may contribute to whole-fruit or syrup bowel effects.

Luminara’s extract has no declared fibre or polysaccharide content. A 300 mg extract may not reproduce a high-fibre food effect.

PHENOLIC COMPOUNDS AND FLAVONOIDS

Jujube fruit contains phenolic and flavonoid compounds with antioxidant activity in laboratory systems.²˒³

Human evidence is less consistent. The 2025 controlled trial did not improve total antioxidant capacity or malondialdehyde compared with control.²²

Laboratory antioxidant activity should not be translated automatically into a systemic human antioxidant benefit.

TRITERPENIC ACIDS AND SAPONIN-RELATED COMPOUNDS

Fruit contains triterpenic acids and related constituents that have been investigated in laboratory metabolic and inflammatory pathways.²˒³

The specific compounds and amounts in Luminara’s extract are unknown.

GLUCOSE AND INSULIN PATHWAYS

Possible mechanisms proposed from food and animal research include:

• slower carbohydrate absorption;
• fibre effects;
• polyphenol-mediated enzyme activity;
• insulin-signalling pathways;
• changes in food intake or body weight.

Human findings are inconsistent and strongly influenced by the amount and form of fruit.

Dried jujube also contains sugars and can increase postprandial glucose when consumed as a carbohydrate food.¹¹˒²³

SEED SEDATIVE PATHWAYS DO NOT ESTABLISH FRUIT EFFECTS

Jujube seed research has explored:

• GABA-related pathways;
• serotonergic signalling;
• jujubosides;
• spinosin;
• sleep-regulation mechanisms.

Luminara’s fruit extract is not standardised to those seed markers.

The seed mechanism cannot be treated as the mechanism of the formula’s fruit ingredient without direct analytical and clinical evidence.


SAFETY AND RESPONSIBLE USE

Jujube fruit is widely consumed as food, but concentrated-extract safety is less well characterised than food use.

Across the located fruit trials, short-term tolerability was generally acceptable. Reported concerns or limitations include:

• hypotension-related withdrawal in one diabetes study described in later evidence reviews;
• one report of mild constipation in the 2026 PCOS trial;
• carbohydrate and sugar exposure with whole dried fruit;
• uncertain interaction effects at concentrated-extract doses;
• limited pregnancy and breastfeeding data for extracts and multi-herb formulas.

A preclinical study reported that a hydroalcoholic Ziziphus jujuba extract altered the effects or concentrations of several anti-seizure medicines in rats.³³

This does not prove a human interaction, but it supports professional review for people using:

• phenytoin;
• phenobarbital;
• carbamazepine;
• other medicines for epilepsy;
• sedative medicines;
• diabetes medicines;
• antihypertensive medicines.

Rare allergy is possible. A recent case report described anaphylaxis associated with Ziziphus seed in a traditional-medicine context.³⁴

That case involved seed and does not establish the same risk for fruit, but people with known jujube or related-fruit allergy should avoid the ingredient.

Pregnancy and breastfeeding safety of Luminara’s complete multi-herb formula has not been established.

Anyone who is pregnant, breastfeeding, taking prescription medicine, preparing for surgery or managing a medical condition should consult a qualified healthcare professional before using Luminara.


PLAIN-ENGLISH SUMMARY

Jujube fruit has a genuine human evidence base—but it is different from the evidence most people associate with the word “jujube.”

Luminara contains fruit extract.

The strongest fruit-specific clinical research relates to bowel function and constipation, with additional studies investigating metabolic outcomes, blood pressure, insulin resistance, skin, human milk, neonatal jaundice, tuberculosis treatment support, urticaria and PCOS.⁴–²⁴

Most of those studies used:

• syrups, pastes or infusions;
• whole dried fruit;
• 15–30 grams daily;
• topical preparations;
• diagnosed medical populations.

They do not establish that 300 mg of Luminara’s 10:1 extract produces the same result.

The direct human sleep evidence belongs primarily to jujube seed or seed-centred multi-herb formulas.²⁵–³¹ Luminara’s fruit extract has not been shown to match those preparations and should not be described as clinically proven for sleep.

Luminara’s CoA confirms a 10:1 fruit extract with positive TLC identity and acceptable listed quality results. It does not state the Latin species, extraction solvent, carrier percentage or chemical marker. The nominal 3-gram fruit-equivalent calculation should not be made publicly until the supplier confirms the ratio basis.

The most accurate positioning is:

Jujube contributes a long traditional history as a nourishing, restorative fruit, supported by human research in digestive and metabolic areas. Direct clinical sleep evidence for the fruit remains absent, because the existing sleep studies principally use the seed.


REFERENCES

1. Royal Botanic Gardens, Kew. Ziziphus jujuba Mill.. Plants of the World Online. Accessed 1 August 2026.

2. Chen J, Liu X, Li Z, Qi A, Yao P, Zhou Z, Dong TTX, Tsim KWK. A Review of Dietary Ziziphus jujuba Fruit (Jujube): Developing Health Food Supplements for Brain Protection. Evid Based Complement Alternat Med. 2017;2017:3019568. doi:10.1155/2017/3019568. PMID: 28680447.

3. Gao QH, Wu CS, Wang M. The jujube (Ziziphus jujuba Mill.) fruit: a review of current knowledge of fruit composition and health benefits. J Agric Food Chem. 2013;61(14):3351-3363. doi:10.1021/jf4007032. PMID: 23480594.

4. Naftali T, Feingelernt H, Lesin Y, Rauchwarger A, Konikoff FM. Ziziphus jujuba extract for the treatment of chronic idiopathic constipation: a controlled clinical trial. Digestion. 2008;78(4):224-228. doi:10.1159/000190975. PMID: 19142004.

5. Ebrahimi S, Ashkani-Esfahani S, Poormahmudi A. Investigating the efficacy of zizyphus jujuba on neonatal jaundice. Iran J Pediatr. 2011;21(3):320-324. PMID: 23056808.

6. Sabzghabaee AM, Khayam I, Kelishadi R, Ghannadi A, Soltani R, Badri S, Shirani S. Effect of Zizyphus jujuba fruits on dyslipidemia in obese adolescents: a triple-masked randomized controlled clinical trial. Med Arch. 2013;67(3):156-159. doi:10.5455/medarh.2013.67.156-159. PMID: 23848030.

7. Mostafa UES, Labban L. Effect of Zizyphus jujuba on serum lipid profile and some anthropometric measurements. Adv Med Plant Res. 2013;1(3):49-55.

8. Hemmati M, Zohoori E, Mehrpour O, Karamian M, Asghari S, Zarban A, Nasouti R. Retraction note: Anti-atherogenic potential of jujube, saffron and barberry: anti-diabetic and antioxidant actions [EXCLI Journal 2015;14:908-915]. EXCLI J. 2025;24:1224. doi:10.17179/excli2025-8875. [Official retraction notice; the retracted 2015 paper is not used as evidence of benefit.]

9. Kelishadi R, Hasanghaliaei N, Poursafa P, Keikha M, Ghannadi A, Yazdi M, Rahimi E. A randomized controlled trial on the effects of jujube fruit on the concentrations of some toxic trace elements in human milk. J Res Med Sci. 2016;21:108. doi:10.4103/1735-1995.193499. PMID: 28250785.

10. Yazdanpanah Z, Ghadiri-Anari A, Vahidi Mehrjardi A, Dehghani A, Zare Zardini H, Nadjarzadeh A. Effect of Ziziphus jujube Fruit Infusion on Lipid Profiles, Glycaemic Index and Antioxidant Status in Type 2 Diabetic Patients: A Randomized Controlled Clinical Trial. Phytother Res. 2017;31(5):755-762. doi:10.1002/ptr.5796. PMID: 28271568.

11. Zhu R, Fan Z, Dong Y, Liu M, Wang L, Pan H. Postprandial Glycaemic Responses of Dried Fruit-Containing Meals in Healthy Adults: Results from a Randomised Trial. Nutrients. 2018;10(6):694. doi:10.3390/nu10060694. PMID: 29848962.

12. Irannejad Niri Z, Shidfar F, Jabbari M, Zarrati M, Hosseini A, Malek M, Dehnad A. The effect of dried Ziziphus vulgaris on glycemic control, lipid profile, Apo-proteins and hs-CRP in patients with type 2 diabetes mellitus: A randomized controlled clinical trial. J Food Biochem. 2021;45(3):e13193. doi:10.1111/jfbc.13193. PMID: 32227501.

13. Shahrahmani N, Amir Ali Akbari S, Mojab F, Mirzai M, Shahrahmani H. The Effect of Zizyphus Jujube Fruit Lotion on Breast Fissure in Breastfeeding Women. Iran J Pharm Res. 2018;17(Suppl):101-109. doi:10.22037/ijpr.2018.2215. PMID: 29796034.

14. Farhadnejad H, Asghari G, Hedayati M, Sahranavard S, Teymoori F, Mirmiran P, Azizi F. Effect of Ziziphus jujube on cardiometabolic factors and systemic inflammation in type 2 diabetic patients: A randomized controlled trial. Clin Nutr ESPEN. 2022;49:53-60. doi:10.1016/j.clnesp.2022.03.043. PMID: 35623863.

15. Maddahi SZ, Jokar A, Kamalinejad M, Behnampur N. The efficacy of Jujube syrup on the prevention of drug-induced hepatotoxicity in pulmonary tuberculosis patients: A pilot randomized double-blind placebo-controlled clinical trial. Pharmacol Res Perspect. 2022;10(1):e00902. doi:10.1002/prp2.902. PMID: 34939363.

16. Aafi E, Shams Ardakani MR, Ahmad Nasrollahi S, Mirabzadeh Ardakani M, Samadi A, Hajimahmoodi M, Naeimifar A, Pourjabbar Z, Amiri F, Firooz A. Brightening effect of Ziziphus jujuba (jujube) fruit extract on facial skin: A randomized, double-blind, clinical study. Dermatol Ther. 2022;35(7):e15535. doi:10.1111/dth.15535. PMID: 35460145.

17. Yousefi A, Behnoud N, Ghobadi A, Amini Behbahani F, Norouzi E. Jujube Versus Polyethylene Glycol for Maintenance Treatment of Pediatric Functional Constipation: A Randomized Clinical Trial. Iran J Pediatr. 2023;33(4):e131550. doi:10.5812/ijp-131550.

18. Zare H, Nabavizadeh SH, Jaladat AM, Zarshenas MM, Moghtaderi M, Basirat A, Nasri N. The Added-on of Ziziphus jujube Syrup in the Treatment of Chronic Spontaneous Urticaria Resistant to Standard-Dose of Secondary-generation H1 Antihistamine: A Double-Blind Randomized Clinical Trial. Iran J Med Sci. 2023;48(6):582-590. doi:10.30476/IJMS.2023.95531.2690. PMID: 38094286.

19. Taghavi Shirazi M, Goodarzi A, Ghobadi A, Eghbalian F. Jujube Oxymel for the Treatment of Chronic Spontaneous Urticaria: Efficacy and Safety. Adv Biomed Res. 2024;13:91. doi:10.4103/abr.abr_426_23. PMID: 39512402.

20. Parastouei K, Nashtar SB, Al-Attar Z, Shekarchizadeh-Esfahani P, Askari G. The effects of jujube (Ziziphus jujube) on metabolic and mental health outcomes in patients with metabolic syndrome: A randomized controlled trial. Complement Ther Med. 2024;82:103041. doi:10.1016/j.ctim.2024.103041. PMID: 38648942.

21. Keihanian F, Maleknejad S, Saeidinia A, Soltanipour S, Pirooz A. Comparison of Ziziphus jujube Mill. Syrup versus polyethylene glycol in children with functional constipation: a randomized clinical trial. Sci Rep. 2025;15:1674. doi:10.1038/s41598-025-85801-w. PMID: 39799261.

22. Farhadnejad H, Hedayati M, Sahranavard S, Kazemi Jahromi M, Asghari G, Teymoori F, Mirmiran P, Azizi F. Effect of dried Ziziphus Jujube Consumption on Plasma Insulin, Blood Pressure, Oxidative Stress, and Advanced Glycation End Products in Diabetic Patients with Excess Weight: A Randomized Controlled Trial. Int J Prev Med. 2025;16:49. doi:10.4103/ijpvm.ijpvm_144_24. PMID: 40964206.

23. Wei J, Liu A, Fan Z, Peng X, Lou X, Lu X, Hu J. Cooking Increased the Postprandial Glycaemic Response but Enhanced the Preload Effect of Air-Dried Jujube. Foods. 2025;14(7):1142. doi:10.3390/foods14071142. PMID: 40238265.

24. Mashhadi F, Khadem Ghaebi N, Rakhshandeh H, Khadem-Rezaiyan M, Roudi F, Nematy M. Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial. J Ovarian Res. 2026;19(1):51. doi:10.1186/s13048-025-01867-0. PMID: 41618368.

25. Mahmoudi R, Ansari S, Haghighizadeh MH, Shakiba Maram N, Montazeri S. Investigation the effect of jujube seed capsule on sleep quality of postmenopausal women: A double-blind randomized clinical trial. Biomedicine (Taipei). 2020;10(4):42-48. doi:10.37796/2211-8039.1038. PMID: 33854934.

26. Shergis JL, Hyde A, Meaklim H, Varma P, Da Costa C, Jackson ML. Medicinal seeds Ziziphus spinosa for insomnia: A randomized, placebo-controlled, cross-over, feasibility clinical trial. Complement Ther Med. 2021;57:102657. doi:10.1016/j.ctim.2020.102657. PMID: 33385511.

27. Chan YY, Chen YH, Yang SN, Lo WY, Lin JG. Clinical Efficacy of Traditional Chinese Medicine, Suan Zao Ren Tang, for Sleep Disturbance during Methadone Maintenance: A Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2015;2015:710895. doi:10.1155/2015/710895. PMID: 26346534.

28. Zhou QH, Wang HL, Zhou XL, Xu MB, Zhang HF, Huang LB, Zheng GQ, Lin Y. Efficacy and safety of suanzaoren decoction for chronic insomnia disorder in adults: study protocol for randomised, double-blind, double-dummy, placebo-controlled trial. BMJ Open. 2017;7(4):e014280. doi:10.1136/bmjopen-2016-014280. PMID: 28377394.

29. Birling Y, Zhu X, Avard N, Tannous C, Fahey PP, Sarris J, Bensoussan A. Zao Ren An Shen capsule for insomnia: a double-blind, randomized, placebo-controlled trial. Sleep. 2022;45(2):zsab266. doi:10.1093/sleep/zsab266. PMID: 34788454.

30. Yang M, Wang H, Zhang YL, Zhang F, Li X, Kim SD, Chen Y, Chen J, Chimonas S, Korenstein D, Mao JJ. The Herbal Medicine Suanzaoren (Ziziphi Spinosae Semen) for Sleep Quality Improvements: A Systematic Review and Meta-analysis. Integr Cancer Ther. 2023;22:15347354231162080. doi:10.1177/15347354231162080. PMID: 37014010.

31. Zhou QH, Zhou XL, Xu MB, Jin TY, Rong PQ, Zheng GQ, Lin Y. Suanzaoren Formulae for Insomnia: Updated Clinical Evidence and Possible Mechanisms. Front Pharmacol. 2018;9:76. doi:10.3389/fphar.2018.00076. PMID: 29479317.

32. Ahmadi M, Shirafkan H, Mozaffarpur SA, Rezghi M. Impact of jujube fruit on serum lipid profile, glycemic index, and liver function: a systematic review and meta-analysis. Nutr Diabetes. 2025;15(1):22. doi:10.1038/s41387-025-00378-7. PMID: 40399274.

33. Pahuja M, Kleekal T, Reeta KH, Tripathi M, Gupta YK. Interaction profile of Zizyphus jujuba with phenytoin, phenobarbitone, and carbamazepine in maximal electroshock-induced seizures in rats. Epilepsy Behav. 2012;25(3):368-373. doi:10.1016/j.yebeh.2012.08.014. PMID: 23103312.

34. Pan Z, Zhan M, Wang Q, Liu J, Li Y, Zhi F, Zhang J, Liu J, Guan K, Wen L. Case Report: Anaphylaxis caused by traditional Chinese medicine in a patient with pollinosis. Front Allergy. 2024;5:1470638. doi:10.3389/falgy.2024.1470638. PMID: 39552699.

35. Alsayari A, Wahab S. Genus Ziziphus for the treatment of chronic inflammatory diseases. Saudi J Biol Sci. 2021;28(12):6897-6914. doi:10.1016/j.sjbs.2021.07.076. PMID: 34866990.

36. Chen J, Tsim KWK. A Review of Edible Jujube, the Ziziphus jujuba Fruit: A Heath Food Supplement for Anemia Prevalence. Front Pharmacol. 2020;11:593655. doi:10.3389/fphar.2020.593655. PMID: 33324222.


These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

PASSIONFLOWER

Passiflora incarnata L.

Passionflower is a climbing perennial vine native to the Americas. Its distinctive flowers gave the plant its common name, while its above-ground parts developed a long history of use in Western herbal medicine for nervousness, restlessness and difficulty settling into sleep.¹–⁴

Luminara uses Passiflora incarnata—the medicinal species most commonly addressed in European herbal monographs and modern clinical research—not the edible passionfruit species Passiflora edulis and not ornamental blue passionflower, Passiflora caerulea. Research involving another Passiflora species cannot automatically substantiate Luminara’s ingredient.¹–⁴

Passionflower is one of the better clinically investigated calming herbs in Luminara. Human studies have examined:

• short-term situational anxiety before surgery or dental procedures;
• generalized anxiety disorder;
• perceived stress and nervous restlessness;
• subjective and objective sleep outcomes;
• menopause-related symptoms;
• opioid-withdrawal symptoms;
• benzodiazepine tapering;
• children with attention-deficit/hyperactivity disorder;
• children and adolescents with anxiety or insomnia in complex clinical populations;
• electroencephalographic and stress-related biological measures.⁵–³⁴

The evidence is encouraging, but it is not uniform.

Several controlled studies reported reduced situational anxiety before procedures, often without the marked amnesia or psychomotor impairment associated with benzodiazepines.⁹–¹⁷ One small 2025 trial found no significant difference in subjective anxiety, although salivary cortisol after surgery was lower with Passionflower and midazolam than placebo.¹⁷

Sleep studies are also mixed. A seven-day tea study improved subjective sleep quality; a two-week polysomnography study increased total sleep time but did not improve most other sleep measures; and a 2024 trial reported broader improvements in stress and several subjective sleep outcomes.¹⁸–²⁰ Another twelve-week study found selected quality-of-life benefits but no significant sleep advantage.²¹

The European Medicines Agency recognises Passionflower preparations for relief of mild symptoms of mental stress and to aid sleep only on the basis of long-standing traditional use. It concluded that the small number of clinical participants and important study-design shortcomings prevented firm conclusions of well-established clinical efficacy.²–⁴

The most accurate interpretation is:

Passionflower has meaningful human research for calm, situational anxiety and selected stress- and sleep-related outcomes. The findings are preparation-specific, not every outcome has improved, and the evidence does not support describing it as a treatment for an anxiety disorder or insomnia.


PASSIONFLOWER AT A GLANCE

Botanical name: Passiflora incarnata L.

Botanical family: Passifloraceae

Common names: Passionflower, purple passionflower, maypop

Part used in Luminara: Herb—the above-ground or aerial parts

Ingredient form in Luminara: Extract

Current manufacturing-formula amount: 120 mg daily

Formula quotation description: Passion Flower Extract, 5% flavones

Supplier CoA specification: Not less than 10% flavones

Raw-material batch result: 10.25% flavones by ultraviolet-visible spectrophotometry

Identity: Identical by high-performance thin-layer chromatography

Country of origin: People’s Republic of China

Batch number: NS26020095-PSF-01

Manufacture date: 13 February 2026

Test/report date: 27 February 2026

Expiry date: 12 February 2028

The supplied batch CoA provides useful quality information. It confirms:

• Passiflora incarnata;
• herb or aerial material;
• HPTLC identity;
• 10.25% flavones;
• low measured levels of lead, arsenic, cadmium and mercury;
• acceptable listed microbial results;
• compliance with the stated residual-solvent specification.

However, the CoA does not state:

• the extraction ratio or native drug-extract ratio;
• the extraction solvent;
• the carrier or excipient and its percentage;
• the flavone reference standard used for the UV assay;
• which individual flavones are present;
• a quantitative HPLC or UPLC flavonoid profile.

There is also a documentation discrepancy that must be resolved.

The current manufacturing quotation describes the ingredient as 5% flavones, while the supplied batch CoA reports 10.25% flavones.

If 120 mg of the 10.25% raw material is used, the nominal calculation is:

120 mg × 10.25% = 12.3 mg measured flavones daily.

If the production formula instead uses a 5% material, the nominal amount would be:

120 mg × 5% = 6 mg measured flavones daily.

Neither figure should be presented publicly as the verified finished-product amount until the manufacturer confirms:

• which raw material will be used in the production batch;
• whether the 5% quotation is outdated or generic;
• whether the 10.25% CoA material is the approved production ingredient;
• whether the carrier is included in the 120 mg label amount;
• the finished-product potency and identity results.

Until then, the safest wording is:

Luminara provides 120 mg of Passiflora incarnata herb extract daily.

The public Evidence Centre can describe the supplied raw-material CoA separately, while clearly stating that finished-product equivalence has not yet been verified.


HOW CLOSELY DOES LUMINARA’S PASSIONFLOWER MATCH THE CLINICAL RESEARCH?

Luminara aligns with the clinical literature in several useful ways:

• the botanical species is Passiflora incarnata;
• the plant material is the herb or aerial parts;
• it is an extract rather than an unidentified mixed-species powder;
• the raw material has a quantified flavone assay;
• identity was assessed by HPTLC.

Direct clinical equivalence still cannot be claimed.

Human research has used very different Passionflower preparations, including:

• 500 mg taken once before surgery;⁹
• 700 mg of an aqueous extract before spinal anaesthesia;¹⁰
• 260 mg before dental extraction;¹²
• 500 mg before third-molar surgery;¹³
• other proprietary oral drops or tablets before dental procedures;¹¹˒¹⁴–¹⁷
• 2 grams of dried aerial herb prepared as tea each evening;¹⁸
• 60 mg of a proprietary extract nightly;¹⁹
• 600 mg of a standardised aerial-parts extract nightly;²⁰
• 200 mg daily of an aqueous-ethanol extract standardised to 3% flavonoid glycosides;²¹
• 425 mg proprietary tablets in nervous-restlessness studies;²²
• 45 drops daily in generalized anxiety disorder;⁵
• 60 drops daily as an add-on during opioid withdrawal;⁶
• 200–1,600 mg daily in observational benzodiazepine-tapering research;²⁸–³⁰
• tea, liquid extracts and dry extracts with a wide range of traditional drug-extract ratios.²–⁴

Most positive acute-anxiety trials used 260–700 mg as a single dose—more than Luminara’s 120 mg daily extract mass.

The 60 mg insomnia study used a lower nominal extract mass than Luminara, but its extract chemistry was not shown to match Luminara.¹⁹

The 2024 stress and sleep trial used 600 mg of the proprietary SIVI aerial-parts extract. The paper did not provide a flavone assay that allows direct comparison with Luminara’s CoA.²⁰

The twelve-week Japanese study is useful for marker comparison because it used 200 mg daily standardised to 3% flavonoid glycosides—nominally 6 mg daily by that study’s assay.²¹ That number appears similar to the 6 mg nominally implied by the manufacturer’s 5% quotation, but the analytical definitions may differ and chemical equivalence has not been established.

A total-flavone percentage cannot be compared safely without knowing:

• whether the assay is expressed against vitexin, rutin or another reference standard;
• whether it measures flavones, flavonoid glycosides or a broader UV-absorbing fraction;
• the extraction solvent;
• the native extract ratio;
• the individual concentrations of vitexin, isovitexin, orientin, isoorientin, schaftoside and related compounds;
• the carrier content.

The accurate conclusion is:

Luminara uses the same species and aerial plant material found in the human evidence, with a strong raw-material flavone result. Its 120 mg daily amount and chemical profile have not been matched directly to a completed clinical trial.


TRADITIONAL USE

Passionflower’s above-ground parts have a long tradition of use for nervous-system and sleep-related wellbeing.¹–⁴

Traditional associations include:

• nervousness;
• worry and irritability;
• restlessness;
• difficulty winding down;
• disturbed sleep;
• emotional tension;
• stress-related digestive discomfort;
• nervous palpitations;
• spasmodic complaints.

Traditional preparations have included:

• dried-herb infusions;
• tinctures and fluid extracts;
• dry extracts;
• powders;
• combination formulas with valerian, hops, lemon balm or other calming herbs.

The European Medicines Agency defines the medicinal material as Passiflora incarnata herba—the dried above-ground parts—and recognises traditional use for mild symptoms of mental stress and to aid sleep.²–⁴

That recognition is based on long-standing use, not proof that every modern extract or dose has demonstrated clinical efficacy.


WHAT HUMAN CLINICAL STUDIES HAVE INVESTIGATED


SITUATIONAL ANXIETY BEFORE SURGERY OR DENTAL PROCEDURES

The most consistently positive direct human evidence relates to short-term situational anxiety.

MOVAFEGH ET AL., 2008

Sixty surgical outpatients were randomised to receive:

• 500 mg of oral Passiflora incarnata; or
• placebo;

ninety minutes before surgery.⁹

Passionflower reduced preoperative anxiety compared with placebo.

The researchers did not find significant impairment of psychomotor function or marked sedation.

The study supports acute situational use of that 500 mg preparation. It does not show that 120 mg daily has the same effect.


ASLANARGUN ET AL., 2012

Sixty patients undergoing spinal anaesthesia received:

• 700 mg of an aqueous Passionflower extract; or
• placebo;

thirty minutes before the procedure.¹⁰

Anxiety increased less in the Passionflower group. Sedation, psychomotor performance, haemodynamic measures and recovery were not meaningfully impaired.

The preparation and 700 mg dose are substantially different from Luminara.


KAVIANI ET AL., 2013

Sixty-three periodontal patients were allocated to:

• Passionflower drops;
• placebo drops;
• or no premedication.¹¹

Dental-anxiety scores improved more with Passionflower.

The study was described as randomised but one-sided or single-blind, and the preparation was not characterised sufficiently for direct product matching.


DANTAS ET AL., 2017

Forty adults requiring bilateral third-molar extraction participated in a randomised double-blind crossover study.¹²

Before separate procedures, they received:

• 260 mg of Passionflower; or
• 15 mg of midazolam.

Both reduced anxiety.

Midazolam caused anterograde amnesia in approximately one-fifth of participants, while Passionflower produced little or no comparable memory interference.

The study did not include a placebo condition and cannot establish equivalence to a prescription medicine across broader clinical settings.


DA CUNHA ET AL., 2021

Two hundred participants were assigned in a randomised, placebo-controlled, triple-blind trial to:

• Passionflower, 500 mg;
• Erythrina mulungu, 500 mg;
• midazolam, 15 mg;
• or placebo;

sixty minutes before mandibular third-molar extraction.¹³

Passionflower reduced situational anxiety similarly to midazolam and differed from placebo and mulungu.

Heart rate, blood pressure and oxygen saturation did not show clinically important between-group differences.

This is one of the stronger acute Passionflower trials, but it still addresses a single 500 mg medical premedication rather than ongoing daily wellness support.


CHRISTOFFOLI ET AL., 2021

A small randomised split-mouth crossover study compared Passionflower with midazolam in approximately twenty participants undergoing third-molar surgery.¹⁴

Anxiety control was similar, while drowsiness, muscle relaxation and dizziness were more prominent with the benzodiazepine.

The final sample was small, so the result requires cautious interpretation.


VELASQUEZ ET AL., 2024

Fifty-four participants undergoing third-molar extraction were randomised in a triple-blind trial to:

• Passiflora incarnata;
• Valeriana officinalis;
• or placebo.¹⁵

State-anxiety scores decreased over time in both herbal groups but not significantly in the placebo group.

Surgical discomfort did not improve, and vital-sign results varied.

This supports a possible situational-anxiety effect while showing that the intervention did not improve every procedural outcome.


LIMA NETO ET AL., 2025

Thirty participants were randomised to Passionflower, midazolam or placebo before impacted third-molar extraction.¹⁷

The study did not find significant differences in subjective anxiety or most physiological outcomes.

Postoperative salivary cortisol was lower in the Passionflower and midazolam groups than placebo.

This is important negative and mixed evidence. A biomarker difference without a clear subjective-anxiety difference does not establish a clinically noticeable benefit.


CURRENT CONCLUSION FOR SITUATIONAL ANXIETY

Multiple controlled studies support Passionflower’s potential to reduce short-term anxiety before procedures.

However:

• most studies are small or confined to dental surgery;
• products and doses vary;
• several compare Passionflower with midazolam rather than including a strong placebo design;
• one recent small trial did not improve subjective anxiety;
• the usual acute doses were substantially above Luminara’s 120 mg daily amount.

Evidence strength: good but preparation-specific.

Appropriate wording:

“Several controlled human studies have investigated Passiflora incarnata for short-term situational anxiety before medical or dental procedures.”

Inappropriate wording:

“Luminara treats anxiety” or “works like a benzodiazepine.”


GENERALIZED ANXIETY DISORDER

AKHONDZADEH ET AL., 2001

Thirty-six outpatients diagnosed with generalized anxiety disorder received either:

• Passionflower extract, 45 drops daily; or
• oxazepam, 30 mg daily;

for four weeks.⁵

Both groups improved on the Hamilton Anxiety Rating Scale.

Oxazepam appeared to act more quickly, while greater impairment of job performance was reported with oxazepam.

Important limitations include:

• only thirty-six participants;
• no placebo-only group;
• short duration;
• inadequate extract characterisation;
• uncertain equivalence of drops to Luminara;
• comparison with an active medicine does not establish non-inferiority without adequate statistical design.

A Cochrane review concluded that the number and quality of randomised trials were too limited to draw firm conclusions for anxiety disorders.³⁶

Passionflower should not be marketed as treating generalized anxiety disorder.


EVERYDAY STRESS, NERVOUS RESTLESSNESS AND QUALITY OF LIFE

HARIT ET AL., 2024

Sixty-five adults experiencing stress and sleep problems were randomised to:

• 600 mg of the standardised SIVI aerial-parts extract nightly; or
• placebo;

for thirty days.²⁰

All participants completed the study.

Compared with placebo, Passionflower produced greater improvements in:

• perceived stress;
• subject-reported total sleep time;
• general psychological health;
• sleep onset;
• number of awakenings;
• wake time after sleep onset;
• insomnia-severity scores;
• fatigue;
• Pittsburgh Sleep Quality Index scores;
• self-rated daytime mood, work function, concentration and memory.

Serum cortisol decreased within both groups, but the between-group difference was not significant.

No adverse events were reported.

Important limitations include:

• pilot-sized sample;
• one-month duration;
• subjective diaries for many outcomes;
• no formal sample-size calculation;
• industry involvement;
• proprietary extract;
• 600 mg dose, five times Luminara’s nominal extract mass;
• no chemistry establishing equivalence to Luminara.

The trial supports emerging evidence for stress-related wellbeing and selected sleep outcomes, not a broad cortisol or medical-insomnia claim.


GIBBERT ET AL., 2017

A twelve-week non-interventional study evaluated a proprietary ethanolic Passionflower dry extract in adults experiencing nervous restlessness.²²

Approximately 150 participants were enrolled.

Resilience, nervous-restlessness symptoms and quality-of-life measures improved over time.

Mild tiredness was reported in a small number of participants.

Because there was no placebo group, the findings cannot separate the extract’s effect from expectancy, natural improvement, regression to the mean or other care.


TAKARA ET AL., 2019

Forty-four Japanese adults participated in a twelve-week randomised double-blind placebo-controlled study.²¹

The active product provided:

• 200 mg daily of an aqueous-ethanol Passionflower extract;
• standardised to 3% flavonoid glycosides;
• nominally 6 mg daily by that assay.

Selected SF-36 quality-of-life measures—including social functioning, role-emotional, vitality or the mental-component score—improved.

The study did not find significant improvements on the Oguri-Shirakawa-Azumi sleep questionnaire.

This trial supports selective mental-wellbeing effects but not consistent sleep improvement.


QUANTITATIVE EEG STUDIES

Small placebo-controlled studies of a proprietary 425 mg Passionflower tablet have examined quantitative electroencephalography, cognitive testing and examination-related stress.²³˒²⁴

The researchers reported an EEG pattern interpreted as calming without clear cognitive impairment.

These are surrogate and exploratory outcomes. They do not establish that consumers will experience reduced anxiety or better sleep.


CURRENT CONCLUSION FOR EVERYDAY STRESS

Controlled and observational studies support an emerging role in stress-related mental wellbeing.

The evidence is not strong enough to claim that Passionflower:

• lowers cortisol reliably;
• treats chronic stress;
• prevents burnout;
• treats an anxiety disorder;
• improves every dimension of quality of life.

Appropriate wording:

“Passionflower has been studied for everyday stress, nervous restlessness and the ability to unwind.”


SLEEP

Passionflower has a traditional sleep association and several direct human studies.

The evidence is promising but mixed.


NGAN AND CONDUIT, 2011

Forty-one healthy adults completed a double-blind placebo-controlled crossover study.¹⁸

Participants drank 250 mL each evening of:

• Passionflower tea prepared from 2 grams of dried aerial herb; or
• placebo tea;

for seven days per condition.

Subjective sleep quality improved with Passionflower.

A polysomnography subgroup included only ten participants and did not establish broad objective-sleep changes.

State anxiety did not improve significantly.

This supports short-term subjective sleep quality for tea, not direct equivalence to an extract capsule.


LEE ET AL., 2020

A double-blind placebo-controlled study enrolled 110 adults aged approximately thirty to fifty-two with insomnia disorder.¹⁹

Eighty-four were included in the reported analysis.

Participants received:

• 60 mg of Passionflower extract nightly; or
• placebo;

for two weeks.

Polysomnography showed a greater increase in total sleep time with Passionflower.

Most other measures—including insomnia severity, subjective sleep quality, sleep latency, arousal, wake time after sleep onset and stress—did not differ significantly from placebo.

This is the best direct objective-sleep evidence, but the benefit was selective and the treatment period was short.


HARIT ET AL., 2024

The 600 mg SIVI trial reported broader improvement in sleep duration, onset, awakenings, wake time after sleep onset, insomnia severity, fatigue and PSQI scores.²⁰

The findings are encouraging but require independent replication using well-characterised extracts.


TAKARA ET AL., 2019

The twelve-week 200 mg flavonoid-standardised study did not significantly improve its sleep questionnaire outcomes.²¹

This prevents the sleep evidence from being presented as uniformly positive.


COMBINATION SLEEP FORMULAS

Passionflower has also appeared in human combination products with:

• valerian;
• hops;
• lemon balm;
• St John’s wort;
• other calming botanicals or nutrients.³²–³⁵

Some combination studies report improved sleep or restlessness.

Their results cannot be assigned specifically to Passionflower.


CURRENT CONCLUSION FOR SLEEP

The evidence supports cautious wording that Passionflower has been investigated for sleep quality and sleep continuity.

It does not support claiming that Luminara:

• treats insomnia;
• guarantees faster sleep onset;
• works as a sedative medicine;
• has been proven effective at Luminara’s exact dose and extract composition.


MENOPAUSE, HOT FLASHES AND WOMEN’S HORMONAL TRANSITIONS

FAHAMI ET AL., 2010

Fifty-nine menopausal women were randomised to receive either:

• a Passionflower preparation; or
• St John’s wort;

for six weeks.²⁵

Menopause symptom scores decreased in the Passionflower group between weeks three and six.

The symptom index included areas such as:

• vasomotor symptoms—hot flashes or flushes;
• insomnia;
• depressed mood;
• anger;
• headache;
• musculoskeletal discomfort;
• other menopause-related complaints.

There was no placebo group, and the study did not show a clear superiority of Passionflower over St John’s wort.

The extract description and dosing were insufficient for direct matching to Luminara.

This study provides preliminary menopause-related evidence but does not demonstrate that Passionflower:

• balances hormones;
• alters oestrogen or progesterone;
• treats vasomotor symptoms;
• directly relieves vaginal dryness;
• treats menopause-related sexual concerns.

The most responsible wording is:

“One small comparative study investigated Passionflower for a range of menopausal symptoms, including hot flashes and sleep-related concerns, but it lacked a placebo group and requires confirmation.”


PMS, MENSTRUAL-CYCLE SYMPTOMS AND YOUNGER WOMEN

Traditional records have included dysmenorrhoea and nervous complaints, but no controlled human trial was located that directly tested Passiflora incarnata alone for:

• premenstrual syndrome;
• menstrual-cycle mood changes;
• menstrual pain;
• cycle-related sleep disturbance;
• hormonal biomarkers in menstruating women.

Passionflower may still be relevant to younger women through its broader stress and calm evidence.

It should not be presented as a clinically established PMS or hormone-balancing ingredient.


SEXUAL DESIRE, AROUSAL AND INTIMATE WELLNESS

No controlled standalone human study was located that tested Passionflower for:

• female sexual desire;
• arousal;
• lubrication;
• orgasm;
• sexual satisfaction;
• sexual distress;
• vaginal dryness;
• pain during intimacy.

Its relevance to Luminara’s intimate-wellness philosophy is indirect.

Stress, anxiety and poor sleep can influence how a person feels, but clinical evidence for calm or sleep is not the same as evidence that Passionflower increases libido.

Appropriate wording:

“Passionflower supports the calm and unwinding side of Luminara’s whole-body philosophy.”

Inappropriate wording:

“Passionflower increases libido” or “improves female sexual function.”


OPIOID WITHDRAWAL

AKHONDZADEH ET AL., 2001

Sixty-five outpatients undergoing opioid withdrawal received:

• clonidine plus Passionflower extract, 60 drops daily; or
• clonidine plus placebo;

for fourteen days.⁶

Physical withdrawal symptoms improved similarly in both groups.

Mental-symptom scores improved more in the Passionflower group.

This was adjunctive medical treatment in opioid dependence. It does not support self-directed withdrawal, treatment of addiction or general mood claims.

A later small randomised trial compared Passionflower with piroxicam for withdrawal-related myalgia and anxiety, but reporting and journal quality limit confidence.³¹


BENZODIAZEPINE TAPERING

ZANARDI ET AL., 2023

A retrospective real-world study compared adults with anxiety or depressive disorders undergoing supervised benzodiazepine tapering.²⁸

Ninety-three received add-on Passiflora incarnata herba, and ninety-three matched participants followed standard tapering without Passionflower.

The Passionflower group reduced diazepam-equivalent doses more rapidly and to a greater extent.

This was not randomised, and treatment selection could reflect clinical differences between groups.


CARMINATI ET AL., 2024

A longer-term observational follow-up reported sustained benzodiazepine-dose reduction and no clear new safety signal with the medicinal Passionflower product.²⁹

The data remain observational and come from a specialised clinical setting.


CARMINATI ET AL., 2026

A further real-world analysis explored Passionflower alongside cognitive behavioural therapy during benzodiazepine reduction.³⁰

The cohorts may overlap substantially with the earlier reports, so these papers should not be counted as three independent randomised replications.

Passionflower must not be marketed for treating benzodiazepine dependence or used to encourage unsupervised tapering.


CHILDREN, ADHD, ANXIETY AND INSOMNIA

AKHONDZADEH ET AL., 2005

Thirty-four children aged six to thirteen with ADHD were randomised to:

• Passionflower; or
• methylphenidate;

for eight weeks.⁷

Parent and teacher rating scales improved in both groups, with no significant between-group difference.

Reduced appetite and anxiety or nervousness were more common with methylphenidate.

Important limitations include:

• very small sample;
• no placebo group;
• uncertain dose reporting;
• no replication;
• inadequate extract characterisation;
• comparison design was not sufficient to establish equivalence.

Passionflower should not be described as treating ADHD.


LA TEMPA ET AL., 2025

A retrospective observational study reviewed children and adolescents with feeding and eating disorders who received Passionflower for anxiety or insomnia.²⁷

Most had complex psychiatric and nutritional care, and many received additional medicines.

Improvement was documented in some anxiety and insomnia records, with no reported adverse events attributed to Passionflower.

Because the study was retrospective, uncontrolled and highly confounded, it provides only preliminary safety and feasibility information.

The European Medicines Agency does not recommend traditional Passionflower medicines for children under twelve because adequate data are unavailable.²–⁴


EVIDENCE STRENGTH


HOW WE RATE THE EVIDENCE

★★★★★ — Strong

Multiple high-quality controlled human trials and/or systematic reviews with consistent findings, relevant preparations and independent replication.

★★★★☆ — Good

Several controlled human studies with broadly consistent findings, but limitations remain in sample size, setting, dose, product characterisation or replication.

★★★☆☆ — Emerging

At least one relevant controlled human study, with mixed results or additional confirmation required.

★★☆☆☆ — Preliminary

Small, uncontrolled, indirect, comparator-only or disease-population evidence.

★☆☆☆☆ — Traditional or preclinical

Traditional use, laboratory research, animal evidence or no direct human confirmation.

The rating applies to the specific outcome and Luminara’s ingredient—not to every Passionflower product.


HEALTH AREA | EVIDENCE STRENGTH | CURRENT ASSESSMENT

Acute situational anxiety before procedures | ★★★★☆ | Multiple controlled trials, usually positive, but doses and products vary and one recent small trial was subjectively negative

Everyday perceived stress | ★★★☆☆ | Positive 2024 placebo-controlled trial at 600 mg; smaller or observational supporting studies

Nervous restlessness and resilience | ★★☆☆☆ | Large uncontrolled study and small product-specific research

Subjective sleep quality | ★★★☆☆ | Positive tea and 2024 extract trials, but a twelve-week study was negative

Objective total sleep time | ★★★☆☆ | Positive two-week polysomnography trial; other objective and subjective outcomes largely unchanged

Broad insomnia treatment | ★★☆☆☆ | Mixed and short-term evidence; no established treatment claim

Sleep onset and awakenings | ★★★☆☆ | Positive in the 2024 trial, not consistent across all studies

Generalized anxiety disorder | ★★☆☆☆ | One tiny active-comparator trial without placebo

Menopausal symptoms overall | ★★☆☆☆ | One small active-comparator study without placebo

Hot flashes or vasomotor symptoms | ★★☆☆☆ | Included in one weak menopause study; not independently established

Menopause-related sleep and mood | ★★☆☆☆ | Preliminary single-study evidence

PMS or menstrual symptoms | ★☆☆☆☆ | Traditional references but no direct controlled human evidence located

Female sexual desire and function | ★☆☆☆☆ | No direct human evidence located

Opioid-withdrawal mental symptoms | ★★☆☆☆ | One small add-on controlled trial

Benzodiazepine tapering | ★★☆☆☆ | Observational real-world evidence only

ADHD-related symptoms | ★★☆☆☆ | One very small active-comparator trial without placebo

Children’s anxiety or insomnia | ★★☆☆☆ | Retrospective and indirect evidence; no strong paediatric RCT

GABA-related mechanisms | ★☆☆☆☆ | Laboratory and animal evidence only

Short-term tolerability | ★★★☆☆ | Generally acceptable in studies; drowsiness, dizziness and muscle relaxation possible

Long-term safety | ★★☆☆☆ | Observational experience exists, but matching-extract and broad-population data remain limited

Pregnancy and breastfeeding | ★☆☆☆☆ | Safety not established; use not recommended by EMA

Clinical match to Luminara | ★★☆☆☆ | Correct species and plant part with quantified flavones, but dose, extraction chemistry and 5% versus 10.25% documentation are unresolved


WHAT THE KEY STUDIES FOUND


MOVAFEGH ET AL., 2008⁹

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Sixty surgical outpatients.

Intervention: 500 mg Passionflower or placebo ninety minutes before surgery.

Finding: Lower preoperative anxiety without significant psychomotor impairment or marked sedation.

Limitation: Single acute dose, small sample and preparation not matched to Luminara.


DA CUNHA ET AL., 2021¹³

Design: Randomised, placebo-controlled, triple-blind parallel trial.

Participants: Two hundred dental-surgery patients.

Interventions: Passionflower 500 mg, mulungu 500 mg, midazolam 15 mg or placebo.

Finding: Passionflower reduced anxiety similarly to midazolam and differed from placebo.

Limitations: Procedure-specific outcome and dose more than four times Luminara’s daily extract mass.


VELASQUEZ ET AL., 2024¹⁵

Design: Randomised, triple-blind clinical trial.

Participants: Fifty-four people undergoing third-molar extraction.

Interventions: Passionflower, valerian or placebo.

Finding: State anxiety decreased over time in the herbal groups but not placebo.

Null finding: Surgical discomfort did not improve; vital-sign findings varied.

Limitation: Preparation characterisation and dose matching remain uncertain.


LIMA NETO ET AL., 2025¹⁷

Design: Randomised, triple-blind trial.

Participants: Thirty.

Interventions: Passionflower, midazolam or placebo before oral surgery.

Finding: Postoperative salivary cortisol was lower with Passionflower and midazolam than placebo.

Null findings: Subjective anxiety and most physiological measures did not differ significantly.

Why it matters: It prevents the acute-anxiety evidence from being described as uniformly positive.


AKHONDZADEH ET AL., 2001—GENERALIZED ANXIETY⁵

Design: Double-blind randomised active-comparator trial.

Participants: Thirty-six outpatients.

Interventions: Passionflower drops or oxazepam for four weeks.

Finding: Both groups improved; oxazepam appeared faster, while job-performance impairment was more common with oxazepam.

Limitations: No placebo, tiny sample and inadequate extract description.


NGAN AND CONDUIT, 2011¹⁸

Design: Double-blind placebo-controlled crossover trial.

Participants: Forty-one healthy adults.

Intervention: Tea made with 2 grams of dried Passionflower herb nightly for seven days.

Finding: Subjective sleep quality improved.

Null or uncertain findings: State anxiety did not significantly improve; polysomnography subgroup was too small for broad conclusions.

Limitation: Tea preparation is not equivalent to a concentrated extract.


LEE ET AL., 2020¹⁹

Design: Double-blind placebo-controlled trial.

Enrolled: One hundred and ten adults with insomnia; eighty-four included in the reported analysis.

Intervention: 60 mg nightly for two weeks.

Finding: Total sleep time increased on polysomnography.

Null findings: Most other objective and subjective sleep outcomes and stress did not differ significantly.

Why it matters: It provides selective objective evidence rather than broad proof of improved sleep.


HARIT ET AL., 2024²⁰

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Sixty-five adults with stress and sleep problems.

Intervention: 600 mg nightly of the SIVI aerial-parts extract.

Duration: Thirty days.

Findings: Greater improvement in perceived stress, total sleep time, sleep onset, awakenings, wake time after sleep onset, insomnia severity, fatigue, PSQI and general psychological health.

Null finding: Cortisol declined within both groups, with no significant between-group difference.

Safety: No adverse events were reported.

Limitations: Pilot size, no formal sample-size calculation, many subjective outcomes, proprietary extract and industry involvement.


TAKARA ET AL., 2019²¹

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Forty-four adults.

Intervention: 200 mg daily, standardised to 3% flavonoid glycosides.

Duration: Twelve weeks.

Findings: Selected mental and social quality-of-life scores improved.

Null finding: Sleep questionnaire outcomes did not significantly improve.

Why it matters: It shows that a flavonoid-standardised extract did not consistently improve sleep.


FAHAMI ET AL., 2010²⁵

Design: Randomised active-comparator clinical study.

Participants: Fifty-nine menopausal women.

Interventions: Passionflower or St John’s wort.

Duration: Six weeks.

Finding: Menopause symptom scores decreased with Passionflower from weeks three to six.

Limitations: No placebo, no clear superiority, small sample and poor extract characterisation.

Interpretation: Preliminary evidence only for a broad menopause-symptom index.


ZANARDI ET AL., 2023²⁸

Design: Retrospective matched real-world cohort.

Participants: One hundred and eighty-six adults with anxiety or depression tapering long-term benzodiazepines.

Finding: Greater and faster benzodiazepine-dose reduction with add-on Passionflower.

Limitations: Non-randomised, specialist setting, possible treatment-selection bias and not a consumer self-care application.


HOW PASSIONFLOWER MAY WORK

No single mechanism has been established as the explanation for Passionflower’s human effects.


FLAVONES AND FLAVONOID GLYCOSIDES

Passiflora incarnata herb contains several C-glycosyl flavones and related flavonoids, commonly including:

• vitexin;
• isovitexin;
• orientin;
• isoorientin;
• schaftoside;
• isoschaftoside;
• related glycosides.³⁷–⁴¹

The amount and pattern vary according to:

• cultivar;
• plant part;
• harvest;
• drying;
• extraction solvent;
• drug-extract ratio;
• analytical method.

“Total flavones” is not one active molecule.

Luminara’s 10.25% UV result does not establish the amount of each individual compound or prove equivalence to another extract standardised by HPLC.


GABA-RELATED PATHWAYS

Laboratory studies have investigated Passionflower extracts in GABA uptake and receptor-binding systems.⁴²˒⁴³

Some extracts influenced GABAergic signalling, but activity differed according to extraction method.

It is not accurate to say that Passionflower “is a natural benzodiazepine.”

A laboratory interaction with a GABA-related target does not mean that an oral supplement has the same potency, receptor profile, pharmacokinetics, dependence risk or clinical effect as a benzodiazepine.


SLEEP-RELATED RECEPTOR RESEARCH

A 2026 laboratory study reported multi-target effects of a Passionflower extract on selected receptors relevant to sleep and arousal.⁴⁴

This is mechanistic research, not a human sleep trial and not evidence that Luminara reproduces the effect.


STRESS AND CORTISOL

Several human studies measured stress-related outcomes or cortisol.¹⁷˒²⁰˒²³

Results are not consistent enough to claim that Passionflower reliably lowers cortisol.

In the 2024 stress trial, cortisol decreased in both Passionflower and placebo groups, without a significant between-group difference.²⁰


PRECLINICAL RESEARCH BEYOND CALM AND SLEEP

Animal and laboratory studies have explored:

• anticonvulsant activity;
• pain and inflammatory pathways;
• cough and airway effects;
• glucose metabolism;
• neuroprotection;
• antioxidant activity;
• gastrointestinal effects;
• reproductive and hormonal models.³⁷–⁴⁸

These findings should not be converted into claims that Passionflower treats seizures, pain, inflammation, asthma, diabetes, neurodegenerative disease or reproductive conditions.


SAFETY AND RESPONSIBLE USE

Passionflower has generally been tolerated in short-term clinical studies, but it is not free of potential effects.

Reported or plausible effects include:

• drowsiness;
• tiredness;
• dizziness;
• muscle relaxation;
• reduced alertness;
• nausea or digestive discomfort;
• allergy.

The European Medicines Agency advises that Passionflower preparations may impair the ability to drive or operate machinery. Pregnancy and breastfeeding safety have not been established, and use is not recommended during those periods.²–⁴

A single published case described severe nausea, vomiting, drowsiness, QT-interval prolongation and a short episode of ventricular tachycardia after a Passionflower-containing product used at a labelled therapeutic dose.⁴⁹

A single case cannot establish frequency or causation, and the exact product composition may not represent Luminara. It nevertheless supports caution in people with:

• known long-QT syndrome;
• clinically important arrhythmias;
• medicines known to prolong the QT interval;
• significant cardiac disease.

Because Passionflower may be calming or sedating, additive effects are possible with:

• benzodiazepines;
• opioids;
• sleeping medicines;
• sedating antihistamines;
• antipsychotics;
• some antidepressants;
• alcohol;
• anaesthetic medicines;
• other calming herbs.

Clinical interaction data are limited, so this is a precaution rather than proof of a specific interaction.

People should tell their surgical, dental or anaesthetic team about Passionflower and all other supplements.

Passionflower should not be used to replace prescribed psychiatric, sleep, seizure or withdrawal treatment.

Anyone who is pregnant, breastfeeding, taking prescription medication, preparing for surgery or managing a medical condition should consult a qualified healthcare professional before using Luminara.


PLAIN-ENGLISH SUMMARY

Passionflower has one of Luminara’s clearer human evidence stories for calm and stress-related wellbeing.

Several controlled studies have investigated Passionflower before surgery or dental procedures. Most reported lower situational anxiety, often without major psychomotor impairment or memory loss.⁹–¹⁶ A small 2025 trial did not improve subjective anxiety, although it reported a salivary-cortisol difference.¹⁷

Sleep findings are encouraging but mixed. A tea study improved subjective sleep quality, and a short insomnia study increased objective total sleep time while leaving most other sleep outcomes unchanged.¹⁸˒¹⁹ A 2024 trial reported broader improvements in stress, sleep continuity, fatigue and psychological wellbeing at 600 mg nightly.²⁰ A different twelve-week study reported selected quality-of-life benefits but no significant sleep improvement.²¹

One small study in menopausal women reported lower overall symptom scores—including vasomotor and sleep-related complaints—but had no placebo group and did not establish direct hormonal action.²⁵ There is no controlled evidence that Passionflower balances hormones, treats PMS, relieves vaginal dryness or directly improves female sexual function.

Luminara provides 120 mg daily of Passiflora incarnata herb extract. The supplied batch CoA reports 10.25% flavones, but the current manufacturing quotation describes 5% flavones. That discrepancy must be resolved before a precise finished-product flavone amount is claimed.

The most accurate positioning is:

Passionflower contributes human clinical research for calm, situational anxiety, everyday stress and selected sleep outcomes. Its effects are not universal, the evidence is preparation-specific, and its role in women’s intimate wellness is through the broader conditions of calm, rest and emotional wellbeing rather than a direct libido or hormone claim.


REFERENCES

1. Royal Botanic Gardens, Kew. Passiflora incarnata L.. Plants of the World Online. Accessed 1 August 2026.

2. European Medicines Agency, Committee on Herbal Medicinal Products. Passiflorae herba - herbal medicinal product. EMA. Summary of HMPC conclusions on the medicinal uses of passion flower. First published 6 October 2016.

3. European Medicines Agency, Committee on Herbal Medicinal Products. Community herbal monograph on Passiflora incarnata L., herba. EMA/HMPC/669740/2013. Adopted 25 March 2014; published 18 June 2014.

4. European Medicines Agency, Committee on Herbal Medicinal Products. Assessment report on Passiflora incarnata L., herba. EMA/HMPC/669738/2013. Adopted 25 March 2014; published 18 June 2014.

5. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26(5):363-367. doi:10.1046/j.1365-2710.2001.00367.x. PMID: 11679026.

6. Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther. 2001;26(5):369-373. doi:10.1046/j.1365-2710.2001.00366.x. PMID: 11679027.

7. Akhondzadeh S, Mohammadi MR, Momeni F. Passiflora incarnata in the treatment of attention-deficit hyperactivity disorder in children and adolescents. Therapy. 2005;2(4):609-614. doi:10.1586/14750708.2.4.609.

8. Miyasaka LS, Atallah ÁN, Soares B. Passiflora for anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD004518. doi:10.1002/14651858.CD004518.pub2. PMID: 17253512.

9. Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg. 2008;106(6):1728-1732. doi:10.1213/ane.0b013e318172c3f9. PMID: 18499602.

10. Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth. 2012;26(1):39-44. doi:10.1007/s00540-011-1265-6. PMID: 22048283.

11. Kaviani N, Tavakoli M, Tabanmehr M, Havaei R. The Efficacy of Passiflora Incarnata Linnaeus in Reducing Dental Anxiety in Patients Undergoing Periodontal Treatment. J Dent (Shiraz). 2013;14(2):68-72. PMID: 24724122.

12. Dantas LP, de Oliveira-Ribeiro A, de Almeida-Souza LM, Groppo FC. Effects of Passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction. Med Oral Patol Oral Cir Bucal. 2017;22(1):e95-e101. doi:10.4317/medoral.21140. PMID: 27918731.

13. da Cunha RS, Amorim KS, Gercina AC, de Oliveira ACA, Menezes LDS, Groppo FC, Souza LMA. Herbal medicines as anxiolytics prior to third molar surgical extraction. A randomized controlled clinical trial. Clin Oral Investig. 2021;25(3):1579-1586. doi:10.1007/s00784-020-03468-1. PMID: 32951121.

14. Christoffoli M, et al. Assessment of Passiflora incarnata L. for conscious sedation of patients during the extraction of mandibular third molars: a randomized, double-blind, crossover study. Quintessence Int. 2021;52(10):868-878. doi:10.3290/j.qi.b1492199. PMID: 34076379.

15. Abregu Velasquez AC, Tsuji M, Cordeiro LDS, Petinati MFP, Rebellato NLB, Sebastiani AM, da Costa DJ, Scariot R. Effects of Passiflora incarnata and Valeriana officinalis in the control of anxiety due to tooth extraction: a randomized controlled clinical trial. Oral Maxillofac Surg. 2024;28(3):1313-1320. doi:10.1007/s10006-024-01259-6. PMID: 38743126.

16. Stonkutė I, Afanasjevas D, Janovskienė A, et al. Preoperative Anxiolysis in Surgical Care Without Sedation or General Anesthesia: A Systematic Review. Dent J (Basel). 2026;14(6):327. doi:10.3390/dj14060327. PMID: 42345918.

17. Lima Neto TJ, Ribeiro NP, Souza MB, Freitas RN, Karande S, Mourão CF, Chaves-Neto AH, Faverani LP. Effects of Passiflora incarnata on salivary biomarkers and anxiety in patients undergoing third molar extraction surgery. Sci Rep. 2025;15:43616. doi:10.1038/s41598-025-27468-x. PMID: 41381570.

18. Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata herbal tea on subjective sleep quality. Phytother Res. 2011;25(8):1153-1159. doi:10.1002/ptr.3400. PMID: 21294203.

19. Lee J, Jung HY, Lee SI, et al. Effects of Passiflora incarnata Linnaeus on polysomnographic sleep parameters in subjects with insomnia disorder: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2020;35(1):29-35. doi:10.1097/YIC.0000000000000291. PMID: 31714321.

20. Harit MK, Mundhe N, Tamoli S, Pawar V, Bhapkar V, Kolhe G, Mahadik S, Kulkarni A, Agarwal A. Randomized, Double-Blind, Placebo-Controlled, Clinical Study of Passiflora incarnata in Participants With Stress and Sleep Problems. Cureus. 2024;16(3):e56530. doi:10.7759/cureus.56530. PMID: 38646244.

21. Takara T, Yamamoto K, Suzuki N, Hirano M, Shimizu N, Shimoda H. Passionflower Extract Improves Diurnal Quality of Life in Japanese Subjects with Anxiety: A Randomized, Placebo-controlled, Double-blind Trial. Funct Foods Health Dis. 2019;9(5):305-319. doi:10.31989/ffhd.v9i5.593.

22. Gibbert J, Kreimendahl F, Lebert J, Rychlik R, Trompetter I. Improvement of Stress Resistance and Quality of Life of Adults with Nervous Restlessness after Treatment with a Passion Flower Dry Extract. Complement Med Res. 2017;24(2):83-89. doi:10.1159/000464342. PMID: 28407638.

23. Dimpfel W, Koch K, Weiss G. Single Dose Effects of Pascoflair® on Current Source Density (CSD) of Human EEG. Neurosci Med. 2012;3(2):130-140. doi:10.4236/nm.2012.32018. ClinicalTrials.gov: NCT01047605.

24. Dimpfel W, Chiegoua Dipah G, Suliman S. Proof of Effectiveness of PASCOFLAIR® in Subjects Suffering from Examination Anxiety Using Quantitative EEG in Combination with Eye-Tracking (EnkephaloVision). A Double-Blind, Randomized, Placebo Controlled, 2-Armed, Phase IV Study in Parallel Design. Pharmacol Pharm. 2016;7:424-442. doi:10.4236/pp.2016.710050. EudraCT: 2014-003369-50.

25. Fahami F, Asali Z, Aslani A, Fathizadeh N. A comparative study on the effects of Hypericum perforatum and passion flower on the menopausal symptoms of women referring to Isfahan city health care centers. Iran J Nurs Midwifery Res. 2010;15(4):202-207. PMID: 22049281.

26. Villa P, Amar ID, Bottoni C, Cipolla C, Dinoi G, Moruzzi MC, Scambia G, Lanzone A. The impact of combined nutraceutical supplementation on quality of life and metabolic changes during the menopausal transition: a pilot randomized trial. Arch Gynecol Obstet. 2017;296(4):791-801. doi:10.1007/s00404-017-4491-9. PMID: 28852842. [Combination evidence.]

27. La Tempa A, et al. Passiflora Incarnata L. Herba in the Treatment of Anxiety Symptoms and Insomnia in Children and Adolescents with Feeding and Eating Disorders. Adolescents. 2025;5(2):24. doi:10.3390/adolescents5020024.

28. Zanardi R, Attanasio F, Carminati M, et al. Add-On Treatment with Passiflora incarnata L., Herba, during Benzodiazepine Tapering in Patients with Depression and Anxiety: A Real-World Study. Pharmaceuticals (Basel). 2023;16(3):426. doi:10.3390/ph16030426. PMID: 36986524.

29. Carminati M, Tondello M, Zanardi R. Passiflora incarnata L., herba, in benzodiazepine tapering: long-term safety and efficacy in a real-world setting. Front Psychiatry. 2024;15:1471083. doi:10.3389/fpsyt.2024.1471083. PMID: 39429529.

30. Carminati M, Tondello M, Zappia M, Zanardi R. Synergistic Effect of Passiflora incarnata L., Herba, and Cognitive Behavioral Therapy in the Management of Benzodiazepine Misuse. Pharmaceuticals (Basel). 2026;19(1):141. doi:10.3390/ph19010141. PMID: 41599739.

31. Nemat-Shahi M, Mir Mohammadi SM, Soroosh D, Asadi A, Nakhaee S, Mehrpour M. Comparison of the Effects of Passiflora Incarnata and Piroxicam in Opioids Withdrawal-Induced Myalgia and Anxiety: A Randomized Clinical Trial. Indian J Forensic Med Toxicol. 2020;14(2):1766-1770. doi:10.37506/ijfmt.v14i2.3192.

32. Maroo N, Hazra A, Das T. Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial. Indian J Pharmacol. 2013;45(1):34-39. doi:10.4103/0253-7613.106432. PMID: 23543804.

33. Trompetter I, Krick B, Weiss G. Herbal triplet in treatment of nervous agitation in children. Wien Med Wochenschr. 2013;163(3-4):52-57. doi:10.1007/s10354-012-0165-1. PMID: 23179673.

34. European Medicines Agency, Committee on Herbal Medicinal Products. European Union herbal monograph on Species sedativae. EMA/HMPC/438183/2017. Adopted European Union herbal monograph covering sedative herbal-tea combinations including Passiflora incarnata, Melissa officinalis and Valeriana officinalis.

35. de Oliveira Araújo J, Bergamaschi CC, Lopes LC, Guimarães CC, de Andrade NK, Ramacciato JC, Motta RHL. Effectiveness and safety of oral sedation in adult patients undergoing dental procedures: a systematic review. BMJ Open. 2021;11(1):e043363. doi:10.1136/bmjopen-2020-043363. PMID: 33495257.

36. Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. J Ethnopharmacol. 2013;150(3):791-804. doi:10.1016/j.jep.2013.09.047. PMID: 24140586.

37. Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K. Passiflora incarnata in Neuropsychiatric Disorders-A Systematic Review. Nutrients. 2020;12(12):3894. doi:10.3390/nu12123894. PMID: 33352740.

38. Ulbricht C, Basch E, Boon H, et al. An evidence-based systematic review of Passionflower by the Natural Standard Research Collaboration. J Diet Suppl. 2008;5(3):310-340. doi:10.1080/19390210802414360. PMID: 22432466.

39. Dhawan K, Dhawan S, Sharma A. Passiflora: a review update. J Ethnopharmacol. 2004;94(1):1-23. doi:10.1016/j.jep.2004.02.023. PMID: 15261959.

40. Krenn L. Passion flower (Passiflora incarnata L.)--a reliable herbal sedative. Wien Med Wochenschr. 2002;152(15-16):404-406. doi:10.1046/j.1563-258x.2002.02062.x. PMID: 12244887.

41. Ożarowski M, Karpiński TM. Extracts and Flavonoids of Passiflora Species as Promising Anti-inflammatory and Antioxidant Substances. Curr Pharm Des. 2021;27(22):2582-2604. doi:10.2174/1381612826666200526150113. PMID: 32452323.

42. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L.. Phytother Res. 2011;25(6):838-843. doi:10.1002/ptr.3352. PMID: 21089181.

43. Elsas SM, Rossi DJ, Raber J, White G, Seeley CA, Gregory WL, Mohr C, Pfankuch T, Soumyanath A. Passiflora incarnata L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine. 2010;17(12):940-949. doi:10.1016/j.phymed.2010.03.002. PMID: 20382514.

44. Appel K, Schwarzensteiner I, Zimmermann C, Tober C, Günnewich N. A Passiflora incarnata extract exerts multi-target effects on selected sleep-related receptors. J Ethnopharmacol. 2026;372:122198. doi:10.1016/j.jep.2026.122198. PMID: 42462921.

45. Grundmann O, Wang J, McGregor GP, Butterweck V. Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med. 2008;74(15):1769-1773. doi:10.1055/s-0028-1088322. PMID: 19006051.

46. Aman U, Subhan F, Shahid M, Akbar S, Ahmad N, Ali G, Fawad K, Sewell RDE. Passiflora incarnata attenuation of neuropathic allodynia and vulvodynia apropos GABA-ergic and opioidergic antinociceptive and behavioural mechanisms. BMC Complement Altern Med. 2016;16:77. doi:10.1186/s12906-016-1048-6. PMID: 26912265.

47. Gupta RK, Kumar D, Chaudhary AK, Maithani M, Singh R. Antidiabetic activity of Passiflora incarnata Linn. in streptozotocin-induced diabetes in mice. J Ethnopharmacol. 2012;139(3):801-806. doi:10.1016/j.jep.2011.12.021. PMID: 22212504.

48. Dhawan K, Sharma A. Prevention of chronic alcohol and nicotine-induced azospermia, sterility and decreased libido, by a novel tri-substituted benzoflavone moiety from Passiflora incarnata Linneaus in healthy male rats. Life Sci. 2002;71(26):3059-3069. doi:10.1016/S0024-3205(02)02168-9.

49. Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata L.. J Toxicol Clin Toxicol. 2000;38(1):63-66. doi:10.1081/CLT-100100919. PMID: 10696928.


These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

BAIKAL SKULLCAP

Scutellaria baicalensis Georgi

Baikal Skullcap is a perennial plant in the mint family whose dried root has been used for centuries in East Asian medicine. The medicinal root is commonly known as Huang Qin, Scutellariae Radix or Chinese Skullcap.

The name “skullcap” requires particular care.

Baikal Skullcap—Scutellaria baicalensis—is not the same ingredient as American Skullcap, Scutellaria lateriflora. Baikal Skullcap research generally concerns the root and flavonoids such as baicalin, baicalein, wogonin and oroxylin A. American Skullcap research generally concerns the aerial parts and cannot be used as evidence for Luminara’s ingredient.¹–⁴

Luminara’s current manufacturing quotation specifies 300 mg daily of a Scutellaria baicalensis root extract standardised to 30% baicalin.

Until recently, most evidence relevant to mood, stress, sleep and neuroinflammatory pathways was preclinical. In 2025, the first substantial randomised, double-blind, placebo-controlled human trial of a standalone, highly baicalin-standardised Scutellaria baicalensis extract was published in adults experiencing mild-to-moderate depressive symptoms.⁵

That trial is encouraging—but its findings are more selective than a broad “mood support” headline may suggest.

The study’s primary outcome, the Beck Depression Inventory, improved in every group, including placebo, with no significant treatment-by-time difference. The standalone Scutellaria group showed selected later improvements in clinician-rated depressive symptoms and WHO-5 wellbeing, but it did not clearly outperform placebo across most mood, anxiety and emotional measures.⁵

Other human research has investigated Baikal Skullcap:

• with saffron for mood;⁵
• with hawthorn, magnesium and chromium for stress, cognition and sleep;⁶
• alongside metformin in type 2 diabetes;⁷
• with Acacia catechu for cognition, vaccine response and osteoarthritis;⁸–¹⁵
• as Scutellariae Radix powder in a human pharmacokinetic study;¹⁶
• through isolated baicalein, baicalin or oroxylin A pharmacokinetic and drug-interaction studies;¹⁷–²⁵˒⁴⁵
• in a topical human formulation;²⁶
• and in laboratory research using human cells rather than oral supplementation.²⁷

Most of those studies do not test Luminara’s ingredient alone.

The most accurate conclusion is:

Baikal Skullcap now has emerging human evidence for selected aspects of mood regulation and emotional wellbeing from one highly standardised standalone extract. Broader claims involving sleep, cognition, inflammation, immunity, blood sugar, menopause or sexual wellbeing rely on combination studies, disease-specific research or preclinical evidence.


BAIKAL SKULLCAP AT A GLANCE

Botanical name: Scutellaria baicalensis Georgi

Botanical family: Lamiaceae

Traditional medicinal name: Huang Qin or Scutellariae Radix

Common names: Baikal Skullcap, Chinese Skullcap, Baical Skullcap

Part used in Luminara: Root

Ingredient form in Luminara: Plant extract

Current manufacturing-formula amount: 300 mg daily

Current formula description: Baical Skullcap Root Extract, 30% baicalin

Supplier raw-material specification: Not less than 30% baicalin

Supplied raw-material batch result: 31.15% baicalin by high-performance liquid chromatography

Nominal baicalin amount if the supplied assay result applies to 300 mg of the complete production ingredient:

300 mg × 31.15% = 93.45 mg measured baicalin

Extraction solvent: 60% ethanol and 40% water

Carrier: 10% maltodextrin

Country of origin: China

Batch number on supplied document: SBB230627

Manufacture date: 27 June 2023

Stated shelf life: Three years

Calculated end of stated shelf life: 27 June 2026

The supplied raw-material document is therefore outside its stated shelf life as of 2 August 2026.

That does not establish that Luminara’s future production ingredient is expired. It means the document supplied for this Evidence Centre is not adequate evidence for the current production batch.

Before launch, Trab Health should obtain:

• the current production-batch CoA;
• its manufacturing and expiry or retest dates;
• the actual baicalin assay result;
• confirmation of botanical identity;
• confirmation that the 10% maltodextrin is included within the declared 300 mg ingredient weight;
• the native drug-extract ratio;
• and finished-product identity and potency results.

The 93.45 mg calculation is raw-material mathematics only.

It should not be described as an independently verified amount in every finished serving unless the manufacturer confirms that:

• the production batch uses this specification;
• 300 mg refers to the complete extract powder, including any carrier;
• the current batch meets its baicalin specification;
• and finished-product testing supports the declared amount.


HOW CLOSELY DOES LUMINARA’S BAIKAL SKULLCAP MATCH THE CLINICAL RESEARCH?

Luminara has a stronger analytical match to the emerging mood research than many unidentified or unstandardised Skullcap products.

The similarities include:

• the same botanical species—Scutellaria baicalensis;
• the same medicinal plant part—the root;
• an extract rather than unidentified root powder;
• baicalin as a quantified marker;
• and high-performance liquid chromatography as the assay method.

The principal standalone mood study used:

• 20 mg daily of SCUTELL’UP;
• standardised to 90.04% baicalin by HPLC;
• providing 18.08 mg measured baicalin daily;
• for six weeks.⁵

Luminara’s current formula and supplied raw-material documents indicate:

• 300 mg extract powder daily;
• 31.15% measured baicalin on the supplied batch CoA;
• nominally 93.45 mg measured baicalin daily if the production batch and declared amount are confirmed;
• 10% maltodextrin;
• and a 60% ethanol and 40% water extraction solvent.

The nominal raw-material baicalin calculation is higher than the amount used in the SCUTELL’UP trial.

That does not establish clinical equivalence, greater efficacy or superiority.

The extracts may differ in:

• extraction ratio;
• native extract concentration;
• baicalin-to-baicalein ratio;
• concentrations of wogonin, wogonoside, oroxylin A and other root flavonoids;
• particle and delivery characteristics;
• carrier composition;
• pharmacokinetics;
• stability;
• and the proportion of compounds not captured by the baicalin assay.

The standalone trial used an extract containing approximately 90% baicalin. The supplied Luminara raw-material document reports approximately 31% baicalin and 10% maltodextrin, leaving a substantially different remaining chemical matrix.

A greater nominal amount of one marker does not make two botanical extracts interchangeable.

Other human studies are even less comparable.

Examples include:

• 3.52 grams daily of Scutellaria alongside metformin in type 2 diabetes;⁷
• 800 mg daily of Scutellaria root material within a four-ingredient stress supplement;⁶
• 240 mg of stem extract combined with 51 mg of Acacia catechu in a cognition trial;⁸
• proprietary Scutellaria–Acacia combinations for cognition, vaccination response and osteoarthritis;⁹–¹⁵
• 5.2 grams of commercial Scutellariae Radix powder in healthy men;¹⁶
• and isolated baicalein tablets at hundreds or thousands of milligrams.¹⁷–²¹

The accurate conclusion is:

Luminara’s extract shares the species, root part and HPLC-measured baicalin marker used in the most relevant standalone clinical trial. Its complete chemical profile, dose, delivery characteristics and current production-batch status have not been clinically matched.


BAIKAL SKULLCAP IS NOT AMERICAN SKULLCAP

Baikal Skullcap: Scutellaria baicalensis

• The medicinal material is generally the root.
• Major studied flavonoids include baicalin, baicalein, wogonin, wogonoside and oroxylin A.
• It is traditionally known as Huang Qin or Scutellariae Radix.
• It is the species used in Luminara.

American Skullcap: Scutellaria lateriflora

• The medicinal material is generally the aerial parts.
• It has a different phytochemical profile and a different traditional evidence base.
• Human calm or anxiety studies involving American Skullcap cannot substantiate Luminara’s Baikal Skullcap ingredient.⁴⁴

Generic references to “skullcap” should therefore be checked at species and plant-part level before being used.


TRADITIONAL USE

Scutellaria baicalensis root has a long history in Chinese, Japanese and Korean herbal traditions.

Traditional use has included patterns associated with heat, inflammation, respiratory and digestive complaints, bleeding, infection-related presentations and agitation.¹–⁴

Traditional use contributes historical context.

It does not by itself establish that a modern 300 mg standardised extract:

• improves mood;
• reduces anxiety;
• supports sleep;
• balances hormones;
• relieves menopause;
• improves libido;
• treats inflammation;
• or prevents disease.

Modern claims must be matched to the species, plant part, preparation, dose and quality of contemporary evidence.


HUMAN EVIDENCE


STANDALONE MOOD TRIAL

DORMAL ET AL., 2025

This is the most important standalone human study for Luminara’s Baikal Skullcap ingredient.⁵

One hundred and eighty adults experiencing mild-to-moderate depressive symptoms were randomised to receive:

• SCUTELL’UP alone;
• saffron alone;
• Scutellaria plus saffron;
• or placebo;

for six weeks.

Forty-two participants were assigned to standalone Scutellaria.

The Scutellaria intervention provided:

• 20 mg daily of Scutellaria baicalensis root extract;
• 90.04% baicalin by HPLC;
• and 18.08 mg measured baicalin daily.

PRIMARY OUTCOME: BECK DEPRESSION INVENTORY

Beck Depression Inventory scores improved over time.

However, there was no significant treatment-by-time interaction.

This means the improvement was not demonstrated to differ reliably among:

• standalone Scutellaria;
• saffron;
• the combination;
• and placebo.

The primary outcome therefore did not establish that standalone Scutellaria was superior to placebo.

CLINICIAN-RATED HAMILTON DEPRESSION SCALE

Hamilton Depression Rating Scale scores improved across groups.

The standalone Scutellaria group showed a statistically significant within-group decline between weeks three and six.

The clearest post-hoc superiority over placebo was reported for saffron rather than standalone Scutellaria.

The Scutellaria result is therefore best described as a selective later signal, not definitive antidepressant efficacy.

STATE ANXIETY

State-anxiety scores did not improve in the Scutellaria group at the first three-week assessment.

A later decline occurred between weeks three and six.

However, the change did not differ significantly among the four groups.

This does not establish standalone anxiolytic efficacy.

POSITIVE AND NEGATIVE AFFECT

Positive-affect scores did not improve from baseline in the Scutellaria group during the active six-week intervention.

Negative-affect scores fell in every group without a significant between-group difference.

Again, this prevents a broad claim that the extract clearly improved emotional state beyond placebo.

WHO-5 WELLBEING

All groups improved from baseline.

Between weeks three and six, the standalone Scutellaria group showed a larger WHO-5 increase than placebo.

This is one of the trial’s more encouraging extract-specific findings.

SLEEP

The authors reported sleep benefits principally for saffron.

The standalone Scutellaria arm should not be credited with a demonstrated sleep benefit from this study.

SAFETY

Supplementation was globally well tolerated.

Across all four groups, sixty-six adverse events were recorded and thirteen were considered possibly related to the study products.

Reported events included headaches, respiratory infections, gastrointestinal complaints and sleep-related complaints.

Severe events were judged unrelated.

Adherence exceeded ninety-nine percent.

FUNDING AND CONFLICTS

Commercial company Quimica Massó funded recruitment, data collection and analysis.

The funder participated in study design and manuscript preparation but was reported not to have participated in data collection, analysis or interpretation.

WHY THE STUDY MATTERS

This trial moves Baikal Skullcap beyond a purely preclinical mood story.

However, the most defensible conclusion is:

A highly baicalin-standardised Scutellaria baicalensis root extract produced selected later improvements in clinician-rated symptoms and wellbeing, but did not outperform placebo on the primary self-reported depression outcome or most anxiety and emotional measures.

It does not show that Luminara treats depression or anxiety.


SCUTELLARIA AND SAFFRON COMBINATION ARM

The same 2025 trial included a combination of Scutellaria and saffron.⁵

The combination did not consistently outperform the single ingredients or placebo across the primary mood measures.

The study therefore did not demonstrate a clear clinical synergy between Scutellaria and saffron.

This is relevant because Luminara contains both ingredients.

It supports studying the combination, but it does not establish that Luminara’s complete formula has been clinically tested or that its ingredients act synergistically in the finished product.


STRESS, COGNITION AND SLEEP COMBINATION TRIAL

DODD ET AL., 2025

A randomised, double-blind, placebo-controlled crossover trial studied a supplement containing:

• Scutellaria baicalensis root extract;
• Crataegus laevigata fruit extract;
• magnesium;
• and chromium.⁶

Forty-three participants entered the study and thirty-five were included in the analysis.

Participants received the active supplement and placebo for fifteen days in crossover periods.

The complete supplement was reported to improve selected measures involving:

• mood;
• subjective anxiety;
• cognition under stress;
• and total sleep time.

The study also reported variable cognitive findings outside the stress condition.

The intervention reportedly included 800 mg of Scutellaria root material.

However, the results cannot be assigned to Baikal Skullcap alone because the study tested a four-ingredient product.

It does not establish that Luminara’s 300 mg extract:

• reproduces the stress findings;
• increases sleep duration;
• or provides the same magnesium, chromium or hawthorn-related effects.

Current evidence rating: promising combination evidence, not standalone substantiation.


TYPE 2 DIABETES AND GUT MICROBIOTA

A clinical study examined Scutellaria baicalensis alongside metformin in people with type 2 diabetes.⁷

Participants already taking metformin received either:

• 3.52 grams daily of Scutellaria baicalensis;
• or placebo.

The study reported changes involving:

• glucose tolerance;
• inflammatory markers;
• gene expression;
• and gut microbiota.

The study is relevant to human exposure and biological plausibility.

It does not substantiate a blood-sugar claim for Luminara because:

• participants had diagnosed type 2 diabetes;
• Scutellaria was added to metformin;
• the daily Scutellaria amount was more than eleven times Luminara’s 300 mg ingredient mass;
• the preparation was not chemically matched;
• and blood-glucose treatment claims are outside Luminara’s intended positioning.


COGNITION RESEARCH

Baikal Skullcap has been tested with Acacia catechu in proprietary cognitive products.

YIMAM ET AL., 2016

A small trial and associated preclinical work reported selected cognitive improvements with a Scutellaria–Acacia combination.⁹

A corrigendum later clarified that the human dose was 300 mg daily, not 300 mg twice daily.

The intervention was a two-botanical proprietary product.

The findings cannot be attributed to Scutellaria alone.

HAGELE ET AL., 2025

A later randomised, double-blind, placebo-controlled trial studied eighty-five healthy adults for four weeks.⁸

The product provided:

• 240 mg Scutellaria baicalensis stem extract;
• and 51 mg Acacia catechu heartwood extract.

The study found inconclusive evidence and did not demonstrate a clear cognitive benefit over placebo.

This later null or inconclusive trial is important context when interpreting the earlier positive pilot.

Neither study directly supports a cognition claim for Luminara because:

• both used Acacia;
• the later study used stem rather than root;
• the extracts were proprietary and chemically different;
• and cognition is not the primary role of Baikal Skullcap within Luminara.


IMMUNE RESPONSE AROUND INFLUENZA VACCINATION

A randomised, triple-blind, placebo-controlled trial studied a proprietary product containing:

• Acacia catechu;
• and Scutellaria baicalensis;

around influenza vaccination in healthy adults.¹⁰

The study reported improvements in selected measures of humoral immune response.

The result cannot be assigned specifically to Baikal Skullcap.

It also does not establish that Luminara:

• prevents influenza;
• increases vaccine effectiveness;
• treats infection;
• or “boosts” immunity generally.

The evidence belongs to a specific two-botanical combination used around vaccination.


OSTEOARTHRITIS AND JOINT RESEARCH

Baikal Skullcap has appeared in several proprietary Scutellaria–Acacia products investigated for osteoarthritis.

These studies are important to the complete evidence record, but they do not substantiate Luminara’s Baikal Skullcap alone.


UP446 SHORT-TERM STUDY

A one-week trial compared a proprietary Scutellaria baicalensis and Acacia catechu blend with naproxen in adults with knee osteoarthritis.¹¹

Selected pain, mobility and inflammatory-marker improvements were reported.

Limitations include:

• extremely short duration;
• diagnosed osteoarthritis;
• an active medicine comparator;
• a two-botanical formula;
• and no direct relevance to women’s hormonal or intimate wellbeing.


FLAVOCOXID OR LIMBREL STUDIES

Flavocoxid was a prescription medical food containing baicalin- and catechin-rich constituents derived from Scutellaria baicalensis and Acacia catechu.

Clinical studies included:

• a short pilot comparison with naproxen;¹²
• a larger twelve-week randomised comparison with naproxen;¹³
• an open-label post-marketing study;¹⁴
• and a safety evaluation.¹⁵

Some studies reported osteoarthritis symptom improvement or tolerability findings.

They cannot be assigned to Scutellaria alone.

More importantly, the product later became associated with rare but serious adverse events.

In 2018, all unexpired Limbrel products were recalled at the United States Food and Drug Administration’s request following reports involving:

• elevated liver enzymes;
• acute liver injury;
• and hypersensitivity pneumonitis.³⁷–⁴¹

Reported events generally improved after the product was stopped.

The recall does not prove that Baikal Skullcap alone caused the events. Flavocoxid was a specialised concentrated combination, not Luminara.

It does mean that the osteoarthritis studies cannot be cited selectively for benefit while ignoring the product’s later safety history.


SLEEP

Standalone human evidence that Scutellaria baicalensis root improves sleep remains very limited.

The 2025 standalone mood trial did not establish a sleep benefit for its Scutellaria-only group.⁵

The 2025 stress study reported increased total sleep time, but the intervention also contained:

• hawthorn;
• magnesium;
• and chromium.⁶

Preclinical research has reported effects of baicalin and related flavonoids on sleep–wake regulation and GABA-associated pathways.²⁸–³⁵

Animal sleep findings do not establish that Luminara improves:

• sleep onset;
• sleep maintenance;
• insomnia;
• or restorative sleep.

Current evidence rating for standalone oral sleep support: traditional or preclinical only.


ANXIETY AND CALM

The 2025 standalone mood trial measured state anxiety but did not show a significant overall treatment-by-time advantage for Scutellaria over placebo.⁵

The multi-ingredient stress trial reported lower subjective anxiety with the complete formula.⁶

Preclinical studies have investigated:

• GABA-A receptor modulation;
• wogonin as a benzodiazepine-site ligand;
• serotonergic and dopaminergic pathways;
• and inflammatory signalling linked to stress behaviour.²⁸–³⁵

These pathways provide a plausible calm-related rationale.

They do not establish that Luminara:

• treats anxiety;
• has benzodiazepine-like clinical efficacy;
• or should replace medical or psychological care.


MOOD AND EMOTIONAL WELLBEING

Mood is the strongest emerging direct human evidence area for Baikal Skullcap.

However, the evidence remains one preparation-specific standalone trial with mixed results.

The most defensible wording is:

Baikal Skullcap has emerging human evidence for selected aspects of mood regulation and emotional wellbeing from a highly baicalin-standardised root extract.

Stronger wording such as the following would overstate the evidence:

• clinically proven antidepressant;
• treats low mood;
• relieves depression;
• reduces anxiety;
• or works at Luminara’s exact dose.


MENOPAUSE, PMS, HORMONES AND FEMALE SEXUAL FUNCTION

No direct oral human trial was located showing that Scutellaria baicalensis root:

• relieves menopausal symptoms;
• reduces hot flushes;
• improves vaginal dryness;
• supports menstrual regularity;
• relieves PMS;
• balances oestrogen or progesterone;
• improves female sexual desire;
• improves arousal;
• or improves sexual satisfaction.

Some laboratory studies have investigated receptor-related or hormonal effects of individual Scutellaria compounds.

Laboratory receptor activity is not evidence of a clinically appropriate hormone-balancing effect in women.

Baikal Skullcap should therefore not be presented as a direct menopause, hormone or libido herb.

Its role in Luminara is better framed through emerging mood evidence and the broader whole-body context in which emotional wellbeing, stress load and intimate wellness can interact.


HUMAN PHARMACOKINETIC EVIDENCE

Human pharmacokinetic studies help explain how Scutellaria compounds are absorbed and transformed.

They do not demonstrate consumer efficacy.


SCUTELLARIAE RADIX POWDER

A study in healthy men investigated urinary metabolites after 5.2 grams of commercial Scutellariae Radix powder.¹⁶

Baicalein, wogonin and their conjugated metabolites were detected.

This confirms human exposure to root flavonoids after oral use.

It does not establish a mood, sleep or hormone benefit.


ISOLATED BAICALEIN

Phase I studies have investigated oral baicalein tablets.

A 2014 single-ascending-dose trial administered 100 to 2,800 mg to seventy-two healthy adults.¹⁷

The doses were generally well tolerated over the short study period, with mild treatment-related adverse events and no serious adverse events.

Further multiple-dose and food-effect studies explored doses in the hundreds of milligrams.¹⁸–²⁰

These studies:

• concern isolated baicalein rather than whole-root extract;
• use drug-development doses;
• provide short-term safety and pharmacokinetic information;
• and do not prove Luminara efficacy.

A registered Phase IIa influenza study of baicalein tablets was identified, but a result publication was not located by the evidence search cut-off.²¹


ISOLATED OROXYLIN A

A first-in-human phase I study of oroxylin A, another Scutellaria root flavonoid, was published in 2025.⁴⁵

This adds human safety and pharmacokinetic information for an isolated constituent.

It does not establish the clinical effects of Luminara’s whole extract.


MEDICINE-INTERACTION EVIDENCE

Human studies have reported pharmacokinetic interactions involving isolated baicalin or Scutellaria-derived compounds.

Examples include:

• altered rosuvastatin exposure through an OATP-related mechanism;²²
• induction of CYP2B6 activity assessed with bupropion;²³
• no clinically significant change in cyclosporine exposure after a single baicalin dose in a small healthy-volunteer study.²⁴

The direction and clinical importance of an interaction may depend on:

• the compound;
• dose;
• duration;
• medicine;
• genetics;
• liver and kidney function;
• and the complete extract matrix.

The exact effect of Luminara’s 300 mg extract cannot be predicted from these studies.

People taking prescription medicines—particularly medicines with a narrow therapeutic index—should discuss Luminara with a qualified healthcare professional.


MECHANISMS AND BIOLOGICAL PLAUSIBILITY


ABSORPTION AND METABOLISM

Baicalin is a glucuronide.

Gut bacteria can convert baicalin to baicalein, which can be absorbed and then reconjugated in the intestinal wall and liver.

Wogonoside and wogonin undergo related transformations.

This creates complex exposure patterns in which the compound measured in the raw material is not necessarily the compound circulating at the highest concentration in the same form.⁴˒¹⁶–²⁰˒³⁵


GABA-RELATED PATHWAYS

Laboratory and animal studies have investigated wogonin, baicalein and Baikal Skullcap extracts at GABA-related targets.²⁸–³⁴

Wogonin has shown affinity for a benzodiazepine-associated receptor site in laboratory research.³⁰

That does not make Baikal Skullcap a benzodiazepine.

The whole extract:

• contains many compounds;
• has different potency;
• has different absorption;
• has no established benzodiazepine-equivalent dose;
• and has not demonstrated the same clinical efficacy or risk profile.


MONOAMINE AND STRESS-RESPONSE PATHWAYS

Preclinical research has examined:

• serotonin;
• dopamine;
• noradrenaline;
• monoamine oxidase;
• hypothalamic-pituitary-adrenal signalling;
• and stress-induced behavioural changes.²⁸–³⁵

The 2025 human mood trial provides the first clinically relevant bridge, but its selective findings do not validate every proposed pathway in people.


INFLAMMATORY SIGNALLING

Baicalin, baicalein, wogonin and related compounds have been studied in pathways involving:

• NF-kB;
• NLRP3 inflammasome;
• cyclooxygenase and lipoxygenase;
• inflammatory cytokines;
• microglial activation;
• and oxidative signalling.²–⁴˒²⁸–³⁵

These pathways provide biological plausibility for whole-body research.

They do not establish that Luminara:

• treats inflammation;
• lowers inflammatory disease activity;
• prevents neuroinflammation;
• treats autoimmune disease;
• or replaces anti-inflammatory medicines.


ANTIOXIDANT PATHWAYS

Laboratory and animal research describes free-radical-scavenging and antioxidant-enzyme effects.

A compound can show antioxidant activity in a test tube without producing a meaningful systemic health outcome in humans.

No strong standalone clinical trial was located demonstrating a consumer-relevant antioxidant benefit from a Luminara-like Baikal Skullcap extract.


GUT MICROBIOTA

The type 2 diabetes study linked Scutellaria use with gut-microbial and metabolic changes.⁷

Those findings occurred:

• at 3.52 grams daily;
• in people with type 2 diabetes;
• and alongside metformin.

They should not be generalised to Luminara’s 300 mg extract.


ESTROGENIC OR HORMONAL PATHWAYS

Some laboratory studies have investigated hormonal or receptor-related effects of individual Scutellaria compounds.

No direct oral human evidence shows that Scutellaria baicalensis root:

• raises or lowers oestrogen appropriately;
• balances progesterone;
• regulates menstrual cycles;
• relieves menopause by correcting hormones;
• or improves female sexual function through endocrine action.


SAFETY AND RESPONSIBLE USE


SHORT-TERM STANDALONE TRIAL

The 2025 six-week SCUTELL’UP trial was generally well tolerated.⁵

This is reassuring for that highly purified proprietary extract over six weeks.

It does not establish long-term safety for every Baikal Skullcap extract.


ISOLATED-COMPOUND PHASE I STUDIES

Short-term phase I trials of isolated baicalein and oroxylin A provide additional human safety information.¹⁷–²⁰˒⁴⁵

These products and doses differ substantially from Luminara’s whole-root extract.

Their results should not be treated as direct finished-product safety proof.


LIVER AND LUNG SAFETY

Rare liver injury has been reported with products containing Skullcap species or Chinese Skullcap, frequently in:

• multi-ingredient supplements;
• products with uncertain botanical authentication;
• or concentrated proprietary combinations.³⁷–⁴²

Flavocoxid or Limbrel—a Scutellaria–Acacia medical food—was recalled after reports involving liver-test elevations, acute liver injury and hypersensitivity pneumonitis.³⁷–⁴¹

The precise contribution of Scutellaria, Acacia, product concentration, contaminants, co-medications or individual susceptibility is not certain.

A 2024 laboratory study also reported variable hepatocyte toxicity among Scutellaria baicalensis preparations and explored its relationship with composition.⁴²

Laboratory toxicity does not predict the incidence of clinical injury at Luminara’s dose.

It reinforces the importance of:

• authenticated species and plant part;
• current batch testing;
• controlled contaminants;
• appropriate dose;
• medicine review;
• and prompt action if concerning symptoms occur.

People should stop use and seek prompt medical advice if symptoms such as the following occur:

• yellow skin or eyes;
• dark urine;
• pale stools;
• severe itching;
• persistent nausea or abdominal pain;
• unusual fatigue;
• breathlessness;
• persistent cough;
• fever;
• or new chest symptoms.


CURRENT COA STATUS

The supplied Baikal Skullcap CoA relates to material manufactured on 27 June 2023 with a stated three-year shelf life.

That period ended on 27 June 2026.

Trab Health should not rely on it as the launch-batch CoA.

A current production-batch document is required.


MEDICINE INTERACTIONS

Human interaction studies and wider pharmacology support caution with:

• rosuvastatin and medicines dependent on OATP transport;
• bupropion and other CYP2B6 substrates;
• cyclosporine and other medicines with a narrow therapeutic index;
• anticoagulant or antiplatelet medicines;
• sedatives and central-nervous-system medicines;
• diabetes medicines;
• immunosuppressants;
• and multiple concurrent medicines.

The exact clinical effect at Luminara’s dose is not predictable from existing studies.


PREGNANCY AND BREASTFEEDING

Safety of concentrated Baikal Skullcap extract during pregnancy and breastfeeding has not been established.

Traditional practitioner use for selected pregnancy-related patterns is not equivalent to self-directed modern supplement safety.

Luminara should not be used during pregnancy or breastfeeding without qualified medical advice.


SURGERY

Because of potential effects on:

• drug metabolism;
• sedation;
• platelet pathways;
• blood glucose;
• and anaesthetic medicines;

consumers should disclose Luminara to their surgical, dental or anaesthetic team and follow professional advice about stopping supplements before a procedure.


WHO SHOULD SEEK PROFESSIONAL ADVICE BEFORE USE?

Professional advice is particularly important for people who:

• take prescription medicines;
• have liver or kidney disease;
• have a history of supplement-related liver injury;
• have diabetes or unstable blood glucose;
• take anticoagulants, antiplatelets, sedatives or immunosuppressants;
• are pregnant, breastfeeding or trying to conceive;
• are preparing for surgery;
• or are managing a psychiatric, neurological or other significant medical condition.


CLAIMS SUMMARY


SUPPORTED WITH CAREFUL QUALIFICATION

• Baikal Skullcap is Scutellaria baicalensis root, not American Skullcap.
• Luminara uses a baicalin-standardised root extract.
• A 2025 standalone human trial provides emerging evidence for selected aspects of mood regulation and wellbeing.
• Human pharmacokinetic research confirms oral exposure to several Scutellaria flavonoids or their metabolites.
• The ingredient has a substantial preclinical literature involving GABA, monoamine, inflammatory and oxidative pathways.


NOT ESTABLISHED FOR LUMINARA

• clinically proven mood improvement at 300 mg;
• treatment of depression or anxiety;
• improved sleep from standalone Baikal Skullcap;
• clinically proven cognitive enhancement;
• immune boosting or infection prevention;
• treatment of inflammation, osteoarthritis or diabetes;
• menopause relief;
• hormone balancing;
• vaginal or intimate-comfort effects;
• improved female libido or sexual function;
• or equivalence to SCUTELL’UP, UP446, flavocoxid, isolated baicalein or any other proprietary preparation.


PLAIN-ENGLISH SUMMARY

Baikal Skullcap is one of Luminara’s more chemically characterised ingredients, but its direct human evidence is new.

The first substantial standalone human mood trial was published in 2025. It used 20 mg daily of a root extract standardised to 90.04% baicalin, providing 18.08 mg baicalin.⁵

The trial reported selected later improvements in clinician-rated depressive symptoms and WHO-5 wellbeing.

However, its primary Beck Depression Inventory outcome did not show that standalone Scutellaria outperformed placebo. Anxiety and most emotional outcomes were also not clearly superior to placebo.

This supports an emerging mood-regulation story—not a claim that Baikal Skullcap treats depression or anxiety.

Other human studies have used Baikal Skullcap in combinations for:

• stress, cognition and sleep;
• immune response;
• joint discomfort;
• and cognitive performance.

The results belong to the complete multi-ingredient products and cannot be attributed solely to Baikal Skullcap.

One high-dose study alongside metformin reported changes in glucose tolerance and gut microbiota in people with type 2 diabetes. It used 3.52 grams daily and does not support a blood-sugar claim for Luminara.

Luminara’s current manufacturing quotation specifies 300 mg daily of Scutellaria baicalensis root extract.

The supplied raw-material document reports 31.15% baicalin by HPLC, equivalent nominally to 93.45 mg measured baicalin at that ingredient amount.

However, the supplied batch’s stated three-year shelf life ended on 27 June 2026.

A current production-batch CoA and finished-product confirmation are required before the 93.45 mg figure is used publicly as a verified finished-serving amount.

The most accurate positioning is:

Baikal Skullcap contributes emerging human evidence for selected aspects of mood regulation and emotional wellbeing from a highly baicalin-standardised root extract, supported by broader combination and preclinical research. Its role in Luminara should be framed around emerging mood evidence and the wider whole-body context—not as a proven sleep, hormone, menopause or libido ingredient.


REFERENCES

1. Royal Botanic Gardens, Kew. Scutellaria baicalensis Georgi. Plants of the World Online. Accessed 2 August 2026.

2. Zhao Q, Chen XY, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull (Beijing). 2016;61(18):1391-1398. doi:10.1007/s11434-016-1136-5.

3. Zhao T, Tang H, Xie L, Zheng Y, Ma Z, Sun Q, Li X. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol. 2019;71(9):1353-1369. doi:10.1111/jphp.13129.

4. Wang J, Feng X, Li Z, Liu Y, Yang W, Zhang T, Guo P, Liu Z, Qi D, Pi J. The Flavonoid Components of Scutellaria baicalensis: Biopharmaceutical Properties and their Improvement using Nanoformulation Techniques. Curr Top Med Chem. 2023;23(1):17-29. doi:10.2174/1568026623666221128144258. PMID: 36443977.

5. Dormal V, Suchareau M, Copine S, Simar L, Deldicque L. The Effects of Combined Scutellaria and Saffron Supplementation on Mood Regulation in Participants with Mild-to-Moderate Depressive Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2025;17(5):809. doi:10.3390/nu17050809. PMID: 40077679.

6. Dodd F, Weishaupt R, Katumba PKM, Elcoate R, Wightman E. Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: a randomised, double-blind, placebo-controlled, crossover trial. J Psychopharmacol. 2025;39(12):1420-1436. doi:10.1177/02698811251381261. PMID: 41194549.

7. Shin NR, et al.. Combined effects of Scutellaria baicalensis with metformin on glucose tolerance of patients with type 2 diabetes via gut microbiota modulation. Am J Physiol Endocrinol Metab. 2020;318(1):E52-E61. doi:10.1152/ajpendo.00221.2019. PMID: 31770016.

8. Hagele AM, Mumford P, De Gregorio D, Gaige CJ, Hoffman ER, Gross KN, Holley KF, Allen LE, Kerksick CM. Effects of Acacia catechu and Scutellaria baicalensis extract on cognitive function in a healthy adult population: a double-blind, randomized, placebo-controlled trial. Nutr Neurosci. 2025;28(10):975-986. doi:10.1080/1028415X.2024.2442425. PMID: 39701593.

9. Yimam M, Burnett BP, Brownell L, et al.. Clinical and preclinical cognitive function improvement after oral treatment of a botanical composition composed of extracts from Scutellaria baicalensis and Acacia catechu. Behav Neurol. 2016;2016:7240802. doi:10.1155/2016/7240802. PMID: 28042201. See published corrigendum correcting the human dose wording.

10. Lewis ED, et al.. Role of Acacia catechu and Scutellaria baicalensis in Enhancing Immune Function Following Influenza Vaccination of Healthy Adults: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. J Am Nutr Assoc. 2023;42(7):678-690. doi:10.1080/27697061.2022.2145525. PMID: 36413261.

11. Arjmandi BH, Ormsbee LT, Elam ML, Campbell SC, Rahnama N, Payton ME, Brummel-Smith K, Daggy BP. A combination of Scutellaria baicalensis and Acacia catechu extracts for short-term symptomatic relief of joint discomfort associated with osteoarthritis of the knee. J Med Food. 2014;17(6):707-713. doi:10.1089/jmf.2013.0010. PMID: 24611484.

12. Levy RM, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutr Res. 2009;29(5):298-304. doi:10.1016/j.nutres.2009.04.003. PMID: 19555810.

13. Levy RM, Khokhlov A, Kopenkin S, et al.. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther. 2010;27(10):731-742. doi:10.1007/s12325-010-0064-z. PMID: 20845002.

14. Pillai L, Burnett BP, Levy RM; GOAL Study Cooperative Group. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin. 2010;26(5):1055-1063. doi:10.1185/03007991003694522. PMID: 20225990.

15. Morgan SL, Baggott JE, Moreland L, Desmond R, Kendrach AC. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Med Food. 2009;12(5):1143-1148. doi:10.1089/jmf.2008.0244. PMID: 19857081.

16. Lai MY, Hsiu SL, Chen CC, Hou YC, Chao PDL. Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae Radix in humans. Biol Pharm Bull. 2003;26(1):79-83. doi:10.1248/bpb.26.79. PMID: 12520178.

17. Li M, Shi A, Pang H, et al.. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol. 2014;156:210-215. doi:10.1016/j.jep.2014.08.031. PMID: 25219601.

18. Pang H, Xue W, Shi A, et al.. Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers. Clin Drug Investig. 2016;36(9):713-724. doi:10.1007/s40261-016-0418-7. PMID: 27352310.

19. Dong R, Li L, Gao H, Lou K, Luo H, Hao S, Yuan J, Liu Z. Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study. J Ethnopharmacol. 2021;274:114052. doi:10.1016/j.jep.2021.114052. PMID: 33753147.

20. Li L, Gao H, Lou K, et al.. Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study. Clin Transl Sci. 2021;14(5):2017-2024. doi:10.1111/cts.13063. PMID: 34156161.

21. ClinicalTrials.gov. A Phase IIa Study of Baicalein Tablets in Adults With Influenza. ClinicalTrials.gov identifier NCT03830684. Registry record only; no peer-reviewed results publication was located by 2 August 2026 and this record is not evidence of efficacy.

22. Fan L, Wang JC, Jiang F, et al.. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther. 2008;83(3):471-476. doi:10.1038/sj.clpt.6100318. PMID: 17851565.

23. Fan L, Wang JC, Jiang F, et al.. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol. 2009;65(4):403-409. doi:10.1007/s00228-008-0594-3. PMID: 19066872.

24. Liu R, Li X, Wei J, et al.. A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. Front Pharmacol. 2019;10:518. doi:10.3389/fphar.2019.00518. PMID: 31156436.

25. Zhou X, Li CG, Chang D, Bensoussan A. Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: Insights from experimental studies, mechanistic actions to clinical applications. Biomed Pharmacother. 2021;138:111445. doi:10.1016/j.biopha.2021.111445. PMID: 33711551.

26. Seok JK, Kwak JY, Choi GW, et al.. Scutellaria radix Extract as a Natural UV Protectant for Human Skin. Phytother Res. 2016;30(3):374-379. doi:10.1002/ptr.5534. PMID: 26620130.

27. Orzechowska B, et al.. Baicalin from the extract of Scutellaria baicalensis affects the innate immunity and apoptosis in leukocytes of children with acute lymphocytic leukemia. Int Immunopharmacol. 2014;23(2):558-567. doi:10.1016/j.intimp.2014.10.005. PMID: 25448499.

28. Ma Y, et al.. The effect of Scutellaria baicalensis and its active ingredients on major depressive disorder: a systematic review and meta-analysis of literature in pre-clinical research. Front Pharmacol. 2024;15:1313871. doi:10.3389/fphar.2024.1313871. PMID: 38572433.

29. Limanaqi F, Biagioni F, Busceti CL, Polzella M, Fabrizi C, Fornai F. Potential Antidepressant Effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea. Antioxidants (Basel). 2020;9(3):234. doi:10.3390/antiox9030234. PMID: 32178272.

30. Hui KM, Huen MSY, Wang HY, et al.. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 2002;64(9):1415-1424. doi:10.1016/S0006-2952(02)01347-3. PMID: 12392823.

31. Chang HH, Yi PL, Cheng CH, et al.. Biphasic effects of baicalin, an active constituent of Scutellaria baicalensis Georgi, in the spontaneous sleep-wake regulation. J Ethnopharmacol. 2011;135(2):359-368. doi:10.1016/j.jep.2011.03.023. PMID: 21419210.

32. Park HG, Choi JY, Lee GS, Choi JH, Son KH, Yoon SY, Ko HS, Ko KH, Ryu JH, Cheong JH. Different Effects of Flavonoids in Scutellaria baicalensis on Anxious and Sedative Behaviors. Biomol Ther. 2006;14(2):83-89. KCI article ART001013939.

33. Zhu W, Ma S, Qu R, Kang D, Liu Y. Antidepressant Effect of Baicalin Extracted from the Root of Scutellaria baicalensis in Mice and Rats. Pharm Biol. 2006;44(7):503-510. doi:10.1080/13880200600878684.

34. Yoon SY, dela Peña I, Kim SM, et al.. Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro. Arch Pharm Res. 2013;36(1):134-140. doi:10.1007/s12272-013-0009-6. PMID: 23371806.

35. Li C, Lin G, Zuo Z. Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharm Drug Dispos. 2011;32(8):427-445. doi:10.1002/bdd.771. PMID: 21928297.

36. Liao H, Ye J, Gao L, Liu Y. The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review. Biomed Pharmacother. 2021;133:110917. doi:10.1016/j.biopha.2020.110917. PMID: 33217688.

37. National Institute of Diabetes and Digestive and Kidney Diseases. Flavocoxid. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Library of Medicine. Last updated 30 January 2018. NCBI Bookshelf NBK548129.

38. United States Food and Drug Administration. Primus Announces a Voluntary Nationwide Recall of All Lots Within Expiry of Prescription Medical Food Limbrel® Due to Rare But Serious and Reversible Adverse Events. FDA recall notice. Company announcement 25 January 2018; FDA publication 29 January 2018.

39. Chalasani N, Vuppalanchi R, Navarro V, Fontana RJ, Bonkovsky H, Barnhart H, Kleiner DE, Hoofnagle JH. Acute liver injury due to flavocoxid (Limbrel®), a medical food for osteoarthritis: a case series. Ann Intern Med. 2012;156(12):857-860, W297-W300. doi:10.7326/0003-4819-156-12-201206190-00006. PMID: 22711078.

40. National Institute of Diabetes and Digestive and Kidney Diseases. Move Free. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Library of Medicine. NCBI Bookshelf NBK547841.

41. National Institute of Diabetes and Digestive and Kidney Diseases. Skullcap. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Library of Medicine. NCBI Bookshelf NBK548757.

42. Oshima N, Kusamori K, Takasaki R, et al.. Scutellaria Root extract-induced hepatocytotoxicity can be controlled by regulating its baicalin content. J Nat Med. 2024;78(4):978-984. doi:10.1007/s11418-024-01814-1. PMID: 38787459.

43. Shen J, Li P, Liu S, Liu Q, Li Y, Sun Y, He C, Xiao P. Traditional uses, ten-years research progress on phytochemistry and pharmacology, and clinical studies of the genus Scutellaria. J Ethnopharmacol. 2021;265:113198. doi:10.1016/j.jep.2020.113198.

44. Brock C, Whitehouse J, Tewfik I, Towell T. American Skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers. Phytother Res. 2014;28(5):692-698. doi:10.1002/ptr.5044. PMID: 23878109. [Different species; not evidence for Luminara's S. baicalensis root.]

45. Yang F, Meng X, Qin S, Guo Q, Wei L, Zhao D. Safety and pharmacokinetics evaluation of oroxylin A in Chinese healthy volunteers: a phase I, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect study. Clin Transl Oncol. Published online 3 September 2025. doi:10.1007/s12094-025-04017-6. PMID: 40903694.


These statements have not been evaluated by the United States Food and Drug Administration. Luminara is not intended to diagnose, treat, cure or prevent any disease. Information presented in the Luminara Evidence Centre is educational and is not a substitute for individual medical advice.

SAFFRON

Crocus sativus L.

Saffron is the dried red stigma of Crocus sativus, a sterile flowering plant in the iris family. It has been valued for centuries as a culinary spice, colourant and traditional botanical.

Its principal characteristic compounds include:

• crocins, which contribute saffron’s colour;
• crocetin, produced after crocins are metabolised;
• picrocrocin, associated with taste;
• safranal, associated with aroma;
• additional carotenoids, flavonoids and volatile compounds.¹–³

Modern human clinical research has investigated saffron extracts for:

• emotional wellbeing and low mood;
• everyday stress;
• subjective sleep quality and sleep-related impairment;
• perimenopausal psychological symptoms;
• female sexual function;
• premenstrual symptoms;
• eating behaviour;
• cognition and several diagnosed medical conditions.⁴–³⁷

Saffron is one of the most clinically researched ingredients in Luminara.

Its research is particularly relevant because several important trials used 28 mg daily—the same nominal saffron-extract amount listed in Luminara’s current formula.

That dose alignment is a meaningful strength.

However, a milligram match does not prove that two botanical extracts are chemically or clinically equivalent. Many of the strongest trials used proprietary extracts such as Affron, Safr’Inside or Satiereal with preparation-specific extraction methods and marker profiles.

The most accurate interpretation is:

Saffron has good human evidence for selected mood and sleep outcomes, promising evidence for perimenopausal psychological wellbeing and emerging evidence for female sexual wellbeing. Results are preparation- and outcome-specific, and the evidence does not support claims that saffron treats depression, cures insomnia, balances hormones or is a proven aphrodisiac.


SAFFRON AT A GLANCE

Botanical name: Crocus sativus L.

Botanical family: Iridaceae

Common name: Saffron

Part used in Luminara: Stigmas

Ingredient form in Luminara: Extract powder

Current manufacturing-formula amount: 28 mg daily

Supplied specification extract ratio: 0.5:1

Supplied safranal specification: Not less than 0.3%

Supplied crocins specification: Not less than 0.4%

Analytical description on the supplied specification: Absorbance-based marker specifications

Country of origin: Not stated on the supplied document

Extraction solvent: Not stated

Carrier or excipient: Not stated

Document type: Approved ingredient specification—not a production-batch certificate of analysis

Issue date on supplied specification: 1 September 2025

The supplied document provides useful identity and minimum-specification information. It identifies:

• Crocus sativus;
• the stigma plant part;
• an extract rather than unidentified whole spice;
• a 0.5:1 extract ratio;
• minimum safranal and crocin specifications.

However, it does not provide:

• a batch number;
• manufacturing or expiry dates;
• an actual botanical-identity result for the production batch;
• actual crocin or safranal assay results;
• chromatographic fingerprints;
• contaminant results;
• residual-solvent results;
• extraction solvent;
• carrier or excipient identity and percentage;
• country of origin;
• finished-product identity or potency results.

If a material merely meets the listed minimum specification, the nominal marker calculations at 28 mg would be:

Safranal:

28 mg × 0.3% = 0.084 mg

Crocins:

28 mg × 0.4% = 0.112 mg

These are specification-based calculations only.

They must not be presented as measured amounts in each finished Luminara serving unless the manufacturer confirms:

• that the production batch uses this exact specification;
• that 28 mg refers to the complete extract powder, including any carrier;
• the actual production-batch crocin and safranal results;
• and finished-product testing supports the declared amount and identity.

The safest public wording at present is:

Luminara provides 28 mg of Crocus sativus stigma extract daily.


HOW CLOSELY DOES LUMINARA’S SAFFRON MATCH THE CLINICAL RESEARCH?

Luminara aligns with the clinical literature in three important respects:

• the botanical species is Crocus sativus;
• the plant part is the stigma;
• the daily extract amount is 28 mg.

Several directly relevant trials used:

• Affron, 28 mg daily, in adults with low mood;⁵
• Affron, 28 mg daily, in women aged 50–70 with low mood and poor sleep;⁴
• Affron, 28 mg daily, in perimenopausal women;¹⁰
• Affron, 28 mg daily, in adults with self-reported poor sleep;¹³
• Affron, 14 mg or 28 mg nightly, in adults with unsatisfactory sleep;¹⁴
• saffron, 30 mg daily, in female sexual-function studies;¹⁹˒²⁰
• saffron, approximately 20–30 mg daily, in other mood and sleep research.⁶–⁹˒¹⁵˒¹⁷˒¹⁸

This is unusually close nominal dose alignment for a botanical ingredient.

Direct clinical equivalence still cannot be claimed.

Affron is a proprietary saffron extract standardised using a manufacturer-specific combination of compounds sometimes described as Lepticrosalides. Safr’Inside and other research preparations use different extraction, standardisation and delivery systems.

Luminara’s supplied specification instead lists minimum amounts of safranal and crocins and a 0.5:1 extract ratio.

The preparations may differ in:

• total crocin concentration;
• the pattern of individual crocin isomers;
• crocetin availability;
• safranal concentration;
• picrocrocin concentration;
• extraction solvent;
• drying and processing;
• carrier content;
• stability;
• absorption and metabolism;
• compounds not captured by the two marker specifications.

Therefore:

• an exact 28 mg mass match does not establish an exact chemical match;
• a higher or lower marker percentage does not automatically establish superiority;
• findings from Affron cannot be described as clinical proof for Luminara;
• findings from isolated crocin, crocetin or safranal cannot be treated as evidence for the complete Luminara ingredient.

The accurate conclusion is:

Luminara uses the correct saffron species and stigma plant part at a daily amount that closely matches several human trials. The precise chemical profile and clinical equivalence of its production ingredient remain unverified until a current batch CoA and full extract information are obtained.


TRADITIONAL USE

Saffron has a long history in Persian, Mediterranean, Middle Eastern and South Asian food and traditional medicine.

Traditional associations have included:

• mood and emotional brightness;
• sleep and relaxation;
• menstrual complaints;
• women’s reproductive wellbeing;
• sexual wellbeing;
• digestion;
• respiratory complaints;
• pain and inflammation;
• labour-related use;
• colouring and flavouring foods.

Traditional use helps explain why saffron was selected for modern investigation.

It does not establish that a concentrated modern extract:

• treats a disease;
• is safe during pregnancy;
• reproduces the effects of culinary saffron;
• or produces the same effect regardless of dose and preparation.


WHAT HUMAN CLINICAL STUDIES HAVE INVESTIGATED


EMOTIONAL WELLBEING AND LOW MOOD

Saffron has a substantial body of human research related to depressive symptoms, low mood, anxiety and general emotional wellbeing.⁴–⁹˒²⁶˒²⁸–³⁶

The strongest directly relevant recent studies include two large, 28 mg Affron trials.

LOPRESTI ET AL., 2025

Two hundred and two adults aged 18–70 with subclinical depressive symptoms received:

• Affron, 28 mg daily; or
• placebo;

for twelve weeks.⁵

Compared with placebo, saffron produced a greater improvement in the DASS-21 depression score.

A clinically meaningful reduction was achieved by:

• 72.3% of the saffron group;
• 54.3% of the placebo group.

However:

• the effect size was modest;
• placebo response was large;
• no between-group differences were found on the other secondary mood, wellbeing or sleep outcomes overall;
• a sleep-disturbance benefit appeared only in an exploratory subgroup with greater baseline sleep disturbance.

This is encouraging evidence for depressive symptoms in adults experiencing low mood.

It is not evidence that Luminara treats clinical depression or can replace professional care or prescribed medication.


LOPRESTI AND SMITH, 2026

Eighty-six women aged 50–70 experiencing low mood and self-reported poor sleep received:

• Affron, 28 mg daily; or
• placebo;

for twelve weeks.⁴

Compared with placebo, saffron produced greater improvement in:

• the DASS-21 depression score;
• the proportion achieving a clinically meaningful depression-score reduction;
• self-esteem;
• sleep-related impairment.

It did not significantly improve:

• the PROMIS sleep-disturbance score;
• self-rated physical appearance;
• estimated facial skin age.

The sleep-related-impairment and self-esteem outcomes were secondary and exploratory.

The trial was funded by the ingredient manufacturer, which also supplied the investigational products and participated in the initial concept and design.

This is directly relevant women-specific evidence, but the findings should not be simplified into a claim that saffron improves all aspects of sleep, confidence or appearance.


KELL ET AL., 2017

A placebo-controlled trial in healthy adults with low mood investigated Affron at 28 mg daily.⁷

Selected negative-mood, stress and anxiety measures improved.

The study contributed to the evidence reviewed by the European Food Safety Authority.

EFSA concluded that a cause-and-effect relationship had not been established for the proposed broad claim that Affron increases positive mood.³⁴

This regulatory conclusion is an important counterweight to promotional interpretations of a single favourable trial.


JACKSON ET AL., 2020

A randomised controlled study investigated a standardised saffron extract in healthy adults, including mood and response to a psychosocial stressor.⁸

Selected mood, wellbeing or stress-response measures improved.

Not every psychological or biological measure changed.

This supports saffron’s research relevance to everyday emotional wellbeing and stress response, not a medical anxiety or depression claim.


NULL AND MIXED EVIDENCE

A 2025 placebo-controlled study in healthy adults with subclinical symptoms of depression examined a saffron extract over six weeks.⁶

The study did not improve its primary combined measure of:

• depression;
• anxiety;
• fatigue.

A self-perceived mental-health measure improved.

This negative primary outcome is important because it prevents the literature from being described as uniformly positive.


META-ANALYSES

Multiple systematic reviews and meta-analyses have reported average improvements in depressive or anxiety symptoms with saffron compared with placebo.²⁸–³³˒³⁵˒³⁶

A 2026 GRADE-assessed meta-analysis included 34 randomised controlled trials.²⁸

The pooled evidence favoured saffron across selected depression, anxiety and mood outcomes.

However, pooled results combine:

• different extracts;
• stigma and occasionally other plant preparations;
• diagnosed and non-diagnosed populations;
• standalone and adjunctive use;
• different scales;
• varied study quality;
• short treatment periods;
• geographically concentrated research.

Earlier meta-analysis also identified evidence of publication bias and limited regional diversity.³³

A 2025 meta-analysis comparing saffron with selective serotonin reuptake inhibitors found no statistically significant average difference in symptom change.³⁰

That does not prove that saffron is equivalent or non-inferior to an antidepressant. Trials were generally small and short, and a nonsignificant difference is not the same as a properly designed non-inferiority result.

CURRENT CONCLUSION FOR MOOD

Saffron has good human evidence for selected depressive-symptom and emotional-wellbeing outcomes.

The evidence is not perfectly consistent, and much of the dose-matched research involves one proprietary extract and manufacturer-funded trials.

Appropriate wording:

“Saffron has been studied in controlled human trials for supporting emotional wellbeing and mood.”

Inappropriate wording:

“Saffron treats depression,” “works as well as antidepressants,” or “clinically proven to make you happier.”


EVERYDAY STRESS AND STRESS RESPONSE

Human studies have investigated saffron in:

• adults undergoing a psychosocial stress task;⁸
• acute crossover stress research using a proprietary saffron extract or isolated safranal;⁹
• low-mood trials that measured stress and anxiety;⁴–⁷
• recreationally active adults assessed for mood and recovery-related outcomes.²⁵

Selected psychological or biological stress-response findings have been positive.

However:

• not every stress or anxiety outcome improved;
• acute laboratory stress is not the same as chronic real-world stress;
• isolated safranal is not equivalent to a saffron extract;
• cortisol or other biomarker findings have not been sufficiently consistent for a direct claim.

Appropriate wording:

“Saffron has been researched for its role in supporting a healthy response to everyday stress.”

Inappropriate wording:

“Saffron lowers cortisol,” “regulates the HPA axis,” or “treats anxiety.”


SLEEP

Saffron has several controlled sleep trials and a systematic review and meta-analysis.⁴˒⁵˒¹³–¹⁸

LOPRESTI ET AL., 2020

Sixty-three healthy adults with self-reported poor sleep received:

• Affron, 14 mg twice daily—28 mg total daily; or
• placebo;

for twenty-eight days.¹³

Saffron improved selected sleep-quality outcomes, including the primary Insomnia Severity Index.

Most improvement occurred during the first seven days.

The study was short and involved a proprietary extract.


LOPRESTI ET AL., 2021

One hundred and twenty adults with unsatisfactory sleep received:

• placebo;
• Affron, 14 mg nightly;
• or Affron, 28 mg nightly;

one hour before bed for twenty-eight days.¹⁴

Both saffron doses improved selected sleep-quality outcomes.

The study also measured cortisol and melatonin.

Those exploratory hormone findings should not be converted into claims that saffron balances hormones, corrects melatonin deficiency or regulates cortisol.


OTHER SLEEP TRIALS

A 2021 randomised clinical trial reported improved sleep-quality outcomes with a standardised saffron extract.¹⁵

A 2025 pilot trial in adults aged 55–85 with sleep complaints reported improvement in selected subjective sleep and sleep-efficiency measures with 30 mg daily.¹⁷

A separate 2025 trial investigated 20 mg and 30 mg daily in adults with moderate insomnia and reported improvements in selected secondary sleep-quality outcomes.¹⁸

The new 2026 trial in women aged 50–70 improved sleep-related impairment but did not improve the sleep-disturbance scale.⁴

The large 2025 low-mood trial did not improve sleep outcomes in the full study population. An exploratory benefit appeared in a subgroup with more severe baseline sleep disturbance.⁵


SLEEP META-ANALYSIS

A 2022 meta-analysis of randomised trials reported pooled improvement in measures such as:

• Pittsburgh Sleep Quality Index;
• Insomnia Severity Index;
• restorative sleep.¹⁶

The included studies were small, short and preparation-diverse.


CURRENT CONCLUSION FOR SLEEP

Saffron has good emerging-to-moderate human evidence for selected subjective sleep-quality outcomes.

The evidence is not uniform across all studies or scales.

It does not establish that Luminara:

• treats insomnia;
• acts as a sedative medicine;
• guarantees faster sleep onset;
• increases deep sleep;
• normalises melatonin or cortisol;
• reproduces the results of Affron.

Appropriate wording:

“Saffron has been studied for supporting sleep quality in adults experiencing unsatisfactory sleep.”


PERIMENOPAUSAL AND POSTMENOPAUSAL WELLBEING

LOPRESTI ET AL., 2021—PERIMENOPAUSE

Eighty-six perimenopausal women with menopausal complaints received:

• Affron, 14 mg twice daily—28 mg total daily; or
• placebo;

for twelve weeks.¹⁰

Data from eighty-two participants were analysed.

Compared with placebo, saffron produced greater improvement in:

• overall menopausal-complaint scores;
• the psychological symptom subscale;
• anxiety and depression measures.

It did not produce greater improvement in:

• vasomotor symptoms;
• somatic or physical symptoms;
• other measured quality-of-life outcomes.

This is highly relevant because:

• it involved perimenopausal women;
• it used 28 mg daily;
• it lasted twelve weeks.

It does not establish that saffron:

• relieves hot flashes;
• relieves night sweats;
• improves vaginal dryness;
• balances oestrogen or progesterone;
• replaces menopausal hormone therapy.


POSTMENOPAUSAL HOT-FLASH AND MOOD STUDY

A small 2018 placebo-controlled trial investigated saffron in postmenopausal women with major depressive disorder and hot flashes.¹¹

The trial reported improvement in depressive and hot-flash outcomes.

The population had a diagnosed mood disorder and clinically significant hot flashes. The study was small and disease-specific.

It should be included in the evidence archive but should not be used to claim that Luminara treats depression or vasomotor symptoms.


POSTMENOPAUSAL HAPPINESS STUDY

A 2023 trial examined saffron herbal tea and happiness scores in postmenopausal women.¹²

The study reported improved happiness scores.

The preparation was a tea rather than a marker-standardised extract, and study-design and preparation differences limit direct comparison with Luminara.


CURRENT CONCLUSION FOR MENOPAUSAL WELLBEING

The strongest dose-aligned evidence supports perimenopausal psychological and emotional wellbeing.

Direct evidence for hot flashes, night sweats, somatic symptoms and urogenital concerns is weaker and inconsistent.

Appropriate wording:

“Saffron has been studied in perimenopausal women, with encouraging findings for mood and psychological menopausal symptoms.”

Inappropriate wording:

“Saffron balances hormones,” “relieves all menopause symptoms,” “treats hot flashes,” or “replaces HRT.”


FEMALE SEXUAL FUNCTION AND INTIMATE WELLBEING

KASHANI ET AL., 2022

A three-centre, double-blind, randomised, placebo-controlled trial enrolled married women aged 18–55 experiencing severe sexual dysfunction.¹⁹

Participants received:

• saffron, 15 mg twice daily—30 mg total daily; or
• placebo.

The study reported improvement in:

• total Female Sexual Function Index score;
• several individual sexual-function domains.

The sample was modest, the population was clinically selected and the product was not shown to match Luminara chemically.


KASHANI ET AL., 2013—FLUOXETINE-INDUCED SEXUAL DYSFUNCTION

Thirty-eight women with major depressive disorder whose condition was stabilised on fluoxetine and who experienced sexual dysfunction received:

• saffron, 15 mg twice daily—30 mg total daily; or
• placebo;

for four weeks.²⁰

Saffron improved:

• arousal;
• lubrication;
• pain;
• total Female Sexual Function Index score.

It did not clearly improve:

• desire;
• orgasm;
• satisfaction.

This study is especially important because it shows that positive overall findings did not extend to every domain.

The result applies to fluoxetine-induced sexual dysfunction in a small psychiatric population. It does not establish a general libido effect.


IZADI ET AL., 2024

Fifty women of reproductive age with sexual dysfunction were enrolled in a triple-blind randomised trial.²¹

The experimental group received 30 mg saffron daily together with vitamin E, while the comparison group received vitamin E without saffron.

The saffron-plus-vitamin-E group improved more in overall sexual function and selected emotional measures.

Because:

• both groups received vitamin E;
• there was no saffron-only group;
• the saffron product was preparation-specific;

the result cannot be attributed solely to saffron in the same way as a standalone placebo-controlled trial.


SEXUAL-FUNCTION META-ANALYSIS

A 2019 systematic review and meta-analysis reported an overall positive signal across saffron sexual-function studies in men and women.²²

The evidence base was small and heterogeneous.

Male erectile-function studies, topical preparations and studies in medication-induced dysfunction cannot be transferred automatically to general female sexual wellbeing.


CURRENT CONCLUSION FOR FEMALE SEXUAL WELLBEING

Saffron has emerging controlled human evidence for overall female sexual function.

Evidence is more selective for specific domains.

Desire or libido has not improved consistently.

Appropriate wording:

“Saffron has emerging human research in female sexual wellbeing.”

Inappropriate wording:

“Saffron is a proven aphrodisiac,” “increases libido,” “treats sexual dysfunction,” “improves vaginal dryness,” or “guarantees arousal or orgasm.”


PREMENSTRUAL SYMPTOMS

A 2008 double-blind, randomised, placebo-controlled trial investigated saffron at 30 mg daily across two menstrual cycles in women with premenstrual syndrome.²³

The study reported greater improvement in:

• premenstrual symptom scores;
• a depression-rating scale.

This is one older, modest trial with limited replication.

It supports including PMS in the research record.

It does not support a prominent claim that Luminara treats PMS, menstrual pain or mood disorders associated with the menstrual cycle.


VITALITY, FATIGUE AND PHYSICAL WELLBEING

Saffron’s mood and sleep evidence may indirectly influence how people experience daily wellbeing.

Direct anti-fatigue or energy evidence is less convincing.

A 2022 trial in recreationally active adults investigated Affron, 28 mg daily, for mood, wellbeing, recovery and physical measures.²⁵

In the full study population, no statistically significant between-group differences were found in any of the measured outcomes. Exploratory sex-stratified analyses reported greater exercise enjoyment and heart-rate variability in male participants taking saffron, while no significant benefits were identified in female participants.²⁵

The study therefore does not provide general evidence that saffron improves vitality, fatigue, exercise performance or recovery.

The 2025 trial in healthy adults with subclinical depression, anxiety and fatigue did not improve the primary combined outcome or the individual fatigue outcome.⁶

The current evidence does not justify saying that saffron:

• boosts energy;
• treats fatigue;
• improves exercise performance;
• accelerates recovery.


APPETITE, SNACKING AND WEIGHT

A 2010 randomised placebo-controlled trial in sixty mildly overweight women investigated the proprietary Satiereal saffron-stigma extract for eight weeks.²⁴

The study reported reduced snacking frequency and modest weight change.

This finding:

• used a proprietary preparation;
• addressed eating behaviour and weight;
• is not central to Luminara’s intended positioning;
• has limited replication.

Saffron should not be promoted within Luminara as an appetite suppressant or weight-loss ingredient.


OTHER DISEASE-POPULATION RESEARCH

Human research has also investigated saffron or its constituents in:

• diagnosed depressive disorders;
• diabetes and metabolic disorders;
• cognitive impairment and neurological conditions;
• age-related eye conditions;
• cardiovascular and inflammatory conditions;
• male sexual dysfunction;
• attention-deficit/hyperactivity disorder;
• obsessive-compulsive disorder.²⁷–³⁷

These studies may contribute to understanding biological activity and safety.

They do not support disease-treatment or prevention claims for Luminara.


EVIDENCE STRENGTH


HOW WE RATE THE EVIDENCE

★★★★★ — Strong

Multiple high-quality controlled human trials and/or systematic reviews with consistent findings, relevant preparations and independent replication.

★★★★☆ — Good

Several controlled human studies with broadly consistent findings, but limitations remain in preparation matching, population, sample size, duration, sponsorship or independent replication.

★★★☆☆ — Emerging

At least one relevant controlled human study, with mixed findings or further confirmation required.

★★☆☆☆ — Preliminary

Small, indirect, disease-population, combination, active-comparator, uncontrolled or older evidence.

★☆☆☆☆ — Traditional or preclinical

Traditional use, laboratory research, animal evidence or no adequate direct human confirmation.

The rating applies to the specific outcome and Luminara’s ingredient. It is not a guarantee that an individual will experience the benefit.


HEALTH AREA | EVIDENCE STRENGTH | CURRENT ASSESSMENT

Depressive symptoms in adults experiencing low mood | ★★★★☆ | Several controlled trials and meta-analyses, including large 2025 and women-specific 2026 trials, but preparation-specific and with large placebo responses

General emotional wellbeing | ★★★★☆ | Multiple controlled studies with selected positive outcomes; not every wellbeing scale improves

Anxiety and stress symptoms | ★★★☆☆ | Positive pooled and trial findings, but results vary by measure and population

Everyday stress response | ★★★☆☆ | Controlled psychosocial-stress and acute studies with selective outcomes

Treatment of clinical depression or anxiety disorders | ★★★☆☆ | Considerable clinical research exists, but not suitable as a Luminara treatment claim and not proof of equivalence to medication

Subjective sleep quality | ★★★★☆ | Multiple controlled trials and a meta-analysis, including studies at 28 mg daily

Sleep-related daytime impairment | ★★★☆☆ | Improved in the 2026 women-specific trial, but secondary and exploratory

Sleep disturbance across all adults | ★★★☆☆ | Mixed: positive in several trials, null in the full samples of two large recent studies

Broad insomnia treatment | ★★★☆☆ | Several short trials, but insufficient for a treatment claim

Perimenopausal psychological symptoms | ★★★☆☆ | Positive 12-week placebo-controlled study at 28 mg daily

Overall perimenopausal complaints | ★★★☆☆ | Positive total-score finding in one directly relevant trial

Hot flashes and vasomotor symptoms | ★★☆☆☆ | One small disease-specific positive trial; the directly relevant perimenopause trial was negative

Somatic menopause symptoms | ★★☆☆☆ | No benefit in the key dose-aligned perimenopause trial

Hormone balance | ★☆☆☆☆ | No adequate evidence that Luminara’s saffron normalises oestrogen, progesterone or other reproductive hormones

Overall female sexual function | ★★★☆☆ | Several small controlled studies and a meta-analysis

Sexual arousal and lubrication | ★★★☆☆ | Positive findings in a small fluoxetine-induced dysfunction trial and other selected studies

Sexual desire or libido | ★★☆☆☆ | Findings are inconsistent and desire was null in an important controlled trial

Orgasm and satisfaction | ★★☆☆☆ | Mixed by study and population

Vaginal or intimate comfort | ★★☆☆☆ | Pain improved in one medication-induced dysfunction study; no direct vaginal-dryness evidence for Luminara’s saffron

Premenstrual symptoms | ★★☆☆☆ | One older placebo-controlled trial with limited replication

Vitality or fatigue | ★★☆☆☆ | Indirect and inconsistent; a recent primary fatigue-related outcome was negative

Appetite and snacking | ★★☆☆☆ | One proprietary-extract trial; not an intended Luminara claim

Short-term tolerability | ★★★★☆ | Generally acceptable across multiple short controlled trials at approximately 28–30 mg daily

Long-term safety | ★★☆☆☆ | Most directly relevant trials lasted four to twelve weeks; longer matching-extract data remain limited

Pregnancy and breastfeeding | ★☆☆☆☆ | Product-specific safety is not established; concentrated use requires medical guidance and is generally avoided in pregnancy

Clinical match to Luminara | ★★★☆☆ | Exact species, stigma and 28 mg amount align well, but the production-batch chemistry and finished-product potency are not verified


WHAT THE KEY STUDIES FOUND


LOPRESTI AND SMITH, 2026⁴

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Eighty-six women aged 50–70 experiencing low mood and self-reported poor sleep.

Intervention: Affron, 28 mg daily, or placebo.

Duration: Twelve weeks.

Primary finding: Greater improvement in the DASS-21 depression score with saffron.

Other positive findings: A greater proportion achieved a clinically meaningful depression-score reduction; self-esteem and sleep-related impairment improved.

Null findings: Sleep disturbance, self-rated physical appearance and estimated facial skin age did not improve significantly.

Why it matters: This is directly relevant women-specific research at the same nominal daily amount used in Luminara.

Limitations: Proprietary extract; manufacturer funding and involvement in study concept and design; secondary outcomes exploratory; no chemical equivalence to Luminara established.


LOPRESTI ET AL., 2025⁵

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Two hundred and two adults aged 18–70 experiencing subclinical depressive symptoms.

Intervention: Affron, 28 mg daily, or placebo.

Duration: Twelve weeks.

Primary finding: Greater improvement in the DASS-21 depression score.

Clinically meaningful response: 72.3% with saffron versus 54.3% with placebo.

Null findings: No overall between-group differences on other secondary mood, wellbeing or sleep measures.

Exploratory finding: Sleep disturbance improved in a subgroup with greater baseline sleep disturbance.

Why it matters: It is the largest saffron mood trial to date and uses Luminara’s nominal daily amount.

Limitations: Modest effect size, large placebo response, proprietary extract and manufacturer-affiliated authors.


HEALTHY-ADULT SUBCLINICAL-SYMPTOM TRIAL, 2025⁶

Design: Randomised, double-blind, placebo-controlled study.

Participants: Fifty-one healthy adults with subclinical depressive symptoms.

Duration: Six weeks.

Primary outcome: A combined depression, anxiety and fatigue measure.

Finding: Self-perceived mental health improved on one quality-of-life measure.

Null findings: The primary composite and individual depression, anxiety and fatigue outcomes did not improve significantly.

Why it matters: This is important corrective evidence showing that saffron does not improve every mood or fatigue outcome.


LOPRESTI ET AL., 2021—PERIMENOPAUSE¹⁰

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Eighty-six perimenopausal women were randomised; data from eighty-two were analysed.

Intervention: Affron, 14 mg twice daily—28 mg total daily—or placebo.

Duration: Twelve weeks.

Positive findings: Greater improvement in total menopausal complaints, psychological symptoms, anxiety and depression measures.

Null findings: No greater improvement in vasomotor symptoms, somatic symptoms or other quality-of-life measures.

Why it matters: Excellent population and nominal dose relevance to Luminara.

Limitations: One proprietary-extract trial; sponsor involvement; no support for broad hormone, hot-flash or physical-symptom claims.


LOPRESTI ET AL., 2020—POOR SLEEP¹³

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Sixty-three healthy adults with self-reported poor sleep.

Intervention: Affron, 14 mg twice daily—28 mg total daily—or placebo.

Duration: Twenty-eight days.

Finding: Improved selected sleep-quality outcomes, including the Insomnia Severity Index.

Why it matters: Direct 28 mg dose match.

Limitations: Short duration, subjective outcomes and proprietary extract.


LOPRESTI ET AL., 2021—EVENING DOSE-RANGING SLEEP TRIAL¹⁴

Design: Three-arm, parallel, randomised, double-blind, placebo-controlled trial.

Participants: One hundred and twenty adults with unsatisfactory sleep.

Interventions: Placebo; Affron 14 mg; or Affron 28 mg, taken one hour before bed.

Duration: Twenty-eight days.

Finding: Both saffron doses improved selected sleep-quality outcomes.

Exploratory measures: Cortisol and melatonin were measured.

Why it matters: Includes the exact 28 mg nominal Luminara amount.

Limitations: Short, proprietary extract and insufficient basis for hormone-regulation claims.


OLDER-ADULT SLEEP PILOT, 2025¹⁷

Design: Randomised, double-blind, placebo-controlled pilot trial.

Participants: Fifty-two adults aged 55–85 with self-reported sleep complaints.

Intervention: Standardised saffron extract, 30 mg daily, or placebo.

Duration: Four weeks.

Finding: Improved selected subjective sleep-quality and sleep-efficiency measures.

Limitations: Pilot size, short duration and preparation mismatch.


MODERATE-INSOMNIA TRIAL, 2025¹⁸

Design: Decentralised randomised, double-blind, placebo-controlled trial.

Participants: Adults experiencing moderate insomnia.

Interventions: Saffron extract at 20 mg or 30 mg daily, or placebo.

Duration: Four weeks.

Finding: Selected secondary sleep-quality measures improved.

Limitation: Short duration; interpretation of the primary outcome and dose-response pattern requires caution.


KASHANI ET AL., 2022—FEMALE SEXUAL DYSFUNCTION¹⁹

Design: Three-centre, double-blind, randomised, placebo-controlled clinical trial.

Participants: Married women aged 18–55 experiencing severe sexual dysfunction.

Intervention: Saffron, 15 mg twice daily—30 mg total daily—or placebo.

Finding: Improved total sexual-function scores and selected domains.

Why it matters: Direct female sexual-function evidence at a dose close to Luminara’s.

Limitations: Modest sample, clinical population, preparation mismatch and need for independent replication.


KASHANI ET AL., 2013—FLUOXETINE-INDUCED SEXUAL DYSFUNCTION²⁰

Design: Randomised, double-blind, placebo-controlled trial.

Participants: Thirty-eight women with stable depression taking fluoxetine and experiencing sexual dysfunction.

Intervention: Saffron, 15 mg twice daily—30 mg total daily—or placebo.

Duration: Four weeks.

Positive findings: Arousal, lubrication, pain and total sexual-function score improved.

Null findings: Desire, orgasm and satisfaction did not clearly improve.

Why it matters: It supports a selective sexual-function signal while directly showing that libido did not improve.

Limitations: Tiny, short, medication-induced and disease-specific population.


IZADI ET AL., 2024²¹

Design: Triple-blind randomised controlled trial.

Participants: Fifty women of reproductive age with sexual dysfunction.

Interventions: Vitamin E plus 30 mg saffron daily, or vitamin E without saffron.

Duration: Eight weeks, with follow-up.

Finding: The saffron-added group improved more in overall sexual function and selected depression, anxiety or stress measures.

Limitations: Active-comparator design without a saffron-only group; the effect cannot be isolated completely.


AKHONDZADEH ET AL., 2008—PREMENSTRUAL SYNDROME²³

Design: Double-blind, randomised, placebo-controlled trial.

Participants: Women with premenstrual syndrome.

Intervention: Saffron, 15 mg twice daily—30 mg total daily—or placebo.

Duration: Two menstrual cycles.

Finding: Improved premenstrual symptom and depression-rating scores.

Limitations: One older, modest study with limited replication.


GOUT ET AL., 2010—SNACKING²⁴

Design: Randomised, placebo-controlled trial.

Participants: Sixty mildly overweight healthy women.

Intervention: Proprietary Satiereal saffron-stigma extract.

Duration: Eight weeks.

Finding: Reduced snacking frequency and modestly increased weight loss.

Limitations: Proprietary extract, behavioural-weight context and no relevance to Luminara’s intended claims.


HOW SAFFRON MAY WORK

No single mechanism has been established as the explanation for saffron’s human effects.


CROCINS AND CROCETIN

Crocins are water-soluble carotenoid glycosides responsible for much of saffron’s colour.

After ingestion, crocins are substantially converted in the gastrointestinal tract to crocetin, which is then absorbed and further metabolised.

Laboratory and animal studies have investigated crocins and crocetin for:

• antioxidant activity;
• inflammatory signalling;
• neuronal resilience;
• neurotransmitter-related pathways;
• vascular effects;
• metabolic effects.

A whole saffron extract cannot be reduced to its crocin percentage alone.

Different crocin profiles and extraction methods may influence absorption and activity.


SAFRANAL

Safranal is a volatile compound associated with saffron’s aroma.

Preclinical studies have investigated safranal in:

• stress and anxiety models;
• neurotransmitter-related pathways;
• antioxidant systems;
• sleep and arousal pathways.

A 2023 small acute crossover study compared a proprietary saffron extract, synthetic safranal and placebo during a laboratory stress task.⁹

Isolated safranal is not equivalent to a saffron extract, and the results do not establish the effect of Luminara.


NEUROTRANSMITTER-RELATED PATHWAYS

Laboratory and clinical hypotheses include possible influence on:

• serotonin;
• dopamine;
• noradrenaline;
• glutamate;
• GABA-related signalling.

These mechanisms remain incomplete and preparation-dependent.

It is not accurate to describe saffron as:

• a natural SSRI;
• a natural antidepressant medicine;
• equivalent to fluoxetine or another prescription medication.

Similar average outcomes in small comparative trials do not mean identical mechanism, potency, safety or clinical effectiveness.


STRESS, INFLAMMATORY AND OXIDATIVE PATHWAYS

Saffron and its constituents have been studied for possible effects on:

• oxidative stress;
• inflammatory mediators;
• neuroinflammatory pathways;
• stress-related biological responses;
• neurotrophic signalling.

These mechanisms may contribute to research findings.

They do not prove that saffron treats inflammatory disease, prevents neurological decline or reliably lowers stress hormones.


SLEEP-RELATED PATHWAYS

Possible explanations for saffron’s sleep findings include indirect effects through:

• mood;
• stress response;
• circadian signalling;
• neurotransmitter pathways;
• melatonin-related measures.

The existing human evidence does not establish that saffron:

• increases melatonin consistently;
• corrects a melatonin deficiency;
• directly sedates the central nervous system;
• reproduces prescription sleep medicine.


SEXUAL-WELLBEING PATHWAYS

Potential explanations for sexual-function findings include:

• improved emotional wellbeing;
• reduced medication-related sexual impairment;
• vascular or nitric-oxide-related pathways;
• sensory and pain pathways;
• reduced distress;
• changes in arousal-related signalling.

The precise mechanism in women has not been established.

Positive arousal or lubrication findings should not be interpreted as proof of a direct hormone or libido effect.


PRECLINICAL RESEARCH BEYOND LUMINARA’S INTENDED OUTCOMES

Laboratory and animal research has investigated saffron, crocin, crocetin and safranal in:

• neurological and cognitive models;
• eye and retinal models;
• cardiovascular pathways;
• metabolic disorders;
• inflammatory disease;
• cancer models;
• reproductive models;
• pain;
• respiratory conditions;
• liver and kidney injury models.¹–³˒²⁹˒³⁷

These findings should not be converted into consumer claims that Luminara prevents or treats those conditions.


SAFETY AND RESPONSIBLE USE

Saffron extracts at approximately 28–30 mg daily have generally been well tolerated in short controlled trials.⁴˒⁵˒¹⁰˒¹³˒¹⁴˒¹⁹˒²⁰˒³¹

Reported or plausible adverse effects include:

• headache;
• nausea or digestive discomfort;
• appetite changes;
• dizziness;
• drowsiness;
• anxiety or restlessness;
• allergic reaction.

Serious adverse events have not emerged as a common signal at the usual study amounts.

Important limitations remain:

• most directly relevant trials lasted four to twelve weeks;
• long-term safety of a chemically matching Luminara extract has not been established;
• safety of Luminara’s full multi-herb formula cannot be inferred from saffron-alone trials;
• very high saffron doses are not equivalent to the 28 mg extract amount in Luminara.


PREGNANCY

Concentrated saffron use during pregnancy requires particular caution.

Saffron has historical associations with menstrual and uterine effects.

A clinical study investigated saffron in relation to cervical readiness at term pregnancy.³⁹

Animal studies of high experimental doses of crocin and safranal have reported developmental or reproductive toxicity signals.³⁸

These data do not quantify the risk of Luminara’s 28 mg saffron ingredient.

They support the precaution that Luminara should not be used during pregnancy without explicit qualified medical advice and should not be promoted for pregnancy.


BREASTFEEDING

Adequate safety data for concentrated saffron extracts during breastfeeding are not available.

Evidence relating to saffron alone does not establish safety of Luminara’s complete formula.

Anyone who is breastfeeding should obtain qualified medical advice before use.


ANTIDEPRESSANTS AND OTHER PSYCHOTROPIC MEDICINES

Saffron has been investigated:

• as a standalone mood intervention;
• alongside antidepressant treatment;
• in studies comparing average outcomes with antidepressant medicines;
• for antidepressant-induced sexual dysfunction.²⁰˒²⁸–³⁵

This does not establish that combining saffron with every psychiatric medicine is safe.

People taking:

• antidepressants;
• anti-anxiety medicines;
• mood stabilisers;
• antipsychotics;
• stimulant medicines;
• sleeping medicines;

should discuss Luminara with their prescribing clinician.

Saffron must not be used as a reason to stop or reduce prescribed medication without medical supervision.


BLEEDING AND SURGERY

Laboratory and pharmacological literature raises a theoretical possibility of effects on platelet or coagulation pathways at some doses.

Direct clinical interaction evidence at 28 mg daily is limited.

People taking:

• anticoagulants;
• antiplatelet medicines;
• medicines that increase bleeding risk;
• or who have a bleeding disorder;

should seek professional advice.

Consumers should tell their surgical, dental or anaesthetic team about Luminara and follow professional advice about when to stop supplements before a procedure.


BLOOD PRESSURE AND BLOOD GLUCOSE

Some clinical and pharmacological studies have investigated saffron in relation to:

• blood pressure;
• glucose regulation;
• lipid measures.

The effects at Luminara’s dose in generally healthy consumers are not predictable.

People taking antihypertensive or diabetes medicines should seek professional advice and monitor as directed by their clinician.

Saffron should not be marketed as treating high blood pressure or diabetes.


ALLERGY

Allergy to Crocus sativus or related plants is possible.

People should stop use and seek medical care for symptoms such as:

• swelling;
• hives;
• wheezing;
• difficulty breathing;
• severe rash.


AUTHENTICITY AND ADULTERATION

Saffron is a high-value botanical and is vulnerable to substitution, dilution and adulteration.

Potential quality problems include:

• substitution with safflower, turmeric, beet or coloured plant material;
• addition of dyes;
• exhausted or low-marker saffron;
• use of non-stigma floral parts;
• misstatement of origin or grade.

This makes strong quality documentation particularly important.

Before launch, Trab Health should obtain:

• a production-batch CoA;
• botanical identity testing suitable for an extract;
• actual crocin and safranal results;
• a chromatographic fingerprint where feasible;
• heavy-metal, pesticide, microbiological and residual-solvent results;
• extraction-solvent and carrier declarations;
• country of origin;
• finished-product identity and potency testing when feasible.


PLAIN-ENGLISH SUMMARY

Saffron is one of the strongest evidence-aligned ingredients in Luminara.

Several controlled human trials used 28 mg daily—the same nominal amount listed in Luminara’s formula.

The best-supported research areas are:

• emotional wellbeing and selected depressive-symptom outcomes;
• subjective sleep quality;
• the ability to function during the day when sleep feels poor.

The evidence is promising for:

• psychological symptoms during perimenopause;
• overall female sexual function;
• selected domains such as arousal, lubrication or pain in specific clinical populations;
• everyday stress response.

Important limits remain.

The new 2026 trial in women aged 50–70 improved depressive symptoms, self-esteem and sleep-related impairment, but it did not improve sleep disturbance.

The key 2021 perimenopause trial improved mood and psychological symptoms, but it did not improve vasomotor or somatic symptoms.

The 2013 fluoxetine-related sexual-function trial improved arousal, lubrication and pain, but it did not clearly improve desire, orgasm or satisfaction.

A 2025 healthy-adult study did not improve its primary combined depression, anxiety and fatigue outcome.

These mixed and selective findings matter.

They support a credible evidence story without justifying exaggerated claims.

Luminara’s 28 mg dose, correct species and stigma plant part provide strong research alignment.

The major unresolved issue is the extract itself.

The supplied document is an approved specification, not a production-batch CoA. It gives minimum limits of 0.3% safranal and 0.4% crocins but does not report actual batch values, extraction solvent, carrier, contaminants or finished-product potency.

The most accurate positioning is:

Saffron contributes clinically researched support for emotional wellbeing, sleep quality, stress response and women’s wellbeing through hormonal transitions, with emerging evidence in female sexual wellbeing. It should not be positioned as a treatment for depression or insomnia, a hormone balancer or a proven libido ingredient.


REFERENCES

1. Royal Botanic Gardens, Kew. Crocus sativus L.. Plants of the World Online. Accessed 2 August 2026.